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Preface 
 
New Zealand is the world’s third-largest honey exporter by value behind China and Argentina 
and honey accounts for up to 80 % of New Zealand’s exports. However, it is only the 16th 
biggest global supplier by volume. Manuka honey from New Zealand is sold for premium 
prices and merchandised for its health benefits. Because of its exceptional antibacterial 
properties, there is a strong market demand and the price for a kilogram of manuka honey has 
tripled in recent years (Ministry for Primary Industries, 2015). When consumers are willing to 
pay prices up to 200 €/kg manuka honey, the risk of misleading advertisement and intended 
fraud increases. Until now, there is no consequent regulation of the requirements for labelling 
manuka honey. Labels to advertise certain health effects or claims like “active” and “doctor” 
are confusing to consumers and cannot be proven on a scientific basis. Moreover, a lot of 
research focused on the definition of “genuine” manuka honey during recent years. According 
to the Codex Alimentarius and the Codex standard for honey the origin of manuka honey 
should be “wholly or mainly” the manuka plant (Codex Alimentarius Commission, 2001). Up 
to now, a consent about the precise definition of “wholly or mainly” and reliable analytical 
methods to prove the manuka origin do not exist. 
This thesis aims to further characterize manuka honey and contribute to the development of a 
manuka honey definition. The thesis is divided into three chapters. Chapter A deals with the 
antibacterial activity of manuka honey. The effect of manuka honey is mainly due to 
methylglyoxal, whereas the effect of non-manuka honeys is primarily caused by hydrogen 
peroxide. The objective is to develop a method to quantify the effect solely due to one of the 
respective chemical compounds and compare their effectiveness. Finally, an evaluation of the 
contribution of methylglyoxal and hydrogen peroxide to the inhibitory effect of honey should 
be given. In chapter B, chemical reactions of carbonyl compounds in honey will be discussed. 
Because of the reactive nature of carbonyl compounds, the formation of specific glycation 
compounds in honey is assumed. Since the carbonyl profile of manuka honey differs 
remarkably from non-manuka honeys, the reaction products are expected to vary widely. 
Specific compounds, solely present in manuka honey, could serve as quality control 
parameters to ensure manuka honey authenticity. Chapter C deals with the metabolism of 
food-derived carbonyl compounds. Carbonyl compounds, like methylglyoxal or 3-
deoxyglucosone, are discussed to be potentially toxic to human tissues. Until now, only little 
is known about the impact of the diet on the physiological carbonyl-load and the metabolism 
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of carbonyl compounds. With the help of nutrition studies and the analysis of body fluids, the 
metabolic transit of carbonyl compounds shall be investigated.  
Each chapter contains a separate theoretical background including a literature review of the 
current state of knowledge concerning the particular topic. The analytical methods used for 
the respective studies are presented in each of the chapters and the results are summarized 
separately. In the end of all chapters, the results will be presented in a comprehensive 
summary and an outlook for further studies will be given. 
The structure of this thesis allows the reader to either gain an insight into each topic 
individually or gain an extensive view in the unique chemistry of manuka honey. The author 
holds the opinion that the results of this thesis are an important contribution to the last ten 
years of manuka honey science and the characterization of honey chemistry and its health 
benefits.  
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1 Chapter A – The antibacterial effect of manuka honey 
 
1.1  Introduction  
 
This chapter deals with the unique antibacterial properties of manuka honey compared to 
other conventional honeys. Since the discovery of penicillin in the 20th century, antibiotics 
have been a great resource to fight various bacterial infections. From 1935 to 1968, eleven 
classes of drugs had been introduced and approved in the American market. Since 1968, only 
two new classes of antibiotics have been identified and approved (Powers, 2004). Due to the 
lack of new classes, drug developers started to introduce “new generations” of an existing 
antibiotic by chemically modifying previously studied compounds. The increasing number of 
agents within classes and the lack of new classes slowed down the discovery of new drugs. In 
the meantime, antibiotic resistance became a growing problem. There are scientific claims 
that the golden era of antibiotics is over and we reached a “post-antibiotic” age (Alanis, 2005; 
Brown and Wright, 2016). This is due to increasing numbers of antibiotic-resistant bacteria 
leading to less effective antibiotic treatment of certain infections. In recent years, plenty of 
research concerning alternative treatments of bacterial infections has been conducted (Allen et 
al., 2013; Elshafie et al., 2016). The focus of research moved to natural, plant-based products 
and honey became an interesting candidate to fight superficial wound infections (Moore et al., 
2001; Molan, 2006). Various scientific studies documented the exceptional effect of manuka 
honey on different bacterial species (Al Somal et al., 1994; Lusby et al., 2005; Cooper et al., 
2010). The current chapter discusses the antibacterial activity of honey in general and aims to 
reveal the characteristic bioactivity of methylglyoxal in manuka honey. The objective is to 
develop a method to quantify and compare the antibacterial effect of methylglyoxal in 
manuka honey and hydrogen peroxide in conventional honeys. Moreover, the mode of action 
of honey compounds is not thoroughly studied yet. The second part of this chapter deals with 
the question, whether the inhibition of bacterial enzyme systems could be a cause for bacterial 
inhibition. This was studied using the enzyme urease from Canavalia ensiformis, which is 
also present in the bacterium Helicobacter pylori, and its inhibition by manuka honey. In 
conclusion, the results contribute to an evolved explanation of the antibacterial activity of 
manuka honey.  
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1.2  Background 
 
1.2.1 Honey and its antibacterial properties 
Manuka honey is endemic in New Zealand and its antibacterial properties are well known 
from the heritage of New Zealands native inhabitants, the Māori. Long before the Europeans 
arrived in New Zealand in the 18th century, the Māori used local plants for medicinal 
purposes. This traditional medicine is called “Rongoā Māori”, which is still used by 
indigenous populations nowadays (Williams, 2008). Manuka honey was used to treat topical 
wounds and burns since ancient times. The reason for its exceptional antibacterial activity was 
long unknown. Mavric et al. (2008) discovered, that manuka honey contains up to 800 mg/kg 
of the chemical compound methylglyoxal (MGO). This amount is 100 times higher compared 
to conventional honeys and other food stuff. Methylglyoxal is a dicarbonyl compound which 
is normally formed as a by-product of glycolysis and can act cytotoxic. Mavric et al. (2008) 
were able to show, that methylglyoxal in manuka honey is directly responsible for its 
particular antibacterial activity. In general, manuka honeys are considered to exert a distinct 
amount of non-peroxide activity (NPA) due to methylglyoxal. In comparison to this, other 
conventional honeys can have a peroxide activity (PA). This activity is due to certain amounts 
of hydrogen peroxide, which is produced by the enzymatic reaction of glucose oxidase in the 
honey (White et al., 1963). Glucose oxidase catalyzes the reaction of glucose to gluconic acid 
and hydrogen peroxide. The bee-derived enzyme is secreted to the honey to decrease honey 
pH value, which enables better storage conditions. Additionally, in manuka honey MGO is 
formed non-enzymatically from dihydroxyacetone (DHA) (Adams et al., 2009; Atrott et al., 
2012). The nectar of the manuka plant contains unusually high levels of DHA. The 
biochemical reason for the presence of high DHA concentrations in the manuka nectar is yet 
unknown. After collection of the nectar by the bees and honey storage in the hive, MGO is 
formed from DHA via non-enzymatic dehydration (see Figure 1) (Atrott, 2013). It was found, 
that MGO formation is a time-, pH- and temperature-dependent process. Moreover the 
presence of certain amino acids, namely alanine and glycine, is supposed to influence the 
DHA-to-MGO-conversion (Grainger et al., 2016b). In commercial manuka honeys, a good 
linear correlation between DHA and MGO values was observed, with a mean ratio of 
DHA:MGO of 2:1 (Atrott et al., 2012).  
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Figure 1: Non-enzymatic dehydration of dihydroxyacetone to methylglyoxal (based on PhD thesis of 
Julia Atrott: Methylglyoxal in Manuka-Honig: Bildung, Wirkung, Konsequenzen, 2013) 
 
According to the Apiculture Monitoring Report by the New Zealand Ministry for Primary 
Industries, the total annual honey production increased from 12,500 t in 2010 to 19,700 t in 
2015. Moreover in 2010 manuka honey cost was 7-38 NZ$/kg, whereas in 2015 the price 
increased up to 10-117 NZ$/kg (Ministry for Primary Industries, 2015). This clearly indicates 
the importance of manuka honey as one of the leading New Zealand Industries. The high 
market prices of manuka honey are justified by its unique antibacterial activities due to 
methylglyoxal. After the discovery of MGO in 2006, New Zealand honey producing 
companies started with labelling their products with its MGO content in 2007. Before that, it 
was generally recognized to characterise the bioactive effect of manuka honey with the 
“UMF” value. UMF stands for “Unique Manuka Factor”, which describes the antibacterial 
activity of honey compared to an equivalently effective concentration of a phenol solution. 
Besides that, a lot of manuka honey labels exist, which advertise a certain bioactive effect 
(e.g. “active 10+”, “Active AAH”). Since there is no governmental guideline concerning 
manuka honey labelling, the reliability of these labels is questionable. Until now, there exists 
no reliable method to compare and quantify the antibacterial effect due to hydrogen peroxide 
and the effect caused by MGO. To characterise an antibacterial effect, it is necessary to 
understand the mode of action of different antibacterial agents. The following section will 
discuss scientific studies of bacterial inhibition and the role of honey compounds in this 
context. 
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1.2.2. The mechanism of bacterial inhibition 
Bacterial growth can be divided into four different stages. The first stage is the lag phase. 
During this stage, bacteria adapt to their environment and express specific genes, which code 
for enzymes, which are necessary for their metabolism. The length of a lag phase depends on 
the media and the adaptability of the bacterial species. The second stage is called log phase. 
This stage is characterised by cell doubling and exponential growth. If growth is not limited, 
doubling will continue at a constant rate. If media nutrients get depleted over time, bacteria 
will enter stage three, the stationary phase. During this stage, growth and death rate are equal. 
Finally, bacteria enter the death phase, which is characterised by cell lysis and thus, declining 
cell numbers (Novick, 1955; Zwietering et al., 1990). A common characterisation of bacterial 
growth can be achieved by measuring the optical density (OD). The OD, or turbidity, at 600 
nm is a measure for the cell number of a specific kind of bacteria. Figure 2 depicts the classic 
growth phases of bacteria (solid line) and a growth curve of bacteria, treated with a 
bacteriostatic agent (dotted line). 
 
 
Figure 2: Bacterial growth curve, solid line: stages of bacterial growth, dotted line: bacterial growth 
with lag time extension, OD stands for optical density (experimental data of S. aureus growth in 
minimal media) 
 
Antibacterial agents can intervene in the growth behaviour of bacteria. There are two different 
modes of action of antibacterial agents, which need to be differentiated: bacteriostatic and 
bactericidal. A bacteriostatic agent can inhibit bacterial growth for a certain time, but will not 
kill all bacterial cells. Thus, after prolonging the lag phase of bacterial growth, the bacteria 
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will equally enter the exponential growth phase and can rapidly multiply. In contrast 
bactericidal agents will cause complete cell death and thus prevent any further bacterial 
growth. Usually, it depends on the concentration of an antibacterial agent if it acts either 
bacteriostatic or bactericidal. The determination whether an antibacterial agent is considered 
to act bacteriostatic or bactericidal is markedly influenced by experimental conditions like 
media conditions, bacterial density and test duration (Pankey and Sabath, 2004). To quantify 
antibacterial activity, antibacterial agents are diluted in different concentrations in liquid 
media and incubated with a standard number of microorganisms. After incubation at 35-37°C 
for 18 to 24 h, the amount of antibacterial agent, which inhibited visible growth is called the 
minimal inhibitory concentration (MIC). The samples which did not show any growth are 
subcultured on fresh media (usually solid) and again incubated for 18 to 24 h. The minimal 
bactericidal concentration (MBC) represents the lowest concentration of an antibacterial agent 
that either totally prevents growth or results in a 99.9 % reduction of the initial inoculum 
(Pankey and Sabath, 2004). Several papers have been published on the comparison of MIC 
values for various food-derived antibacterial agents (Lin et al., 2011; Krauze-Baranowska et 
al., 2014; Elshafie et al., 2016). Although the MIC value gives a quantitative measure of 
antibacterial activity, it is not an accurate parameter to define bacterial inhibition. For 
example, MIC values of different studies can only be compared if testing conditions 
(incubation time, media and inoculum) are the same. In this context, an interpolation of 
inhibition data, in this case extension of the lag phase, could deliver a more precise measure 
of antibacterial activity. Moreover, the additional information if the tested antibacterial agent 
can also act bactericidal is of fundamental interest.  
There are different mechanisms by which antibacterial agents interact with cells. The major 
targets of common antibacterial agents are cell wall synthesis (e.g. penicillin), cell membrane 
function (polymixin B), protein synthesis (chloramphenicol), nucleic acid synthesis 
(quinolones) or other metabolic processes (sulphonamides) (Kohanski et al., 2009). Especially 
the last mentioned target includes various processes like inhibition of folic acid biosynthesis 
(Ahmad et al., 1998) or acting as enzyme inhibitors (Andreu and Rivas, 1998). Since honey is 
a complex mixture of different bioactive agents, there cannot be made a clear statement on its 
mode of action. Nevertheless, when single honey compounds are studied individually, some 
conclusions about its antibacterial mechanisms can be made. Honey contains mainly fructose 
and glucose, which make up 85 % of its dry matter. The osmotic pressure caused by the 
highly saturated sugar solution and the low pH value of 3.5-4.0 caused by organic acids are 
responsible for the antibacterial effect of conventional honeys (Bogdanov, 1997; Mandal and 
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Mandal, 2011). Moreover, hydrogen peroxide, which originates from honey enzyme glucose 
oxidase, acts antibacterial by causing oxidative stress or even bactericidal by degrading 
bacterial DNA (Brudzynski et al., 2011). In contrast, very little is known about the 
antibacterial mechanism of MGO, which was identified as the main antibacterial factor in 
manuka honey (Mavric et al., 2008). With the exception of a few studies, which deal with 
either MGO or manuka honey, the increased antibacterial effect of manuka honey remains a 
secret. Henriques et al. (2010) studied the intracellular effect of manuka honey on 
Staphylococcus aureus. The authors studied MIC and MBC values of manuka honey and 
structural changes of the cells via scanning and transmission electron microscopy. They 
concluded that honey-treated cells (with 10 % (w/v) manuka honey) failed to progress 
normally through cell cycle and thus accumulate at the stage of cell division. The inclusion of 
a sugar-only control demonstrated, that honeys sugars are not involved in this process. In 
conclusion, the author hypothesized that manuka honey compounds target the cell division in 
S. aureus. No statements concerning the role of methylglyoxal in this process were made. 
Rabie et al. (2016) studied the morphological changes of Escherichia coli and Bacillus subtilis 
in the presence of methylglyoxal concentrations of 0.5 to 2 mM. The authors showed that 
with increasing MGO concentrations the fimbriae and flagella structures, which keep bacteria 
motile, disappear. At the highest concentration tested (2 mM) the structure of the membrane 
appeared shrinked and lost its integrity (see Figure 3). The authors concluded that the main 
reason for the antibacterial effect of MGO is the decrease of bacterial motility and the loss of 
its adherence capacity.  
 
 
 
Figure 3: Images are taken from Rabie et al. (2016), see next page for captions 
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Left side: SEM micrographs of B. subtilis exposed to increasing concentrations of MGO. (A) Control; 
(B) 0.5 mM MGO; (C) 1.0 mM MGO; (D) 2.0 mM MGO. Thin white arrows indicate the flagella; 
thick white arrows indicate the fimbriae; the gray arrow in C shows a pilus; and the gray arrow in D 
indicates a hole in the cell. 
Right side: SEM micrographs of E. coli exposed to increasing concentrations of MGO. (A) Control; 
(B) 0.5 mM MGO; (C) 1.0 mM MGO; (D) 2.0 mM MGO. Thin white arrows indicate the flagella; 
thick white arrows indicate the fimbriae; gray arrow in B shows a pilus. 
 
The effects studied by Henriques et al. (2010) and Rabie et al. (2016) could be an explanation 
for the broad spectrum of bacterial species, which are influenced by manuka honey. Not only 
cell division but also motility is an essential feature for bacterial survival. A loss or restriction 
thereof can lead to decreased viability. Besides these universally effective mechanisms, it 
could be valuable to take a closer look at more bacteria-specific approaches. Over time, some 
bacteria developed a specialised metabolism as an evolutionary advantage, which could be a 
specific antibacterial target nowadays. For example, Helicobacter pylori is a gram-negative 
bacterium, which colonizes the human stomach and neutralizes the acidic pH value with 
continuous ammonia production. Helicobacter pylori infections are made responsible for 
gastric inflammation and ulcers (Marshall et al., 1987). Manuka honey was shown to exhibit 
an antibacterial effect against H. pylori (Al Somal et al., 1994). In the study, five clinical 
isolates of H. pylori were inoculated on agar plates, which contained 2.5 to 10.0 % manuka 
honey. A minimal inhibitory concentration (MIC) of 2.5 % of manuka honey was determined 
visually. A possible target of Helicobacter pylori inhibition is the enzyme urease (Ohta et al., 
2001; Lin et al., 2005). The enzyme urease catalyses the formation of carbon dioxide and 
ammonia from urea. The activity of urease is essential for Helicobacter pylori survival. Until 
now, there is no study about the effect of individual honey compounds on the enzyme urease. 
To target specific enzymes or metabolic pathways in bacterial cells would be an interesting 
strategy for the development of new antibacterial agents or to research the mechanisms of 
existing antibiotics. 
 
1.2.3. Cyclodextrins  
Cyclodextrins (CD) are cyclic oligosaccharides, which consist of at least six α-1,4-linked 
glucose units. CDs are naturally occurring, water soluble glycans, which are produced as a 
result of enzymatic starch degradation. The non-reducing oligosaccharides can consist of six, 
seven or eight glucopyranose units, referred to as α-, β- or γ-cyclodextrins, respectively 
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(Szejtli, 1998; Singh et al., 2002). The hydroxyl groups of cyclodextrin are located on the 
outside of the molecule, whereas the inner part forms a hydrophobic cage-like structure. 
These structures can interact with hydrophobic molecules and form inclusion complexes of 
the “guest-host” type. The properties of the complexed material can change significantly, this 
is why CDs are widely applied in the industry sector, e.g. as drug and flavour carriers, in 
cosmetics or for separation processes. The modification can enhance the guest’s 
physicochemical properties by increasing solubility, stabilizing against degradation processes, 
trapping volatile compounds and controlling the release of bioactive compounds. The 
negligible toxicity of CDs make them good candidates for drug delivery systems. Especially 
β-CD is used in the development of delivery systems due to its optimal inner diameter for the 
molecular size of most drugs. Moreover CDs can be chemically modified (e.g. introduction of 
hydroxypropyl groups) to improve their complexation capacity. Cyclodextrin inclusion 
complexes are also described to interact with cellular membranes and thus increasing cellular 
uptake of the guest molecule. Since there are no physiologically relevant enzymes, which can 
degrade α-cyclodextrin, it is characterized as a food fibre (Singh et al., 2002). 
These advantages of cyclodextrin formulations were crucial for the development of the 
commercial product “Manuka Honey with CycloPowerTM” (CP). The company Manuka 
Health NZ Ltd. produces capsules, which contain 45 % manuka honey MGO 400+ and 55 % 
α-cyclodextrin. The production of the inclusion complexes is described in section 1.4.12 
(taken from the production protocol of Manuka Health NZ Ltd.). The bioactive effect of 
MGO in manuka honey is limited due to reactions with media compounds, mostly proteins or 
amino acids, and thus a decrease of the effective concentration can occur. Cyclopower was 
developed to increase the stability and bioavailability of MGO by slowly releasing MGO 
during digestion and exert a pronounced effect on digestive health. From a scientific point of 
view, it is not clear whether MGO and cyclodextrin form inclusion complexes and if so, how 
strong these interactions are. Moreover, the stability of potential MGO-CD complexes 
towards protein reactions was not studied before. Chepulis & Francis (2012) studied the anti-
inflammatory effect of α-cyclodextrin complexed manuka honey and found contradictory 
results. TNF-alpha secretion was both increased and decreased depending on MGO and other 
honey factors. Moreover, the authors showed a decrease of the antioxidant capacity, which 
was due to honey dilution with α-cyclodextrin. Swift et al. (2014) were the first to show, that 
Manuka Honey with CycloPowerTM had an increased antibacterial activity against S. aureus, 
S. pyogenes and H. pylori compared to manuka honey without cyclodextrin. The authors 
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concluded that manuka honey is an effective antibacterial agent which can be enhanced by 
complexing with α-cyclodextrin. However, until now the functional consequences of manuka 
honey inclusion complexes with cyclodextrin are not profoundly studied yet.  
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1.3. Aims 
 
The focus of this chapter is the comparison of the non-peroxide activity of manuka honey 
with the peroxide activity of conventional honeys. The aim was to quantify the inhibitory 
effect of honeys. This is normally achieved by comparing the minimal inhibitory 
concentration (MIC) of certain compounds. The validity of the MIC is limited due to different 
experimental settings. Moreover, the MIC value does not specify whether an inhibitory 
substance is acting bacteriostatic or bactericidal. The aim was to develop a method, which 
allows a characterization of the inhibitory effect of different concentrations and a kinetic 
prediction of the inhibition. The new method was supposed to compare the effect of non-
peroxide vs. peroxide activity of honey and quantitative measures of their effectiveness on 
two gram-negative and two gram-positive bacteria species. In the end, an evaluation of the 
contribution of MGO and hydrogen peroxide to the inhibitory effect of honey should be 
made. Moreover, the effect of inclusion complexes formed from cyclodextrin and manuka 
honey on bacteria should be elucidated. Therefore, the molecular structure of model 
complexes formed by either MGO or DHA and α-cyclodextrin was studied via NMR 
spectroscopy and the consequences for molecular interactions in Manuka Honey with 
CycloPowerTM were deduced from the results. The antibacterial activity of CycloPower and 
CD alone was studied with the newly developed bacteria assay. Hence, functional 
consequences for manuka honey encapsulated with α-cyclodextrin shall be presented. 
Furthermore, the mechanism of bacterial inhibition with manuka honey should be studied. 
Therefore, the influence of manuka honey compounds MGO and DHA on the enzyme urease, 
which is present in the bacterium Helicobacter pylori, will be studied. The results of the study 
are a contribution to mechanistically explain bacterial inhibition with manuka honey.  
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1.4. Methods 
 
1.4.1. Chemicals 
 
Table 1: List of chemicals used in chapter A 
Chemical Specification Supplier 
1,3-Dihydroxyacetone dimer 97 % 
Sigma-Aldrich, Steinheim, 
Germany 
1-propanol > 99.5 %, p.a.  
2-Methylquinoxaline (2-MQ) 99.2 % 
Sigma-Aldrich, Steinheim, 
Germany 
Abz-FRK(Dnp)P-OH ≥ 95 % (HPLC) 
Sigma-Aldrich, Steinheim, 
Germany 
Acetic acid 100 %, p.a. 
Carl Roth, Karlsruhe, 
Germany 
Acetohydroxamic acid 98 % 
Alfa Aesar, Karlsruhe, 
Germany 
Ammonia 25 % Merck, Darmstadt, Germany 
Angiotensin- converting enzyme  from rabbit lung 
Sigma-Aldrich, Steinheim, 
Germany 
Blood agar for microbiology 
Carl Roth, Karlsruhe, 
Germany 
Brain heart infusion broth for microbiology 
Carl Roth, Karlsruhe, 
Germany 
Brucella broth base for microbiology 
Sigma-Aldrich, Steinheim, 
Germany 
Catalase  
from bovine liver, suspension in 
water, 15 000 000 U/15 ml 
Merck, Darmstadt, Germany 
D(-)Fructose > 99,5 %, for biochemistry 
Carl Roth, Karlsruhe, 
Germany 
D(+)-Glucose anhydrous, p.a. 
Carl Roth, Karlsruhe, 
Germany 
D(+)-Saccharose ≥ 99.5 %, p.a. 
Carl Roth, Karlsruhe, 
Germany 
D-/L-Lactic acid kit  for UV-method R-Biopharm, Darmstadt, 
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Germany 
Deuterium oxide 99.9 atom % D 
Sigma-Aldrich, Steinheim, 
Germany 
Disodium hydrogenphosphate 99 % Grüssing, Filsum, Germany 
Ethanol 
96 %, denatured with light 
petroleum 
Berkel, Berlin, Germany 
Glucose oxidase 
from Aspergillus niger, G-6641 
10 kU, 47200 U/g 
Sigma-Aldrich, Steinheim, 
Germany 
Glutathione (reduced)  Merck, Darmstadt, Germany 
Glyoxalase 1  from Saccharomyces cerevisiae 
Sigma-Aldrich, Steinheim, 
Germany 
Haemoglobin  from bovine blood 
Sigma-Aldrich, Steinheim, 
Germany 
Horse serum  
Sigma-Aldrich, Steinheim, 
Germany 
Hydrochloric acid 37 % 
Sigma-Aldrich, Steinheim, 
Germany 
Hydrogen peroxide 30 %, p.a. 
Sigma-Aldrich, Steinheim, 
Germany 
Hydroxyacetone 90 % 
Sigma-Aldrich, Steinheim, 
Germany 
Lithium chloride p.a. Merck, Darmstadt, Germany 
Lithium citrate buffer 0.12 N, pH 2.2 
Sykam, 
Fuerstenfeldbruck, Germany 
Lithium citrate buffer 0.12 N, pH 2.9 
Sykam, 
Fuerstenfeldbruck, Germany 
Lithium citrate buffer 0.3 N, pH 4.2 
Sykam, 
Fuerstenfeldbruck, Germany 
Lithium citrate-/ borate buffer 0.3 N, pH 8.0 
Sykam, 
Fuerstenfeldbruck, Germany 
Methanol HPLC grade VWR, Darmstadt, Germany 
Methylglyoxal  
~ 40 % (w/w), exact 
concentration was determined 
against 2-MQ 
Sigma-Aldrich, Steinheim, 
Germany 
Ninhydrin p.a., min. 99 % Serva Feinbiochemica, 
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Heidelberg, Germany 
ortho-Dianisidine  
Sigma-Aldrich, Steinheim, 
Germany 
ortho-Phenylenediamine (oPD) ≥98 %, 
Sigma-Aldrich, Steinheim, 
Germany 
Pepsin  
from porcine gastric mucosa, 
3555 U/mg protein 
Sigma-Aldrich, Steinheim, 
Germany 
Peroxidase 
Type I from horseradish, 150 
units/mg solid 
Sigma-Aldrich, Steinheim, 
Germany 
Sodium acetate  99.5 %; p.a Grüssing, Filsum, Germany 
Sodium chloride 99.7 % VWR, Darmstadt, Germany 
Sodium dihydrogenphosphate 99.5 %; p.a Grüssing, Filsum, Germany 
Sodium hydroxide 98.56 % 
Fisher Scientific, 
Loughborough, UK 
Sigma-Aldrich, 
Starch  soluble 
Carl Roth, Karlsruhe, 
Germany 
Sulphuric acid 95-97 %, p.a. Merck, Darmstadt, Germany 
Trichloroacetic acid > 99 %; p.a. 
Carl Roth, Karlsruhe, 
Germany 
Tris(hydroxymethyl)-
aminomethan (TRIS) 
Buffer grade 
Sigma-Aldrich, Steinheim, 
Germany 
Urea > 99.5 % Fluka AG, Basel, Switzerland 
Urease from Canavalia 
ensiformis (Jack bean) 
Type III; 34310 U/g solid 
Sigma-Aldrich, Steinheim, 
Germany 
Yeast extract Biochemika A 1552, 1000 
AppliChem, Darmstadt, 
Germany 
α-Cyclodextrin ≥98%, CAVAMAX® W6 FOOD 
Wacker Chemicals AG, 
Supplied by Manuka Health 
NZ Ltd. 
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1.4.2. Materials 
 
Table 2: List of materials used in chapter A 
Name Specification Supplier 
Amino acid analysator column Cation exchange LCA K07/Li 
Sykam, 
Fuerstenfeldbruck, Germany 
Cuvette Semi-micro, PMMA, 1,5 – 3,0 ml Brand, Wertheim, Germany 
Disposable inoculation loops  
Carl Roth, Karlsruhe, 
Germany 
Glass vessel 10-50 ml VWR, Darmstadt, Germany 
HPLC column 
Eurospher 100 RP18 material 
(250mm x 4.6 mm, 5 µm particle 
size with integrated pre-column 
Knauer, Berlin, Germany 
HPLC vials with lit 1.5 ml, glass VWR, Darmstadt, Germany 
Incubation jar 2.5 l 
Merck Millipore, Darmstadt, 
Germany 
Membrane filter 
Regenerated cellulose, 45 µm, 26 
mm 
Phenomenex, Aschaffenburg, 
Germany 
Membrane filter for solvents 
GH Polypro 0,45 µm, 47 mm 
hydrophilic polypropylene 
Pall, Crailsheim, Germany 
Microtiter plate  
96 flat bottom, transparent, 
pureGrade, nonsterile 
Brand, Wertheim, Germany 
Microtiter plate 
96 well plate, flat bottom, 
polystyrene, 0,34 cm², steril, 
162/cs 
TPP Techno, Plastic Products 
AG, Switzerland 
Microtiter plate UV-star 
Greiner Bio-One, 
Kremsmuenster, Austria 
Multichannel pipette 10-100 µl Brand, Wertheim, Germany 
Oxoid™ CampyGen™ Sachet 
2.5 l, produce gaseous atmosphere 
for growth of microaerophilic 
microorganisms 
Thermo Scietific, Runcorn, 
UK 
Parafilm 4 in x 125 ft Bemis, Neenah, USA 
Pasteur pipettes 230 mm, glass 
VWR International, Leuven, 
Netherlands 
Pipette tips 1-1000 µl Brand, Wertheim, Germany 
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Self-adhesive sealing film 
153x78mm, 25 µm, sterile, gas-
permeable 
Carl Roth, Karlsruhe, 
Germany 
Septa for HPLC vials 8*0.4 mm, PTFE coated VWR, Darmstadt, Germany 
Sterile membrane filter FP 30/0.2 CA-S, 0,2 µm 
GE Healthcare Europe 
GmbH, Freiburg, Germany 
Syringe 50 ml 
Henke Sass Wolf, Tuttlingen, 
Germany 
Syringe 1 ml 
B. Braun, Melsungen, 
Germany 
Tubes 1.5 ml, 2 ml 
Eppendorf, Hamburg, 
Germany 
 
1.4.3. Devices 
 
Table 3: List of devices used in chapter A 
Device Specification Supplier 
Amino acid analysator 
S 4300, Software: Chromstar 6.3 
SCPA GmbH 
Sykam, 
Fuerstenfeldbruck, Germany 
Analytic balance 
BP 121 S, accuracy: 0.0001 g, 
max. 120 g 
Sartorius, Göttingen, 
Germany 
Centrifuge Eppendorf 5804-R 
Eppendorf AG, Hamburg, 
Germany 
Freeze dryer Alpha 1 - 2 
Martin Christ, Osterode, 
Germany 
Freezer Comfort 
Liebherr, Bibrach an der Riss, 
Germany 
Fridge Econoic System, 5°C 
Liebherr, Bibrach an der Riss, 
Germany 
HPLC system 1 
Äkta basic system 
pump P-900 
auto sampler A-900 
UV detector UV-900 
online degasser K-5004 
Amersham Pharmacia 
Biotech, Uppsala, Sweden 
 
 
Knauer, Berlin, Germany 
HPLC system 2 
Smartline 1000 pump  
Dynamic mixing chamber 
Knauer , Berlin, Germany 
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solvent organizer K-1500 
online degasser K-5004 
Basic Marathon auto sampler 
Azura DAD detector 2.1 L 
Knauer , Berlin, Germany 
Knauer , Berlin, Germany 
Sparks , Netherlands 
Knauer, Berlin, Germany 
Incubator  BE 500 
Memmert, Schwabach, 
Germany 
Incubator  BE 400 
Memmert, Schwabach, 
Germany 
Incubator ULM 500 
Memmert, Schwabach, 
Germany 
Incubator shaker Multitron 
INFORS AG, Bottmingen, 
Switzerland 
Laboratory pipette 1-1000 µl 
Eppendorf AG, Hamburg, 
Germany 
LabWater Purelab Plus water 
system 
conductivity 0.055 µS/cm 
ELGA, Celle, Germany  
filter from USFilter, 
Ransbach-Baumbach, 
Germany 
Laminar flow cabinet HeraSafe Heraeus, Hanau, Germany 
Magnetic and heating stirrer 
 
RH basic 
IKA Labortechnik, Staufen, 
Germany 
 
Multimode reader 
(one device: Institute for 
Microbiology, second device: 
Institute for Food Chemistry, TU 
Dresden) 
Tecan infinite M200 Tecan, Mainz, Germany 
NMR device Bruker Avance III 600  Bruker, Billerica, USA 
pH meter 
InoLab Level 1, electrode: InLab 
Semi-Micro 
Mettler-Toledo, Weilheim, 
Germany 
Photometer Spekol 1500 Analytik Jena, Jena, Germany 
Ultrasonic bath Sonorex RK 510 Super Bandelin, Berlin, Germany 
Vortex Minishaker MS-1 IKA 
IKA Labortechnik, Staufen, 
Germany 
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1.4.4. Honey samples 
 
Table 4: List of commercial honey samples used in chapter A 
Honey Quantity Manufacturer, Best before 
Manuka honey MGO 30 1 
Manuka Health NZ Ltd., 
01/2018 
Manuka honey MGO 250 2 
Manuka Health NZ Ltd.  
 
Manuka honey MGO 400 2 Manuka Health NZ Ltd. 
Manuka honey MGO 550 3 Manuka Health NZ Ltd.  
Manuka honey, fresh 1 Manuka Health NZ Ltd. 
Honeydew honey  
Biophar, Fürsten- Reform, 
Braunschweig, 
04/2015 
Canola honey 1 
Bienen Wirtschaft Meißen,  
06/2011 
Polyfloral honey 1 Nektarquell, 04/2014 
Lime honey 1 
Imkerei R. Feldt, Eichede, 
09/2015 
Cyclopower, Manuka honey 400+ with α-
cyclodextrin 
1 
Manuka Health NZ Ltd.  
Produced: 08/2012 
 
 
Table 5: List of spiked honey samples used in chapter A 
Honey Specification Active compound 
AH 
Artficial honey:  
100g AH contain 
46.5g fructose + 34g glucose + 
1.5g sucrose + 18g ultrapure 
water 
- 
AH-GOX 
Artificial honey spiked with 
glucose oxidase 
H2O2: 115 mg/kg*h 
AH-MGO 
Artificial honey spiked with 
methylglyoxal 
MGO: 873 mg/kg 
Canola honey + MGO/DHA,  Canola honey spiked with MGO: 600 mg/kg 
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S2 MGO and DHA DHA: 1550 mg/kg 
Manuka honey + 
glyoxalase/GSG, S5 
Manuka honey MH 3 spiked 
with glyoxalase 1 and GSH 
 
 
 
1.4.5. Quantification of methylglyoxal and dihydroxyacetone via RP-HPLC 
The determination of MGO and DHA was performed according to (Atrott et al., 2012) with 
slight modifications. For quantification of MGO, 1 mL aliquots of 10% (w/v) honey solutions 
in 0.5 M phosphate buffer (pH 6.5) were mixed with 300 µL phosphate buffer (pH 6.5) and 
300 µL oPD solution (1% in phosphate buffer pH 6.5). Samples were incubated in the dark at 
room temperature overnight and membrane filtered (0.45 µm). For quantification of DHA, 
1mL aliquots of 10% honey solutions in 0.5 M acetate buffer (pH 4.0) were mixed with 300 
µL acetate buffer (pH 4.0) and 300 µL oPD solution (1% in acetate buffer pH 4.0), followed 
by incubation for 16 h at 37 °C and membrane filtration (0.45 µm). 
HPLC analyses were performed using the HPLC system 1. Peak evaluation was managed 
using the software UNICORN 4.11. The separation of quinoxalines was realized on a 
stainless steel column filled with Eurospher 100 RP18 material (250mm x 4.6 mm, 5 µm 
particle size with integrated pre-column; Knauer, Berlin, Germany). The mobile phase were 
0.075 % acetic acid in water (solvent A) and a mixture of 80% methanol and 20% solvent A 
(solvent B). The gradient started with 40% solvent B for 1 min and was elevated linearly to 
100% B over a period of 20 min, was changed back to 40% B in 4 min and was held there for 
7 min. The flow rate was 0.9 mL/min, the separation was done at 30 °C, 20 µL sample 
solution was injected and peaks were detected by measurement of UV absorbance at 312 nm. 
Quantification was achieved by external calibration with MGO standard solution or by 
standard addition method for DHA. 
 
1.4.6. Quantification of hydrogen peroxide 
In honey the enzyme glucose oxidase catalyzes the formation of hydrogen peroxide and D-
glucono-δ-lactone from glucose. In sulphuric acid solution in the presence of o-dianisidine 
and peroxidase, hydrogen peroxide forms a red complex, which absorbs at 540 nm. 
All honey samples were diluted to 5 % (v/v) in 0.4 M phosphate buffer (pH 6.5). The 
peroxidase stock solution was prepared by diluting 50 mg peroxidase in 5 ml 0.01 M 
phosphate buffer (pH 6.5). The o-dianisidine stock solution was prepared by diluting 50 mg o-
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dianisidine in 50 ml ultrapure water. The reaction mix was prepared by mixing 20 µl of 
peroxidase stock solution and 500 µl of o-dianisidine stock solution in 10 ml 0.01 M 
phosphate buffer (pH 6.5). 40 µl of honey sample solutions were incubated for 1h at 37 °C in 
a microtiterplate (Greiner 96 flat bottom transparent). After 1h, 135 µl of reaction mix were 
added and samples were incubated for exactly 5 min at room temperature. The reaction was 
stopped with the addition of 120 µl sulphuric acid (6 M) and the absorbance at 540 nm was 
measured with a Tecan multimode reader after shaking for 15 s with 6 mm amplitude and 5 s 
waiting time. Evaluation was achieved by using the software Tecan i-control, version 
1.10.4.0. The quantification of the formed amount of hydrogen peroxide was achieved with an 
external calibration. Therefore, six calibration standards with varying H2O2 concentration 
from 0.1 to 8.0 mg/l were prepared in ultrapure water and treated like samples without 
incubation prior to derivatization. A blank containing 40 µl calibration standard or sample 
solution and 135 µl phosphate buffer (0.01 M) instead of reaction mix was included. The limit 
of detection (LOD) and the limit of quantification (LOQ) was measured based on standard 
deviation of the blank (Leiterer, 2008). 
 
1.4.7. Bacterial assay 
The microbiological studies were performed at the Institute of Microbiology at the TU 
Dresden, Germany. The bacterial strains, which were kindly provided by the Institute of 
Microbiology (TU Dresden), are listed in Table 6. If there were no further information about 
the strains available, the corresponding columns are marked with “-“.  
 
Table 6: List of bacteria used for the antibacterial studies 
Organism Bacillus subtilis Escherichia coli 
Pseudomonas 
aeruginosa 
Staphylococcus 
aureus 
Internal 
labeling 
B04 B44 B12 B22 
date 07.09.1995 28.05.1998 07.09.1995 19.05.1998 
genotype Wild type - - - 
Reference 
number 
- ATCC 25922 ATCC 27853 - 
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For all experiments, sterile ultrapure water, chemicals and consumables were used. The 
experimental work was performed at a laminar flow cabinet. Stock cultures stored at -80 °C 
were cultured to produce single colonies on nutrient agar. The nutrient plate was incubated at 
37 °C for at least 18 h. The liquid culturing media was prepared by mixing 1.5 ml yeast 
extract stock solution (300 g/l), 2.5 ml sodium chloride stock solution (100 g/l) and 2.5 ml 
glucose stock solution (200 g/l) and filling it up to 50 ml with sterile ultrapure water. All 
stock solutions were filter sterilized prior to use. In an Erlenmeyer flask, 10 ml of minimal 
media was inoculated with a single colony forming unit (cfu) of the corresponding bacteria, 
followed by subsequent incubation at 37 °C for 6 h in an incubator shaker at 220 rpm. The 
bacterial suspension, which was used for the growth experiments, was prepared by diluting 
the pre-culture 1:50 in minimal media. 
To keep the osmotic effect of the sugar in all samples constant, the honeys were applied as 5 
% (v/v) sugar solution. Therefore, 0.685 g of honey were weighed in and diluted in 5 ml 
minimal media. The resulting 10 % (v/v) solution is later diluted 1:1 in the assay with 
minimal media and bacteria to reach the final 5 %. To vary the amount of honey compounds 
in the assay, the desired quantity of honey was weighed in and the residual amount to reach 
0.685 g was compensated with artificial honey. The solutions were used for antibacterial 
testing after sterile filtration. For manuka honey testing, two manuka honeys from Manuka 
Health NZ Ltd. were used. Both were labelled with “MGO 550+”, whereby one contained 
663 mg MGO/kg and the other one contained 690 mg/kg. To test the effect of hydrogen 
peroxide on bacterial growth an artificial honey was spiked with glucose oxidase. The 
continuous formation of hydrogen peroxide from the reaction of glucose oxidase and glucose 
provides a honey matrix, which resembles natural levels of hydrogen peroxide in honeys. 
More detailed information about the honeys used for the tests are listed in Table 4 and Table 
5. The weighed portions and the final MGO concentrations and hydrogen peroxide formation 
are listed in Table 7 and Table 8. 
 
Table 7: List of weighed portions of manuka honey and final MGO concentration  
 mMGO550+ [g] mAH [g] cMGO [mg/kg]* cMGO [mg/l]** 
1 0.6850 0 690.00 47.27 
2 0.652 0.0330 656.76 44.99 
3 0.6000 0.0850 604.34 41.40 
4 0.5072 0.1778 510.94 34.99 
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5 0.4500 0.2350 435.48 29.83 
6 0.4000 0.2850 387.09 26.52 
7 0.3000 0.3850 290.32 19.89 
8 0.2500 0.4350 241.93 16.57 
9 0.2000 0.4850 193.55 13.26 
10 0.1500 0.5350 145.16  9.94 
11 0.0450 0.6400  43.55  2.98 
12 0.0045 0.6805  4.35  0.30 
* MGO content of the honey determined via RP-HPLC, see 1.4.5; ** in the final assay 
 
Table 8: List of weighed portions of artificial honey with glucose oxidase and final hydrogen peroxide 
formation 
 mAH-GOX [g] mAH [g] cH2O2 [mg/kg*h] * cH2O2 [mg/l*h]** 
1 0.600 0.085 114.4 7.8 
2 0.500 0.185 104.8 7.2 
3 0.400 0.285   89.0 6.1 
4 0.300 0.385   62.9 4.3 
5 0.200 0.485   36.6 2.5 
6 0.150 0.535   16.6 1.1 
7 0.100 0.585    8.2 0.6 
8 0.075 0.610    3.9 0.3 
9 0.050 0.635    1.8 0.1 
10 0.025 0.660    0.2 0.01 
* photometric measurement, see 1.4.6; ** in the final assay 
 
To test the antibacterial activity of α-cyclodextrin alone (CD) and inclusion complexes 
formed by manuka honey and α-cyclodextrin (CP), different concentrations of CD and CP 
were weighed in and solubilised in minimal media. To maintain a constant sugar 
concentration of 5 %, artificial honey was added to the assay. The sugar content of honey in 
CP was subtracted from the amount of added artificial honey. To the samples containing CD 
alone, always 685 mg artificial honey was added. 
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Tabelle 1: List of cyclopower and cyclodextrin weighed portions and final MGO concentration for 
antibacterial tests 
 Cyclopower α-Cyclodextrin 
mCP 
[g] 
mAH  
[g] 
cMGO*  
[mg/l] 
cCD*  
[mg/l] 
mCD 
[g] 
mKH  
[g] 
cCD*  
[mg/l]  
1 0.90 0.2835 19.26 49860 0.50 0.685 50000 
2 0.80 0.3280 17.12 44320 0.42 0.685 42000 
3 0.60 0.4175 12.84 33240 0.36 0.685 36000 
4 0.50 0.4620 10.70 27700 0.28 0.685 28000 
5 0.40 0.5065 8.56 22160 0.24 0.685 24000 
6 0.30 0.5510 6.42 16620 0.20 0.685 20000 
7 0.10 0.6405 2.14 5540 0.15 0.685 15000 
8 0.01 0.6805 0.21 554 0.05 0.685 5000 
* in the final assay 
 
The honey or cyclodextrin solutions, minimal media and bacterial suspension were mixed 
directly in the wells of a sterile 96-well microtiter plate. Every test was performed five times 
for each bacterium and test substance. The final volume of the incubation mix was 100 µl. 
The starting optical density of the assay solution was 0.01 absorption units. The fixed starting 
OD ensured that every well contained the same number of bacteria cells and thus had identical 
starting conditions. The volume of bacterial solution, which needed to be added to the assay, 
was calculated from the OD of the pre-culture according to Equation 1. This needed to be 
calculated prior to every test, because the pre-culture did not always grow uniformly. The 
final assay consisted of the calculated amount of bacterial solution, 50 µl diluted honey or 
cyclodextrin and the additional volume to fill up the 100 µl was made up with minimal media. 
A bacteria control in minimal media only was included also five times for each fresh pre-
culture. 
 
𝑉𝑏𝑎𝑐𝑡𝑒𝑟𝑖𝑎𝑙 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 =
𝑉𝑡𝑜𝑡𝑎𝑙 ∗ 𝑂𝐷𝑡𝑜𝑡𝑎𝑙
𝑂𝐷𝑝𝑟𝑒−𝑐𝑢𝑙𝑡𝑢𝑟𝑒 1:50
 
 
Equation 1: Calculation of volume of bacterial solution in the assay. 
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The microtiter plate was sealed with a sterile, gas-permeable membrane and incubated in 
multimode reader at 37 °C for 20 h. Every 30 min, the absorption at 600 nm was read. 
Between the readings, the microtiter plate was shaken with amplitude of 3 mm. The data 
evaluation was achieved with the software Tecan i-control, version 1.1.9.0.  
 
1.4.8. Hydrogen peroxide cleavage 
To test whether the bacteria are able to cleave hydrogen peroxide to oxygen and water, 
bacterial cells were suspended in a 3 % hydrogen peroxide solution with a sterile toothpick. 
The formation o bubbles indicate the presence of enzymes, which are able to cleave H2O2. A 
catalase-positive B. subtilis strain served as a positive control and a catalase-negative E. coli 
strain served as a negative control. Both strains were kindly provided by Mrs. Buchwald from 
the strain bank of the Institute for Microbiology, TU Dresden.  
 
1.4.9.  Quantification of “growth delay” 
 
The growth curves, which were obtained with the bacterial assay, were analysed with the 
determination of the corresponding growth delay (GD) of each inhibitor compared to the 
control sample. In the presented thesis, bacterial growth was defined when the OD was ≥ 
0.05. The calculation of the start of bacterial growth was achieved by fitting the growth curves 
with the Boltzmann equation and calculating the x value (time) for y (OD) = 0.05. The 
corresponding growth delay for the inhibitor concentration x (GDx) was obtained by dividing 
the starting time of growth of the inhibited sample with the starting time of growth of the 
control sample (see Equation 2). 
 
𝐺𝐷𝑥 =
𝑡𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟 (𝑂𝐷 0.05)
𝑡𝑐𝑜𝑛𝑡𝑟𝑜𝑙 (𝑂𝐷 0.05)
 
 
Equation 2: Calculation of growth delay (GD) for inhibitor concentration x. 
 
The GD of an inhibitor was plotted against the corresponding concentration and an 
exponential dose-response curve was obtained. Linearization of dose-response curves was 
achieved by plotting the logarithm of the GD against the inhibitor concentration. The 
inhibitors were compared with the help of the slope of their linear fitting curves. In contrast to 
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the determination of MIC values, an interpolation between the readings is possible now. In 
general, the higher the slope of a curve, the stronger is the bacteriostatic effect of an inhibitor.  
 
1.4.10. Determination of bactericidal concentrations 
To test whether an antibacterial effect is of bacteriostatic or bactericidal nature, 70 µl of the 
assay solutions, which did not show any growth after the end of incubation, were incubated 
on fresh, solid nutrient agar plates at 37 °C for 24 h. The cells which were incubated with 
artificial honey only and grew well in the assay, were carried along as a negative control. 
Cells, which were incubated with the antibiotic ampicillin were tested as positive controls. 
The cfu were counted after 24 h and the corresponding honey concentrations of plates without 
any bacterial growth were characterised as bactericidal. 
 
1.4.11. Inhibition of Helicobacter pylori 
The H. pylori pre-culture was obtained from the Deutsche Sammlung für Mikroorganismen 
und Zellkulturen (DSMZ). The DSM number was 21031 and a freeze-dried culture along with 
an active culture was ordered. The reactivation of the freeze-dried culture was achieved 
according to the manufacturer’s information. To study the inhibition of H. pylori with honey, 
a pre-culture of H. pylori on a blood agar plate, which was incubated at 37 °C in a 
microaerophilic environment for 96 h was prepared. The cells of the pre-culture were re-
suspended in brucella broth media, which was brought to pH 2 and pH 7 with HCl. The cell 
number in the inoculums was counted with Thoma cytometers und the microscope. For 
incubation, 60 µl of the cells were further diluted with 200 µl of either brucella broth media 
(serves as a control) or honey solutions (inhibition samples) in a microtiter plate. The plate 
was incubated at 37 °C and microaerophilic conditions and the optical density (OD) of the 
cells at 600 nm was read after 0, 24, 48 and 96 h. Honey was tested in concentrations ranging 
from 0.75 to 30 %, acetohydroxamic acid was tested in concentrations from 1 to 5 mg/l, MGO 
from 5 to 250 mg/l, DHA from 10 to 500 mg/l and cyclopower in concentrations from 0.75 to 
10 %. Since the OD did not change during the incubation, samples were taken from the 
microtiterplate and cultured on fresh blood agar plates after serial dilution. The blood agar 
plates were incubated at 37 °C in a microaerophilic environment for 48 h and cfu were 
counted on appropriately diluted plates. Aliquots of the microtiterplate incubation samples 
were also taken for analysis of MGO and lactate. For MGO analysis, the liquid incubation 
samples were centrifuged and 100 µl of cell supernatant were derivatized according to the 
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MGO derivatization procedure (see section 1.4.5). For lactic acid analysis, the liquid 
incubation samples were centrifuged and 100 µl of cell supernatant was analyzed with a D-/L-
lactic acid kit (R-Biopharm, Darmstadt, Germany). The kit is based on the reaction of D-/L-
lactic acid with D-/L-lactate dehydrogenase to form pyruvate and NADH+H+, which can be 
detected photometrically at 340 nm. 
 
1.4.12. Studies on the structure of cyclodextrin inclusion complexes 
Model complexes containing honey compounds and α-cyclodextrin were prepared according 
to the protocol for the pilot scale production of “MGO 400+ Manuka Honey with 
CyclopowerTM” (Manuka Health NZ Ltd., 2013) with slight modifications. Briefly, 10 ml 
ultrapure water was heated to 50 °C and 1 mmol of α-CD was added. The turbid solution was 
stirred for 10 min and cooled down to 40 °C. The honey compounds (MGO or DHA) or the 
control compounds (1-propanol or hydroxyacetone) were added in the ratio presented in Table 
9 and the solution was stirred for exactly ten minutes. The mixture was subsequently frozen 
and lyophilized. The lyophilized complexes were stored at -20 °C. As a negative control, 
starch and glucose instead of α-cyclodextrin were used to prepare complexes with MGO and 
DHA. Approximately 80 mg of each complex was solubilised in 700 µl D2O and analysed 
with 1H-NMR. All 1H-NMR spectra were recorded at a Bruker Avance III 600 device with a 
central frequency of 600 MHz. The chemical shift is referenced to tetramethylsilane (TMS) 
resonance at 0 ppm. For visualization of spatial interactions between protons, ROESY-NMR 
was used. All spectra were acquired and processed using Topspin software (Bruker). 
 
Table 9: Model complexes 
Model complex Consists of Molar ratio 
MGO-CD MGO and α-cyclodextrin 1:1 
DHA-CD DHA and α-cyclodextrin 1:1 
MGO-DHA-CD MGO, DHA and α-cyclodextrin 1:2:1 
MGO-DHA-Glc MGO, DHA and glucose 1:2:1 
MGO-Starch MGO, DHA and starch 1:2:1 
PrOH-CD 1-propanol and α-cyclodextrin 2:1 
HA-CD Hydroxyacetone and α-cyclodextrin 3:1 
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1.4.13. Enzyme inhibition with manuka honey 
 
1.4.13.1. Urease activity assay 
The commercial jack bean urease was solubilized in ultrapure water (80 kU/l). To measure the 
enzyme activity, 25 µl of urease solution were mixed with 10 µl ninhydrin (2 % (w/w) in 
ethanol), 90 µl phosphate buffer (200 mM, pH 6.8) and 100 µl ultrapure water in a 96-well 
microtiter plate. The mixture was pre-incubated at 37 °C for 2 hours. The reaction was started 
by adding 50 µl of urea solution (550 mM in ultrapure water). For the enzyme working at its 
maximum velocity, the final urea concentration for the assay was set to 100 mM, which is 
approximately 5 times the Michaelis-Menten constant (see below). The microtiter plate was 
further incubated at 37 °C for 80 min and the detection of ammonia released from urea 
cleavage was continuously monitored by measuring the absorption at 440 nm with a 
multimode reader Tecan Infinite M200 (Mainz, Germany). A blank with 50 µl ultrapure water 
instead of the substrate urea was included in the assay to test whether ninhydrin reacts with 
any other compounds than ammonia to form a yellow complex which absorbs at 440 nm. 
Urease activity was defined as the linear slope of absorbance between 10-30 min of 
incubation.  
 
1.4.13.2. Urease inhibition assay 
To measure the inhibition of the enzyme activity caused by honeys, methylglyoxal or 
dihydroxyacetone, respectively, 25 µl of urease solution were mixed with 10 µl ninhydrin 
(2 % (w/w) in ethanol), 90 µl phosphate buffer (200 mM, pH 6.8) and 100 µl of the solution 
of the inhibitory compound in a 96-well microtiter plate. The mixture was pre-incubated at 37 
°C for 2 hours and the reaction was started by adding 50 µl of the substrate urea solution (550 
mM in ultrapure water). The microtiter plate was further incubated at 37 °C for 80 min and 
the detection of ammonia release from urea cleavage was continuously monitored by 
measuring the absorption at 440 nm with a multimode reader Tecan Infinite M200 (Mainz, 
Germany). A blank of each inhibitory compound without urease but 25 µl ultrapure water 
instead was included in the assay to test for any interfering substances which absorb at 440 
nm. Urease activity was defined as the linear slope of absorbance between 10-30 min of 
incubation. The results are expressed as a percentage of the residual activity measured in the 
presence of an inhibitor compared to the urease activity of a control (water) sample. 
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1.4.13.3. Inhibitory test compounds 
Lime, honeydew, canola and artificial honey, as well as four manuka honeys with MGO and 
DHA contents classified as low, medium, high and very high (see Table 4) were analysed for 
their inhibitory effect. Hydrogen peroxide, which is formed via enzymatic glucose oxidation 
in diluted honey, inhibits the ninhydrin-ammonia reaction, what leads to apparently decreased 
activities. Therefore, hydrogen peroxide was eliminated by the addition of 20 µl catalase to 
each honey stock solution (75 % w/v). The honey stock solutions were diluted with ultrapure 
water to reach a final concentration of 0.04, 0.4, 1.8, 5.5, 10.9, 16.4, 21.8 and 27.3 % (w/v) in 
the assay. Eight concentrations ranging between 0.4 to 83.3 and 0.2 to 44.4 mM of 
methylglyoxal (MGO) and dihydroxyacetone (DHA), respectively, were tested for their 
inhibitory effect. Acetohydroxamic acid (AHA) was used as a positive control according to 
(Tanaka et al., 2004) and tested in eight concentrations ranging between 1.9 and 400.0 µM. 
All tested substances were diluted in ultrapure water. Canola honey was artificially spiked 
with MGO and DHA by adding 114 µl of a MGO stock solution (39.2 g/l) and 1 ml of a DHA 
stock solution (12.0 g/l) to 7.5 g honey in 10 ml ultrapure water. The aqueous solution with 
MGO and DHA was prepared as the spiked canola honey, but without honey addition. To 
eliminate the effect of MGO in manuka honey, glutathione (GSH) and glyoxalase were added 
in a final concentration of 0.5 mM and 141 mU/ml to the 75 % (w/v) stock solution of 
manuka honey sample MH 3, respectively. The honey sample MH 3 was a commercial 
manuka honey MGO 400+ with a MGO content of 595 mg/kg (determined with RP-HPLC-
UV). 
 
1.4.13.4. Determination of Michaelis-Menten constant 
To determine the affinity of urease to the substrate urea, the urease assay conditions 
mentioned above were used. The velocity of the reaction was measured using eight different 
concentrations of the substrate urea (15-100 mM) and a constant enzyme concentration in the 
absence of inhibitors. 
 
1.4.13.5. Chromatographic quantification of ammonia 
In order to check values obtained from photometric quantitation of ammonia, data were 
compared with results obtained from quantitation via an amino acid analyser based on ion-
exchange chromatography and post-column derivatization with ninhydrin. The ammonia 
content of the samples was further quantitated chromatographically. For this, incubation of 
urease with or without inhibitory substances was conducted without the addition of ninhydrin. 
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Volume correction was achieved by adding 10 µl phosphate buffer (100 µl phosphate buffer 
in total) instead of ninhydrin solution. Urease was pre-incubated with the inhibitors 2 h prior 
to start of the reaction with substrate addition (50 µl urea, 550 mM). The samples were further 
incubated for 30 min and directly diluted 1:250 with lithium citrate buffer (0.12 N, pH 2.2) to 
stop the enzymatic reaction. The analyses were performed using a SYKAM S4300 amino acid 
analyser (Fuerstenfeldbruck, Germany) with conditions according to manufacturer’s 
instructions. Ammonia eluted at 59.6 min and was detected after post-column derivatization 
with ninhydrin at 570 nm. External calibration with ammonia standards was performed. 
 
1.4.13.6. Further enzyme activity assays 
To show that urease was specifically inhibited and other enzymes are less affected by 
methylgoyxal and dihydrocyacetone, two exemplary, physiologically relevant enzymes were 
tested for their inhibition with MGO and DHA. 
Pepsin activity was measured in the presence and absence of MGO or DHA, respectively, 
according to (Minekus et al., 2014). All reagents were solubilised in ultrapure water unless 
otherwise stated. Trichloroacetic acid (TCA) was diluted to 5 % (w/w) and MGO stock 
solution was diluted to 4mM. DHA was solubilised and diluted to a final concentration of 7 
mM. 0.5 g of the substrate haemoglobin was diluted in 20 mL of ultrapure water and further 
diluted with 5 ml HCl (300 mM) to reach a final concentration of 2 % (w/v) with a pH of 2. 
For the pepsin stock solution, 20 mg of pepsin was diluted in 20 mL NaCl solution (150 mM). 
To prevent autolysis, the pH was brought to 6.5 with 100 mM NaOH. The pepsin stock 
solution was diluted 1:10 in 100 mM HCl freshly for each test. Inhibitor solutions and diluted 
pepsin were pre-incubated at 37 °C for 2 h. The reaction was started with the addition of 
haemoglobin substrate and the reaction mixture was incubated for exactly 10 min at 37 °C. 
The reaction was stopped with the addition of TCA, followed by centrifugation at 10,000 rpm 
for 10 min. 200 µl of the supernatant were transferred in a UV-star microtiter plate (from 
Greiner) and UV absorbance at 280 nm was measured with a multimode reader Tecan Infinite 
M200 (Mainz, Germany). A blank, containing no enzyme but inhibitor and substrate, was 
included in the assay and subtracted from the inhibitor sample and control sample. The results 
are expressed as a percentage of the residual activity measured in the presence of an inhibitor 
compared to the pepsin activity measured for a control sample. 
ACE activity assay in the absence or presence of methylglyoxal (MGO) or dihydroxyacetone 
(DHA) was carried out according to Lunow et al. (2015). Briefly, the ACE-induced cleavage 
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of the fluorescence resonance energy transfer (FRET) substrate Abz-FRK(Dnp)P-OH was 
continuously monitored by measuring the fluorescence at λex/λem = 320/420 nm for 60 min at 
37° C with a multimode reader Tecan Infinite M200 (Mainz, Germany). MGO stock solution 
was diluted to give a final concentration of 4 mM. DHA was dissolved and diluted in Tris-
HCl buffer to a final concentration of 7 mM. Inhibitor solutions and ACE were pre-incubated 
at 37 °C for 2 h. The reaction was started with the addition of the FRET-substrate and 
substrate cleavage control samples, which correspond to 100 % activity, were prepared by 
adding Tris-HCl buffer instead of inhibitor solutions to the enzyme. A blank, containing no 
enzyme but inhibitor and substrate, was included in the assay and subtracted from the 
inhibitor sample and control sample. The results are expressed as a percentage of the residual 
activity measured in the presence of an inhibitor compared to the ACE activity measured for a 
control sample. 
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1.5. Results and discussion 
 
1.5.1. Antibacterial compounds in honey 
Honey is used as an antibacterial wound dressing since ancient time (Eteraf-Oskouei and 
Najafi, 2013). In the past, the antibacterial effect of honey was attributed to osmotic pressure, 
its acidic pH value or lysozyme and other minor compounds (Mandal and Mandal, 2011). 
This section will focus on two of the most potent antibacterial ingredients in honey: hydrogen 
peroxide and methylglyoxal.  
The results of this section are partly originating from the experimental work of master student 
Constanze Polster and were primarily published in her master thesis (Polster, 2015).  
 
1.5.1.1. Hydrogen peroxide formation in honeys 
To evaluate the antibacterial effect due to hydrogen peroxide, it was necessary to measure the 
hydrogen peroxide formation in honeys. H2O2 is formed enzymatically in honey by the 
oxidation of glucose to glucono-δ-lactone with the bee-derived enzyme glucose oxidase. Due 
to the low water activity in undiluted honey and its acidic pH, the activity of glucose oxidase 
is rather low and thus, the formation of hydrogen peroxide in undiluted honey is negligible 
(White et al., 1963). Only after dilution of honey, the enzyme gets active and hydrogen 
peroxide is formed, which can act antibacterial. The measurement of hydrogen peroxide was 
carried out according to 1.4.6. Briefly, aqueous honey solutions were incubated to produce 
hydrogen peroxide, which was photometrically quantified at 540 nm after the reaction with o-
dianisidine and peroxidase under acidic conditions. The limit of detection (LOD) was 0.9 
mg/kg*h and the limit of quantification was 2.7 mg/kg*h (determined according to 1.4.6). 
The hydrogen peroxide formation of four commercial honeys is presented in Table 10. 
 
Table 10: Hydrogen peroxide formation of commercial honey samples, results are expressed as mean 
values of triplicate measurement with standard deviation 
Honey Manuka MGO 400 Manuka MGO 550 Lime honey Polyfloral honey 
H2O2 
mg/kg*h 
7.1 ± 0.8 3.9 ± 0.3 66.7 ± 0.6 6.1 ± 1.3 
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The hydrogen peroxide formation of the two manuka honeys can be classified as low. Manuka 
honeys are known to produce relatively low amounts of hydrogen peroxide (Kwakman et al., 
2011a; Müller, 2013), which might be due to reduced glucose oxidase activity in the presence 
of methylglyoxal (Majtan et al., 2013). In contrast, the tested non-manuka honeys gave a 
diverse picture: the lime honey formed around 10-fold higher amounts of hydrogen peroxide 
than the manuka honeys, whereas the polyfloral honey formed the same low hydrogen 
peroxide level as the manuka honeys. All honeys were tested after 1 h incubation as 5 % (v/v) 
solutions. The dilution plays an important role for the comparison of hydrogen peroxide levels 
in honey, since the activity of glucose oxidase depends on the water activity and thus 
increases with higher dilution. Moreover, highly diluted honey solution contain less 
substances, which counteract with hydrogen peroxide production through degradation 
reactions, leading to apparently higher H2O2 values (White et al., 1963; Molan, 1992a). The 
incubation conditions were the same for all honey samples tested in this study, so the varying 
levels of H2O2 are solely due to plant-derived characteristics. The hydrogen peroxide 
formation can be influenced by the botanical origin of the plant, climate conditions or 
environmental factors. Commercial processing and especially heat treatment can also 
significantly influence the hydrogen peroxide formation in honey (Chen et al., 2012). Since 
there was no information available about the treatment of the commercial honeys tested in this 
study, it was difficult to define factors responsible for the formation of hydrogen peroxide 
presented here. To exclude unpredictable influences on H2O2 formation in honey, an artificial 
honey containing sugars only and the enzyme glucose oxidase (from Aspergillus niger) was 
prepared by spiking an artificial honey with 50 µg glucose oxidase per g honey, resulting in a 
specific activity of 2.4 U/g honey. The stock honey, named AH-GOX, was subsequently 
diluted with artificial honey (AH) to obtain seven model honeys with varying glucose oxidase 
concentrations (7-50 µg/g and 0.3-2.4 U/g). The model honeys were diluted to 5 % (v/v) with 
buffer and after 1 h incubation at 37 °C, the hydrogen peroxide formation was measured. 
Figure 4 shows the hydrogen peroxide formation of each AH-GOX dilution dependent on its 
GOX activity. 
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Figure 4: Hydrogen peroxide production in artificial honeys with varying activity of glucose oxidase, 
single determination in 5 % (v/v) solutions 
 
The hydrogen peroxide formation in the artificial honeys increased with increasing GOX 
activity. The seven model honeys with varying GOX concentrations produced between 8 and 
115 mg H2O2/kg honey after 1 h incubation. Until a GOX activity of 1.6 U/g honey, the 
hydrogen peroxide formation correlated linearly with the enzyme activity. At enzyme 
activities higher than 2.0 U/g honey, the H2O2 formation reached saturation and no further 
increase of hydrogen peroxide was observable. Since glucose, the educt of the reaction is 
abundantly available, a continuous increase of H2O2 concentration was expected. The 
flattening of the curve is a sign for an inhibition of the enzymatic reaction. This could be due 
to inhibition of glucose oxidase by one of the reaction products. Glucono-δ-lactone acts as a 
weak inhibitor of glucose oxidase by docking into the catalytic centre of the enzyme 
(Nakamura and Ogura, 1962; Gibson et al., 1964). Moreover, hydrogen peroxide was 
identified to inhibit glucose oxidase of Aspergillus niger (Kleppe, 1966; Buchholz and 
Goedelmann, 1978). Hydrogen peroxide is a strong oxidative reagent, which can modify 
amino acid residues of proteins. Kleppe (1966) discusses the oxidation of methionine residues 
of glucose oxidase close to the catalytic centre of the enzyme and the subsequent loss of 
enzymatic activity. It was concluded that high amounts of hydrogen peroxide can decrease 
enzyme activity and thus lead to stagnation of the hydrogen peroxide formation in the AH-
GOX model. 
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1.5.1.2. Influence of methylglyoxal on hydrogen peroxide formation in honey 
The reactive compound methylglyoxal may react with enzymes and influences its enzymatic 
activity (Rabbani and Thornalley, 2008). The remarkably low levels of hydrogen peroxide 
formation in manuka honeys indicate that methylglyoxal may modify honey-derived glucose 
oxidase and thus decrease hydrogen peroxide accumulation in manuka honeys. This 
hypothesis was earlier expressed by Majtan et al. (2013), who described a dose-dependent 
effect of artificially added methylglyoxal to honeys on hydrogen peroxide accumulation. 
Moreover, the authors observed cross-linking of glucose oxidase after 48 h incubation with 
methylglyoxal, which might decrease enzymatic activity. To test, whether methylglyoxal is 
responsible for low levels of hydrogen peroxide formation, a non-manuka honey (lime honey) 
was mixed in a 1:1 ratio with either sugars only (AH), methylglyoxal and sugars (AH-MGO) 
or manuka honey MGO 400+. The blends were diluted to 5 % (w/v) and hydrogen peroxide 
production was analysed according to 1.4.6. The samples were incubated for 1 h at 37 °C 
prior to detection of hydrogen peroxide. The H2O2 formation of the blends are shown in Table 
11. 
 
Table 11: Hydrogen peroxide formation of lime honey blends, results are expressed as mean values of 
triplicate measurement with standard deviation 
Honey 1 Lime honey Lime honey Lime honey Manuka honey 
Honey 2 AH AH-MGO Manuka honey AH 
H2O2 
mg/kg*h 
32.1 ± 0.6 33.7 ± 1.6 36.4 ± 3.3 5.4 ± 0.7 
 
There was no significant decrease of hydrogen peroxide formation after the incubation of lime 
honey with methylglyoxal compared to the incubation of lime honey with sugars only (AH). 
The results suggest that after 1 h aqueous incubation, bee-derived glucose oxidase activity 
was not influenced by methylglyoxal. This is in accordance with Majtan et al. (2013), who 
neither detected a significant decrease of hydrogen peroxide production nor any cross-links of 
glucose oxidase after 2 h incubation at 37 °C. Only after 24-48 h aqueous incubation, a 
significant change of enzyme activity and molecular structure became detectable. The reason 
why both test systems failed to present any influence of MGO on glucose oxidase may be that 
the artificial adding of MGO to honey does not decently reproduce natural MGO formation in 
honey. Plant nectar contains up to 80 % water, which is evaporated during honey ripening in 
the comb down to a water content of 16-20 % in the final honey (Semkiw et al., 2008). This 
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process takes approximately 3-5 days at temperatures of 30-35 °C. These are optimal 
conditions for glycation reactions, which could lead to enzymatic inhibition of glucose 
oxidase in the commercial honey. For example, dihydroxyacetone, which is present in high 
concentrations in manuka nectar, is known for its ability to react with proteins (Molin et al., 
2007). Moreover, Bilova et al. (2016) were able to show, that advanced glycation endproducts 
(AGE) are formed in plants and can be transported into plant tissue. The main glycating 
agents were identified to be phosphorylated sugars or triose phosphates. Because of the poor 
reaction conditions in honey (low water activity and slightly acidic) it is more likely that 
glycation reactions occur during earlier stages of honey formation, e.g. in the plant phloem or 
during nectar harvest by the bees. Nevertheless, it is also possible that hydrogen peroxide 
formation is rather low in manuka honey because the honey contains lower amounts of the 
enzyme glucose oxidase. According to Azeredo et al. (2003), the protein content of honey 
depends on the floral and geographical origin. Besides glucose oxidase, honey contains the 
enzyme catalase which catalyzes the reaction of hydrogen peroxide to water and oxygen. The 
ratio of both enzymes in honey ultimately determines its hydrogen peroxide level. Until now, 
no quantitative data of catalase and glucose oxidase activity in manuka honey is available.  
 
1.5.1.3. Methylglyoxal 
Methylglyoxal (MGO) is only present in honey varieties from the plant family 
Leptospermum. It was described in New Zealand manuka honey (Leptospermum scoparium) 
for the first time (Mavric et al., 2008), but it was recently also found to be present in honeys 
from Australia (Windsor et al., 2012; Cokcetin et al., 2016). Honeys with increased levels of 
MGO belonged to the species L. continentale, L. liversidgei and especially to L. 
polygalifolium. Methylglyoxal in honey is stable towards light and heat (Molan and Russell, 
1988). Moreover it was shown that the antibacterial effect of manuka honey was not affected 
by increasing the pH to 11 or storing the honey over 7 years at 4 °C (Bogdanov, 1997; 
Cokcetin et al., 2016). The varying levels of MGO in Leptospermum honey are caused by a 
wide concentration range of its precursor compound dihydroxyacetone in the plant nectar 
(Williams et al., 2014; Norton et al., 2015). The reason for the high variations of DHA is 
unknown. Effects of the environment or climate have been discussed (Williams et al., 2014). 
In commercial honeys, the MGO level is relatively stable during storage. Figure 5 shows the 
MGO and DHA concentration of a manuka honey with a starting concentration of 6 and 12 
mmol/kg, respectively, during storage at room temperature over 90 days. There is a loss of 1 
Chapter A           37 
 
 
 
mmol/kg of DHA whereas the MGO level rises by 0.5 mmol/kg. The missing 0.5 mmol/kg 
could have reacted with other honey compounds, whereby it is not clear, whether DHA is 
initially dehydrated to MGO, which continues reacting or if DHA reacts with other honey 
compounds independently from MGO. Nevertheless, in comparison to hydrogen peroxide, 
MGO can be classified as a chemically stable compound in the honey matrix. 
 
 
 
Figure 5: Concentration of methylglyoxal (MGO) and dihydroxyacetone (DHA) during 90 days 
storage at room temperature, results are expressed as mean values of duplicate measurement 
 
1.5.2. The antibacterial effect of honey 
The level of antibacterial activity in honey is highly variable and mostly depends on its floral 
source, processing and storage conditions. Antibacterial activity, which remains in honey after 
neutralization of hydrogen peroxide, is commonly referred to as “non-peroxide activity” 
(NPA) (Cokcetin et al., 2016). NPA was first identified in honey from New Zealand’s 
Leptospermum species (Molan and Russell, 1988; Allen et al., 1991). Until now, there exists 
no method to quantitatively compare PA and NPA in honey. The aim of this study was to 
evaluate the effect of manuka honey containing methylglyoxal and artificial honey, which 
produces hydrogen peroxide, on four different bacteria species. Eventually, a statement 
concerning the effectiveness of hydrogen peroxide in comparison to methylglyoxal in honey 
should be given. 
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1.5.2.1. Bacterial growth curves  
To evaluate the effect of methylglyoxal and hydrogen peroxide in honey on bacterial growth, 
all tests were performed in solutions containing 5 % (w/v) sugars. In higher dilutions of 
honey, this amount was achieved by adding the additional amount of artificial honey (see 
Table 7 and Table 8). All dilutions were prepared in minimal medium and the assay was 
performed according to 1.4.7. The bacterial suspensions were incubated with different 
inhibitory solutions at 37 °C for 16 h. During that time, a photometric measurement of the 
optical density (OD) at 600 nm was performed every 30 min. The increase of OD indicates 
bacterial growth. Figure 6 shows the growth of Escherichia coli in media alone or in the 
presence of 5 % (v/v) artificial honey. Both controls were always included in every assay. The 
control of bacteria in media alone was carried out to test the overall conditions of the bacteria 
and the control in 5 % (v/v) artificial honey was used to calculate the growth delay of the 
inhibitor solutions.  
 
Figure 6: Growth curve of Escherichia coli in media alone, with artificial honey or manuka honey 
MGO 250+. Samples were incubated for 17 h at 37 °C. 
 
Since the control with media alone contains no substances which could limit E. coli growth, 
this growth curve can be considered as optimal growth under the present conditions. After 2 h 
the bacteria leave the lag phase and enter exponential growth phase. After approximately 
seven hours, the maximum cell density is reached and no further growth occurs. At a 
concentration of 5 % (v/v) artificial honey and its osmotic effect does not influence the 
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growth of E. coli. In general, a bacteriostatic effect of artificial honey on all four tested 
bacteria was only detectable in concentrations above 20 % (v/v) (data not shown).  
The presence of manuka honey delays the onset of bacterial growth. The cells incubated with 
5 % (v/v) manuka honey MGO 250+ started growing after approximately 6 h, which is 4 h 
later than the control samples. Nevertheless, when the cells incubated with manuka honey 
entered the log phase of growth, they reached the same OD as the control sample, which 
indicates that the growth is delayed but not hindered completely. The incubation of bacteria 
cells in liquid media is an advantage compared to other established microbiological tests like 
the agar well or agar disc diffusion assay. In these tests, the inhibitory substance needs to 
diffuse through the media to interact with bacteria. Especially large molecules or viscous 
solutions can hamper these processes. Thus, incubation in liquid media reduces diffusion 
problems and the concentration of inhibitory substance is more homogenous. The continuous 
photometric measurement of the optical density is also a better way to study bacterial 
inhibition compared to detecting the growth after only one certain time point. With regard to 
the above mentioned growth curves of E. coli, when the OD would have been measured after 
11 h incubation only, there would be no difference in the effect of artificial honey or manuka 
honey (see Figure 6). This could lead to an underestimation of the effect, which can be 
avoided by measuring the growth curve instead of measuring the OD at only one time point. 
Moreover, the presented assay allows studying various concentrations of inhibitory 
substances and enables the determination of dose-response curves. The effect of different 
antibacterial substances in honey will be discussed in the following sections in detail. 
 
1.5.2.2. The antibacterial effect of hydrogen peroxide 
To study the antibacterial activity of hydrogen peroxide, dose-response curves for varying 
levels of H2O2 were determined. Therefore, the artificial honey which contained glucose 
oxidase (AH-GOX) was diluted with artificial honey (AH) to yield different amounts of 
hydrogen peroxide in the assay. The final H2O2 formation varied between 4 to 114 mg/kg*h 
(see 1.4.7). In lime honey, which is described as a hydrogen peroxide-rich honey (Molan, 
1992b; Müller, 2013), 67 mg H2O2/kg*h was formed. Thus the model honey AH-GOX can be 
used to cover a wide range of hydrogen peroxide formation in honey. Figure 7 shows the 
dose-response curve of two gram-positive bacteria, namely S. aureus and B. subtilis and two 
gram-negative bacteria, namely E. coli and P. aeruginosa, against hydrogen peroxide. 
Hydrogen peroxide had a bacteriostatic effect on all bacteria, except B. subtilis. The growth 
delay (y-axis) was referenced to a 5 % (v/v) solution of sugars (AH). Therefore, a GD of 1 
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means the antibacterial compound has no stronger effect than a 5 % (v/v) solution of sugar. 
The dose-dependent effect of antibacterial compounds is reflected by an increase of the GD 
value. On the x-axis, the corresponding H2O2 concentrations of the model honeys (AH-GOX 
± AH) are shown. The figure on the right side shows the linearization of GD by plotting the 
logarithm of the GD against the corresponding hydrogen peroxide formation. The red stars 
indicate the growth delay caused by lime honey. The inhibition values of the lime honey fitted 
well to the dose-response curves obtained with the model honey AH-GOX, which shows that 
the model honey is suitable to simulate hydrogen peroxide formation in honey.   
 
 
Figure 7: Dose-response curve of hydrogen peroxide towards S. aureus, B. subtilis , E. coli and P. 
aeruginosa before and after linearization. GD of hydrogen peroxide was referenced to 5 % (v/v) AH 
solution. Red stars indicate GD caused by 5 % (v/v) lime honey with 67 mg H2O2/kg*h. 
 
According to the dose-response curves, the influence of hydrogen peroxide on bacterial 
growth differd markedly between the four bacteria species. B. subtilis was the only 
microorganism tested, which was not inhibited by hydrogen peroxide over a honey relevant 
concentration range. The other bacteria showed a concentration-dependent growth delay. The 
sensitivity of the species towards H2O2 can be described with the following ranking: 
 
S. aureus >> P. Aeruginosa > E. Coli 
 
S. aureus was already inhibited in the presence of very low levels of hydrogen peroxide. A 
5 % (v/v) solution of the model honey with a hydrogen peroxide formation of 16.6 mg/kg*h 
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was able to delay S. aureus growth by 4 times compared to a 5 % (v/v) sugar solution. 
Hydrogen peroxide levels like this can easily be achieved in natural honeys (Bang et al., 2003; 
Majtan et al., 2013). In contrast, B. subtilis, which is also a gram-positive bacterium, was not 
inhibited by hydrogen peroxide in the tested concentration range. Previous studies showed, 
that some B. subtilis mutants can be resistant to hydrogen peroxide (Hartford and Dowds, 
1994). The resistance is due to an over expression of enzymes, which decompose hydrogen 
peroxide, like catalase and alkyl hydroperoxide reductase, and thus inactivate it. The four test 
bacteria were studied for their ability to cleave hydrogen peroxide (see 1.4.8). Both B. subtilis 
and E. coli were able to cleave hydrogen peroxide, whereas S. aureus and P. aeruginosa 
lacked this ability. This explained the reduced sensitivity of B. subtilis and E. coli towards 
hydrogen peroxide in the bacterial assay. In the presence of a model honey with a hydrogen 
peroxide formation of 114 mg/kg*h, E. coli growth was delayed by factor 2. To reach this 
H2O2 level, a honey either needs to have a high formation capacity of hydrogen peroxide or 
the bacteria need to be incubated over a very long time with a honey with a moderate 
hydrogen peroxide formation. In consideration of the application of honey as a wound 
dressing, an incubation time of 24 h is possible. For other applications, like oral ingestion, this 
incubation time is rather unlikely. Bacteria without enzymes, which can cleave hydrogen 
peroxide are more sensitive to its antibacterial effect. Hydrogen peroxide is a strong oxidant, 
which can form hydroxyl radicals in the presence of metal ions (Brudzynski et al. 2011; 
Molan 1992a). The incubation of bacteria with hydrogen peroxide can lead to damage of the 
cell wall, proteins or even DNA. This results in cell lyses and thus reduced or completely 
inhibited bacterial growth (Davies, 1999; Finnegan et al., 2010). A protection mechanism can 
be the expression of enzymes, located in the cell wall, which can scavenge free radicals and 
thus prevent oxidative damage. Hence, the ability of bacteria to cope with hydrogen peroxide 
is an indication of its sensitivity towards oxidative stress in general (Brudzynski et al., 2011). 
To compare the sensitivity of the tested bacteria towards hydrogen peroxide, the slopes of the 
linearized dose-response curves were calculated and are shown in Table 12.    
 
Table 12: Slopes of dose-response curves when growth delay is plotted logarithmically against 
hydrogen peroxide formation in mg/kg*h 
Bacterium S. aureus B. subtilis E. coli P. aeruginosa 
Slope 0.078 0.001 0.005 0.012 
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The slope values confirmed the observation that S. aureus is the most sensitive bacterium 
towards hydrogen peroxide, followed by P. aeruginosa and to a lesser extent E. coli. To get a 
better idea of the effect of H2O2 on different bacteria, the hydrogen peroxide formation, which 
would be necessary to delay bacterial growth 5-fold stronger than a 5 % (v/v) sugar solution 
was calculated. The results are shown in Table 13.    
 
Table 13: Calculated hydrogen peroxide formation in honey, which would inhibit bacterial growth 5-
fold stronger than a 5 % (v/v) sugar solution. n.d. stands for not determinable 
Bacterium S. aureus B. subtilis E. coli P. aeruginosa 
H2O2 (mg/kg*h) 
to reach GD of 5 
18 n.d. 311 130 
 
According to previous results, which studied hydrogen peroxide formation in different honeys 
(Müller, 2013), the only honey relevant level would be the one necessary to inhibit S. aureus. 
All other hydrogen peroxide formation levels were higher than natural levels in honey. Hence, 
the bacteriostatic effect of hydrogen peroxide is varying towards different bacteria species. In 
honey-relevant concentrations, hydrogen peroxide was only effective against S. aureus. 
 
1.5.2.3. The antibacterial effect of methylglyoxal 
To study the antibacterial activity of MGO in honey, a commercial manuka honey (MGO 
550+) with a high MGO content of 690 mg/kg was diluted with artificial honey to obtain 
varying concentrations of MGO. 5 % (v/v) solutions of the diluted manuka honey were tested 
for their inhibitory effect on S. aureus, B. subtilis, E. coli and P. aeruginosa. The dose-
response curves of the four bacteria are shown in Figure 8. MGO had a bacteriostatic effect on 
all studied bacteria. However, the extent of the antibacterial effect differd markedly between 
the bacterial species. Again, S. aureus was the most sensitive bacteria to the treatment. P. 
aeruginosa was not inhibited by MGO in manuka honey. The sensitivity of the species 
towards MGO can be described with the following ranking: 
 
                  S. aureus ≥ B. subtilis > E. Coli 
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Figure 8: Dose-response curve of methylglyoxal towards S. aureus, B. subtilis , E. coli and P. 
aeruginosa before and after linearization. GD of MGO was referenced to 5 % (v/v) AH solution. 
 
Similar results for the sensitivity towards MGO for these bacteria species were described by 
Lu et al. (2013). To compare the inhibition of the bacteria by MGO, the slopes of the 
linearized dose-response curves are presented in Table 14. 
 
Table 14: Slopes of dose-response curves when growth delay is plotted logarithmically against 
methylglyoxal concentration in mg/kg 
Bacterium S. aureus B. subtilis E. coli P. aeruginosa 
Slope 0.004 0.004 0.003 0.0002 
 
To compare the effect of MGO on the bacteria, the MGO concentrations which would be 
necessary to delay bacterial growth 5-fold stronger than a 5 % (v/v) sugar solution were 
calculated. The results are shown in Table 15.  
 
Table 15: Calculated MGO levels in honey, which would inhibit bacterial growth 5-fold stronger than 
a 5 % (v/v) sugar solution. n.d. stands for not determinable 
Bacterium S. aureus B. subtilis E. coli P. aeruginosa 
MGO (mg/kg) 
to reach GD of 5 
412 438 632 n.d. 
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The MGO concentrations which would be necessary to inhibit bacterial growth 5-fold 
stronger than a control sugar solution (412 to 632 mg/kg), are present in natural manuka 
honeys. There are several studies which show, that manuka honey can contain MGO in 
concentrations up to 1700 mg/kg (Windsor et al., 2012; Pappalardo et al., 2016). The 
sensitivity towards MGO depends on the bacteria species, but all bacteria, with the exception 
of P. aeruginosa, can be inhibited by MGO in manuka honey-relevant concentrations. A 
possible target for methylglyoxal in bacteria cells, are enzymes which are relevant for 
survival. Jenkins et al. (2011) showed that manuka honey influences the expression of murein 
hydrolase, an enzyme which regulates cell separation during cell division. The 
downregulation of enzyme activity resulted in decreased bacterial growth. However, since 
bacterial proliferation is a complex process, the precise mechanism by which MGO inhibits 
bacteria is unknown up to the present day. 
In this study the gram-negative bacteria E. coli and P. aeruginosa were less sensitive to MGO 
compared to the gram-positive bacteria. Other studies found that also gram-negative bacteria 
can be inhibited by MGO in manuka honey (Alnaimat et al., 2012; Hayashi et al., 2014). 
Whether a bacterium is more or less sensitive towards MGO mostly depends on its ability to 
metabolize increasing concentrations thereof. There are several pathways known, which can 
lead to MGO detoxification like glyoxalase, reductase or dehydrogenase systems (Ferguson et 
al., 1998). Since MGO is a common by-product during glycolysis in bacteria, it is necessary 
to reduce its concentration so it will not negatively influence bacterial survival (Kalapos, 
1999). Thus, bacteria which are naturally equipped with enzyme systems to reduce elevated 
MGO levels are more likely to survive treatment with manuka honey. In an earlier study, it 
was shown that P. aeruginosa has three glyoxalase encoding genes, instead of one (Sukdeo 
and Honek, 2007). This could be an explanation for the reduced sensitivity of P. aeruginosa 
towards MGO in this study. Another reason for bacterial growth after initial inhibition could 
be the loss of MGO in the medium. The medium consisted of glucose, sodium chloride and 
yeast extract. The yeast extract is the product of yeast autolysis and contains mainly protein 
degradation products. MGO is known for its reactivity towards proteins or peptides. It is 
possible, that MGO reacted with media components during incubation time and thus became 
unavailable for bacterial inhibition. According to our results, MGO in manuka honey 
decreased by 20 % after 6 h of incubation and by 55 % after 30 h of incubation. Moreover, the 
manuka honey matrix appeared to stabilize MGO to a certain extent, because in an artificial 
honey with added MGO and DHA in the same concentrations as present in manuka honey, 
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MGO is even less stable (see Figure 9). The MGO decrease needs to be taken into account 
when the antibacterial activity in the form of growth delay is plotted against the MGO 
concentration. Thus, the concentrations given in Figure 8 are only apparent MGO 
concentrations, calculated based on the MGO level of the corresponding honey. 
 
Figure 9: MGO stability in nutrient media. 5 % (v/v) solutions of manuka honey with 690 mg/kg 
MGO and of artificial honey with the same amount were incubated in nutrient media at 37 ° C for 30 
h. Measurements were carried out in duplicate and error bars indicate standard deviation. 
 
1.5.2.4. Comparison of hydrogen peroxide and methylglyoxal as antibacterial compounds 
The values of the slopes obtained for the inhibition with hydrogen peroxide (Table 12) can be 
directly compared to the slopes of inhibition with MGO (Table 14). For S. aureus, E. coli and 
P. aeruginosa, the values of the slopes of the linearized dose-response curves are higher than 
the slopes obtained for the inhibition with MGO. That means that these bacteria are more 
sensitive to hydrogen peroxide than to methylglyoxal. However, the concentrations in which 
hydrogen peroxide and methylglyoxal are present in honey differ. Whereas MGO amounts in 
manuka honey range between 40 to 760 mg/kg (Mavric et al., 2008), the formation of 
hydrogen peroxide depends on the honey dilution and reaches its maximum at approximately 
200 mg/kg*30 min in dilutions of 15 to 67 % (v/v) (Bang et al., 2003). During the current 
study, honeys were diluted to 5 % (v/v) and lime honey was the one with the highest level of 
hydrogen peroxide formation with 67 mg/kg*h. The different levels of H2O2 between our 
study and the one of (Bang et al., 2003) could be due to different methods to detect hydrogen 
peroxide. Bang et al. (2003) detected hydrogen peroxide by measuring the release of oxygen 
after the treatment of pre-incubated honey solutions with catalase. Kwakman et al. (2011b) 
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measured hydrogen peroxide with the same method presented in this work and found similar 
levels of approximately 50 to 100 mg/kg*2 h. Moreover the effective amount of hydrogen 
peroxide in honey depends on the presence of compounds which can decompose it. Thus, the 
enzyme catalase or reducing compounds can decrease hydrogen peroxide levels in honey 
(Hartford and Dowds, 1994). The slopes of the linearized dose-response curves do not reflect 
this unequal distribution of the bioactive compounds MGO and hydrogen peroxide in honey. 
Thus, the calculation of the amount of hydrogen peroxide and methylglyoxal which exert the 
same antibacterial activity (e.g. GD of 5) can give a more accurate picture of the impact of 
MGO and H2O2 to the antibacterial effect of honey. Except P. aeruginosa, which was not 
inhibited by manuka honey, all other bacteria can be inhibited by MGO in honey-relevant 
concentrations. Even though most bacteria are more sensitive to hydrogen peroxide, in 
manuka honey MGO is the predominantly antibacterial compound, because of its higher 
concentrations compared to hydrogen peroxide. Figure 10 shows the growth delay which is 
caused by peroxide activity (lime honey) and non-peroxide activity (manuka honey) on S. 
aureus, B. subtilis, E. coli and P. aeruginosa. 
 
Figure 10: Antibacterial activity of manuka honey (non-peroxide effect) and lime honey (peroxide 
effect) on bacteria. Manuka honey contains MGO 488 mg/kg and lime honey contained H2O2 
67 mg/kg*h. Both honeys were diluted to 5 % (v/v) and incubated with bacteria for 18 h at 37 °C. 
Growth delay of 9 indicates no growth during the entire incubation time. 
Taken together, both MGO and hydrogen peroxide can have a bacteriostatic effect on 
bacterial growth. The sensitivity of the bacteria towards the antibacterial compounds differ 
widely and it was found that most bacteria are more sensitive to hydrogen peroxide. However, 
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the amount of antibacterial compounds in manuka honey is higher than in non-manuka honey, 
what enhances the potential effect of manuka honey.  
 
1.5.2.5. Comparison of bacteriostatic versus bactericidal effect 
The MIC (minimum inhibitory concentration) test, which is used to determine the 
antibacterial activity of bioactive compounds, cannot distinguish between bacteriostatic or 
bactericidal mode of action. Until now, there is no information about the potential bactericidal 
effect of honey compounds on bacteria. Thus, the assay developed in this project was used to 
study the bactericidal effect of hydrogen peroxide and methylglyoxal in honey. Therefore, 
bacterial solutions incubated with artificial honey containing GOX or with manuka honey, 
which did not show any bacterial growth after 16 h of incubation, were plated on fresh 
nutrient agar and further incubated for 24 h at 37 °C (see 1.4.10). Thereby, the concentration 
of the inhibitory compounds was diluted and cells which were resting but were not dead, can 
proliferate again. For S. aureus and B. subtilis incubated with MGO in manuka honey the 
concentrations without visible growth after 16 h incubation were ≥ 510mg/kg, whereas with 
hydrogen peroxide only S. aureus growth was inhibited completely above concentrations of 
16.6 mg/kg *h. The minimum bactericidal concentration (MBC) is the amount of test 
compound incubated with bacteria which prevented re-proliferation in fresh nutrient media 
completely. The maximum MGO concentration of manuka honey present in the assay was 
690 mg/kg whereas the maximum H2O2 concentration was 114 mg/kg*h (artificial honey with 
added glucose oxidase). Table 16 shows the MBC values for S. aureus and B. subtilis. The 
growth of E. coli and P. aeruginosa was neither inhibited completely with MGO nor 
hydrogen peroxide over the entire incubation time. Thus, the effect of MGO and hydrogen 
peroxide on the two gram-negative bacteria can be described as bacteriostatic in honey-
relevant concentrations.  
 
Table 16: Bactericidal concentrations (MBC) of MGO in manuka honey and hydrogen peroxide in 
artificial honey with GOX on S. aureus and B. subtilis (one determination per sample)   
Bacterium S. aureus B. subtilis 
Hydrogen peroxide (mg/kg*h) 89 - 
Methylglyoxal (mg/kg) - 657 
 
Although S. aureus growth was completely inhibited by MGO in manuka honey during 16 h 
of incubation, after plating the cells on fresh media they proliferated again. Thus, MGO in 
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manuka honey affects S. aureus bacteriostatically. In contrast, B. subtilis was not able to 
proliferate in fresh media after prior incubation in 5 % (v/v) manuka honey with MGO 657 
mg/kg. Thus, the effect of MGO in manuka honey can be bactericidal for B. subtilis in certain 
concentrations. Figure 11 shows the nutrient agar plates incubated with S. aureus and B. 
subtilis which were previously incubated with MGO in manuka honey for 16 h.  
 
Figure 11: Proliferation of S. aureus and B. subtilis after plating on fresh media after 16 h incubation 
with MGO in manuka honey. Plates were incubated for 24 h at 37 °C. 
 
The plates incubated with B. subtilis show remarkably less growth compared to the plates 
with S. aureus. Although S. aureus and B. subtilis showed almost the same growth delay by 
MGO in manuka honey (both linearized dose-response curves had a slope of 0.004), a 
bactericidal effect was only detectable for B. subtilis. This again showed the different 
sensitivity of the bacteria species towards the inhibitory compounds of honey, which suggests 
differences in the mode of action of MGO on bacteria. Hydrogen peroxide only had a 
bactericidal effect on S. aureus at a concentration of 89 mg/kg*h. This concentration is higher 
than the one measured for lime honey as an example for a peroxide-rich honey (67 mg/kg*h). 
Thus, it is unlikely that commercial honeys with peroxide activity are able to kill S. aureus 
cells completely.  
Although bioactive compounds in honey were only able to kill bacteria to a very limited 
extent, this does not necessarily mean that their antibacterial activity is weak. The 
antibacterial treatment with bacteriostatic compounds is considered to be equally effective 
compared to bactericidal agents, when patients have uncomplicated infections and a healthy 
immune system (Pankey and Sabath, 2004). Most bacteriostatic agents win some time for the 
host defence system and enable the body to fight infections properly. Thus, manuka honey 
with MGO and honey with peroxide activity can present an alternative treatment for bacterial 
S. aureus B. subtilis 
511 mg/kg 604 mg/kg 657 mg/kg 511 mg/kg 604 mg/kg 657 mg/kg 
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infections, especially in times of increasing number of antibiotic-resistant bacteria (Alanis, 
2005).   
 
1.5.3. The antibacterial effect of manuka honey with cyclodextrin 
The cyclic oligo saccharide α-cyclodextrin can potentially form inclusion complexes with 
manuka honey compounds and thus increase its bioactive properties. Therefore, it was tested 
whether the commercial product “Manuka Honey with CycloPowerTM” (CP) has an increased 
antibacterial activity compared to manuka honey. The bacterial assay was performed 
according to section 1.4.7. To compare the antibacterial effect of MGO in CP to MGO in 
manuka honey, CP was mixed with artificial honey to obtain standardized 5 % (v/v) sugar 
solutions (referring to honey sugars). MGO in CP showed no increase of the antibacterial 
effect of manuka honey on S. aureus, E. coli and P. aeruginosa (data not shown). However, 
B. subtilis showed a significantly stronger growth delay when treated with CP compared to 
manuka honey (see Figure 12). 
 
 
 
Figure 12: Dose-response curve of B. subtilis incubated with manuka honey and cyclopower. GD was 
referenced to 5 % (v/v) AH solution. 
To check whether the increased activity of MGO in CP is based on an additive effect of the 
antibacterial effect of α-cyclodextrin (CD) and manuka honey or on a synergistic effect of 
both compounds, a dose-response curve for CD (with 5 % (v/v) artificial honey) was 
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measured (see Figure 13). α-Cyclodextrin alone does not have an antibacterial effect on most 
of the tested bacteria. This is in accordance with Zhang et al. (2008) and Swift et al. (2014), 
who also found no significant inhibition of E. coli and S. aureus by α-cyclodextrin. Only B. 
subtilis was sensitive to α-cyclodextrin in the concentration present in cyclopower. Since α-
cyclodextrin alone inhibits B. subtilis growth, it can be assumed that the inhibition of B. 
subtilis with cyclopower is not only due to methylglyoxal but also α-cyclodextrin itself. 
 
 
Figure 13: Dose-response curve of α-cyclodextrin towards S. aureus, B. subtilis , E. coli and P. 
aeruginosa GD was referenced to 5 % (v/v) AH solution. 
 
The growth delay caused by MGO in manuka honey and α-cyclodextrin was determined 
individually and summed up (orange curve, Figure 14). The addition of the effect of MGO 
and α-cyclodextrin did not fully explain the antibacterial effect caused by cyclopower on B. 
subtilis. This suggested that the antibacterial activity of manuka honey was synergistically 
enhanced by the complexation with α-cyclodextrin. Zhang et al. (2008) were able to show, 
that α-cyclodextrin can interact with certain protein-lipid complexes in the cell wall of 
Bacillus strains. The authors supposed that flotillin-like proteins form a complex with 
unknown lipid molecules present in the cell membranes of the strains and that the complex 
must be very important in the construction and stabilization of their structure. Similar 
complexes, which regulate biofilm formation are discussed by Vlamakis et al. (2013). Those 
complexes might be uniquely present in the mebrane of Bacillus strains. The interaction of α-
cyclodextrin with these membrane microdomains might lead to a destabilization of the 
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bacteria mebrane which eventually leads to lysis of the cells and a decrease of cell number. 
Thus, the synergistic effect of MGO and α-cyclodextrin may be due to increased membrane 
permeability and therefore a facilitated effect of MGO on bacteria cells. As this effect is 
depending on the membrane structure of bacteria, the response of bacterial species to 
cyclopower can differ widely. To exert an antibacterial effect in vivo, the bioactive compound 
needs to interact with bacteria. If the bacteria are present in the gastrointestinal tract, the 
transit time of manuka honey is rather short. All honey compounds, especially sugars, are 
easily digestible and can be absorbed quickly. It was shown in earlier reports that α-
cyclodextrin itself is poorly digested and can slow down gastric emptying (Thompson, 1997; 
Gentilcore et al., 2011). Thus, α-cyclodextrin may enhance the effect of MGO in manuka 
honey by increasing its interaction time with bacteria in the gastrointestinal tract. 
Nevertheless, further research is needed to elucidate the antibacterial effect of cyclopower on 
bacterial systems and to give more profound statements.  
 
 
Figure 14: Dose-response curve for cyclopower and sum of growth delay caused by MGO in manuka 
honey and α-cyclodextrin measured individually 
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1.5.4. The structure of inclusion complexes of manuka honey and cyclodextrin 
With the help of 2-D-NMR methods through-bond or through-space interactions of α-CD and 
possible inclusion partners were analysed. The basis for this technique formed 1-D 1H-NMR 
spectroscopy. Thus, 1-D 1H-NMR spectra of α-cyclodextrin, MGO and DHA were recorded 
and the signals were assigned to their corresponding protons (see Figure 15). In the 1H-NMR 
spectrum, all chemically different protons give a signal. For example, α-cyclodextrin consists 
of six 1,4-α-glycosidically-linked D-glucose units, which form a symmetric cyclic molecule 
leading to the same chemical environment for the protons of each glucose unit. Therefore, the 
multiplet signals describe the –CH2 or –CH groups in each of the glucose units. The peak 
pattern (duplets and triplets) of α-cyclodextrin is due to couplings between the adjacent 
protons. Generally the higher the magnetic shielding, which is caused by electron density, the 
lower the chemical shift. The shielding effect depends on the electronegativity of the adjacent 
atoms, whereby the following applies: the more electronegative neighboring groups, the less 
shielding, the higher the chemical shift. 
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Figure 15: Molecular structures and 1H-NMR spectra of α-cyclodextrin, methylglyoxal and dihydroxyacetone with proton assignment
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For methylglyoxal, two structures were detected. In aqueous solutions, the dicarbonyl 
structure was not present, but the mono- or dihydrate forms dominated. The singlet 
resonances at 1.237 and 2.165 ppm corresponded to the methyl hydrogen atoms in 
methylglyoxal di- and monohydrate, respectively. The resonances at 4.674 and 5.141 ppm 
were assigned to the alkyl protons, although the alkyl proton signal of the methylglyoxal 
dihydrate was not observed well because of the overlapping water signal. The use of 
presaturation for water suppression did not significantly enhance signal separation. The 
resonance signal at 1.9 ppm could be acetic acid as a contamination in the methylglyoxal 
standard. For dihydroxyacetone, the four alkyl protons had all the same chemical 
environment, thus there was only one signal at 4.297 ppm present.  
After the identification of MGO, DHA and α-CD signals, the commercial product cyclopower 
was analyzed. Cyclopower contains manuka honey and α-cyclodextrin in a ratio of 45 to 55 
%, respectively. When cyclopower contains a manuka honey with MGO (500 mg/kg) and 
DHA (1000 mg/kg), this results in a molar ratio of MGO:CD of 1:190 and DHA:CD of 1:110.   
Figure 16 shows the corresponding 1H-NMR spectrum.    
 
 
Figure 16: 1H-NMR spectra of cyclopower, upper right corner: zoom spectrum of cyclopower with 
MGO and DHA signal assignment 
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The large excess of α-cyclodextrin compared to the MGO and DHA content of the honey led 
to a huge α-CD signal, whereas MGO and DHA gave only very small signals. Both 
compounds were only visible in the zoom spectrum. These intensity differences made 2-D 
NMR studies, which were necessary to visualize interactions between α-CD and MGO and 
DHA, impossible with this complex. Thus, model complexes were prepared, which contained 
MGO or DHA and α-CD, but no monosaccharides in an equimolar ratio (see 1.4.12). The 
model complex which contained pure MGO and α-CD was named MGO-CD and the complex 
formed of DHA and α-CD was called DHA-CD. Figure 17 compares the spectra of MGO-CD 
and DHA-CD. In both spectra the intensity of the resonances of α-CD as well as the signals of 
MGO and DHA were about the same size. The following 2-D NMR studies for investigating 
the interactions of α-CD with MGO and DHA were recorded with these model complexes. 
 
 
 
Figure 17: 1H-NMR spectra of the complex MGO-CD (black) and DHA-CD (red) with proton 
assignment 
 
The apllied 2-D-NMR methods aimed to visualize through-bond or through-space interactions 
of α-CD and possible inclusion partners. Through-bond correlations can be analyzed with 
homonuclear proton correlation spectroscopy (COSY, used for indicating correlation with 
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coupled protons), heteronuclear single-quantum correlation spectroscopy (HSQC, detects 
correlations between nuclei of two different types which are separated by one bond) and 
heteronuclear multiple-bond correlation spectroscopy (HMBC, visualizes interactions over 
longer ranges of about 2–4 bonds). The results for the MGO-CD and DHA-CD complexes 
showed that there is no covalent bond between MGO or DHA and α-CD. With the help of 
rotating frame nuclear Overhauser effect spectroscopy (ROESY), non-covalent, through-
space interactions of the complexes were examined.  
Figure 18 shows the ROESY-NMR spectrum of the MGO-CD model complex. When protons 
interact through-space, it becomes visible in the ROESY plot with a cross peak. The cross-
peaks of MGO protons with protons of α-CD are marked with a circle. Concerning MGO, the 
methyl protons and the alkyl protons of the monohydrate form interacted with the protons 
number 3 and 5 of cyclodextrin (see Figure 15 for proton assignment). According to the 
literature, the protons number H-3 and H-5 are located inside of the α-CD cone, whereas all 
other protons (H-1, H-2, H-4 and H-6) are located at the outside of the cage-like structure 
(Anselmi et al., 2008; Salústio et al., 2009). Therefore interactions with these protons were of 
special interest for revealing α-CD inclusion complexes. The proposed structure of α-CD is 
shown in Figure 19. According to the ROESY spectrum the alkyl protons of MGO 
monohydrate interacted slightly stronger with H-3 than H-5, whereas the methyl protons 
interacted with H-3 and H-5 in the same way. This might indicate that the methyl group of 
MGO was able to penetrate into the cone of α-CD and interacted with the H-5 at the narrow 
end of the cone. The outside protons (H-1, H-2, H-4 and H-6) showed no interaction with the 
MGO protons. Moreover, no interaction of the MGO dihydrate protons and α-CD was 
detectable. 
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Figure 18: ROESY-NMR spectrum of model complex containing MGO and α-CD in equimolar ratio, 
protons are assigned to MGO and α-CD (protons 1-6), cross peaks of MGO and α-CD are marked with 
black circle 
 
 
 
Figure 19: Structures of α-cyclodextrin and spatial orientation of protons 
 
Moreover, the model complex which contained DHA and α-CD in a 1:1 ratio was studied 
with ROESY-NMR. Again, there were no through-bond but through-space correlations 
between DHA and α-CD visible. Since DHA is even more hydrophilic than MGO, a strong 
interaction between the cone of α-CD and DHA was not expected. The number of recorded 
spectra was the same for the measurement of the MGO-CD and the DHA-CD complex. 
According to the ROESY-NMR results, the alkyl protons of DHA interacted with the α-CD 
proton H-3 (see Figure 20). Since proton H-3 is located at the wider end of the α-CD cone and 
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there were no interactions with proton H-5 (narrow end) of α-CD and DHA visible, it is quite 
unlikely that the hydroxyl or the keto group of DHA penetrated into α-CD because of the 
cone’s hydrophobic character. In comparison to the interactions between MGO and α-CD, the 
interactions of DHA and the inner protons of α-CD appeared weaker. 
 
Figure 20: ROESY-NMR spectrum of model complex containing DHA and α-CD in equimolar ratio, 
protons are assigned to DHA and α-CD (protons 1-6), cross peak of DHA and α-CD is marked with 
black circle 
 
The experiments were performed with model complexes, which do not have the same 
composition as the commercial product cyclopower. To get closer to the conditions which are 
present in the commercial product, a model complex, which contained MGO, DHA and α-CD 
in a 1:2:1 ratio was prepared (see 1.4.12). Figure 21 shows the ROESY spectrum of this 
model complex. Interestingly, when both compounds MGO and DHA were present in the 
model complex, only MGO interacted clearly with α-cyclodextrin. Again, only the 
monohydrate form of MGO showed interaction with α-CD. The methyl group interacted with 
both inner protons of α-CD (H-3 and H-5), whereas the alkyl group only interacted with the 
proton H-3, which is located at the wider part of the α-CD cone. For the alkyl protons of 
DHA, there appeared only a negligible cross peak with α-CD proton H-3 (not marked with 
circle), which indicated very weak interactions between α-CD and DHA in the presence of 
competitive MGO.  
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Figure 21: ROESY-NMR spectrum of model complex containing MGO, DHA and α-CD in a 1:2:1 
ratio, protons are assigned to DHA, MGO and α-CD (protons 1-6), cross peaks of MGO and α-CD are 
marked with black circle 
 
A possible reason for the weaker interactions of MGO and DHA with α-CD in the mixture 
compared to their complexes formed with α-CD alone, could be the interactions between 
MGO and DHA itself. ROESY-NMR only allows visualizing proton interactions, but MGO 
and DHA probably interacted via hydrogen bridges, which were not visible in the presented 
spectra. The MGO-DHA interaction led to a more complex and hydrophilic nature of the 
compounds, which decreased the single interactions of each compound. Apparently, when 
MGO and DHA were present in the model complex, MGO interacted preferentially with α-
CD. Based on these results, Figure 22 shows proposed spatial structures of the model 
complexes. The proposed structure A (MGO inclusion complex) occurs more likely, whereas 
structure B (DHA inclusion complex) and C (MGO and DHA inclusion complex) are rather 
unlikely formed. 
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Figure 22: Proposed 2-D models structures of inclusion complexes formed by α-CD and MGO (A), 
α-CD and DHA (B) and α-CD, MGO and DHA (C) 
 
Cyclodextrins are cyclic products of enzymatic starch degradation. Alpha-cyclodextrin 
consists of six α-D-glucose units. To assess if the interactions recorded by ROESY-NMR are 
specific for cyclodextrin, model complexes which contained MGO, DHA and glucose as well 
as MGO, DHA and starch were prepared (see 1.4.12). There was no interaction between the 
protons of starch or glucose and MGO and DHA detectable (see Annex-Figure 1 and Annex-
Figure 2 for ROESY-NMR data). That means that neither glucose nor starch interacted with 
MGO or DHA in a manner seen with α-cyclodextrin. Thus, the interactions of α-CD with 
MGO and DHA were specific and proved the formation of inclusion complexes. Moreover, 
the strength of the MGO and DHA inclusion complex should be compared to other α-CD 
complexes. In the literature, the complex of 1-propanol (PrOH) and α-CD was described as 
very stable (Buvari et al., 1983; Funasaki et al., 2002). Thus, a complex of 1-propanol and α-
CD in a 2:1 ratio was prepared and the ROESY-NMR measurement performed according to 
1.4.12. The number of recorded spectra was the same for the measurement of the PrOH-CD 
and the MGO-/DHA-CD complexes. Figure 23 shows the corresponding ROESY spectrum 
and a zoom part of the spectrum. 
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Figure 23: At top: ROESY-NMR spectrum of model complex containing 1-propanol (PrOH) and α-
CD in a 2:1 ratio, protons are assigned to 1-propanol and α-CD (protons 1-6), cross peaks of 1-
propanol and α-CD are marked with black circle; at bottom: zoomed ROESY-NMR spectrum of 
PrOH/ α-CD complex 
 
It becomes visible that the alkyl group of 1-propanol interacted stronger with the α-CD proton 
H-3 than with H-5. For the methyl group the reversed effect was observed. Based on these 
results, the alkyl chain of 1-propanol entered the α-CD cone deeply and formed a stable guest-
host complex with α-CD. Compared to MGO, the interactions with α-CD appeared stronger. 
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Methylglyoxal has no molecule part which is as hydrophobic as the alkyl group of 1-
propanol. Therefore the interactions with the inside of the hydrophobic cone were weaker. 
Weaker interactions are visualized by ROESY-NMR with the intensity and the size of the 
area of the cross peaks. The comparison of Figure 18 and Figure 23 shows, that the cross 
peaks of the MGO/α-CD complex were smaller than the cross peaks of the 1-propanol/α-CD 
complex. To compare MGO to a molecule with a more similar structure, a model complex 
containing hydroxyacetone (HA) and α-CD was prepared (see 1.4.12). Hydroxyacetone 
differs only in one position from MGO, by carrying a hydroxyl instead of an aldehyd group. 
Therefore hydroxyacetone is slightly less hydrophobic than MGO. Figure 24 shows the 
ROESY-NMR spectrum of the HA/α-CD complex. Only a very small cross peak between the 
α-CD proton H-5 and the methyl group of hydroxyacetone was detectable.  
 
Figure 24: ROESY-NMR spectrum of model complex containing hydroxyacetone (HA) and α-CD in a 
2:1 ratio, protons are assigned to hydroxyacetone and α-CD (protons 1-6), cross peak of 
hydroxyaectone and α-CD are marked with black circle 
 
In conclusion, the strength of interaction in α-CD complexes can be ranked as follows: 
1-propanol > methylglyoxal > dihydroxyacetone > hydroxyacetone 
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Until now, it is not clear which influence these interactions have on the stability, 
bioavailability and the bioactive effect of MGO and DHA. Overall, the observed interactions 
were rather weak and are expected to have only a limited influence. Nevertheless, in the 
commercial cyclopower product, α-cyclodextrin is present in an excess of factor 190 or 110 
concerning MGO and DHA, respectively. The huge excess of host to guest molecules makes 
an inclusion of MGO or DHA more likely. However, honey contains also other compounds, 
like polyphenols or peptides, which could interact competitively with α-cyclodextrin and limit 
its ability to complex MGO. During the antibacterial in vitro studies, no enhanced effect of 
cyclopower compared to manuka honey was found for most of the tested bacteria (see 1.5.3). 
However, the gram-positive bacterium B. subtilis showed an increased sensitivity towards 
manuka honey in the presence of α-cyclodextrin. Swift et al. (2014) suggest that the improved 
antibacterial activity of cyclopower may be a result of a slow release of antimicrobial 
components to maintain a bacteriostatic concentration over an extended time period. The 
authors also suggest that α-cyclodextrin may be able to deliver antimicrobial components to 
the bacterium allowing more efficient killing. Based on the results of the weak molecular 
interactions between MGO and α-cyclodextrin, an enhanced effect of manuka honey 
encapsulated with α-cyclodextrin may not be caused by inclusion reactions but could be due 
to synergistic effects. Further research is needed to clarify the influence of α-cyclodextrin 
complexation of manuka honey on its effect and bioavailability.  
 
1.5.5. Influence of manuka honey on urease activity 
Although manuka honey is known for its antibacterial activity for a long time, only limited 
knowledge about the mechanism of inhibition with MGO exists. Possible targets for the 
inhibition of bacteria are enzymes which are relevant for fundamental metabolic processes. 
The current study focused on the enzyme urease, which is present in the bacterium 
Helicobacter pylori. The gram-negative bacterium H. pylori colonizes the human stomach and 
causes chronic inflammation or gastric ulcers. The enzyme urease is an important virulence 
factor of Helicobacter pylori. It catalyzes the reaction of urea to carbon dioxide and ammonia, 
which neutralizes the acidic environment of the stomach. This reaction enables bacteria to 
adapt to an acidic environment, which normally prevents bacterial growth. It was shown that 
manuka honey inhibits H. pylori growth in-vitro (Al Somal et al., 1994; Keenan et al., 2010). 
The inhibition of H. pylori may be due to the inhibition of urease. An inhibition of the 
enzyme could be a possible cause for the decreased growth of H. pylori in the presence of 
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manuka honey. Therefore, the aim of this study was to characterize the effect of the 
compounds MGO and DHA and commercial honeys, including manuka and non-manuka 
varieties, on urease. Urease from jack bean (Canavalia ensiformis) was used for the studies. 
The study is supposed to contribute to the understanding of the mode of action of manuka 
honey on bacteria.  
The results of this section are partly originating from the experimental work of master student 
Oliver Klemm and were published in his master thesis (Klemm, 2016) and in Food Chemistry 
(Rückriemen, Klemm, et al., 2017).  
 
1.5.5.1. Development of a photometric method to measure urease activity  
There are several methods published in the literature to study urease activity in vitro. Tanaka 
et al. (2004) used an approach based on the pH increase caused by the continuous ammonia 
production to analyse the inhibitory effect of α-hydroxyketones. Phenol red was used to 
indicate appropriate ammonia production through urease with a color change from yellow to 
pink. Sahin (2015) measured the urease inhibiting effect of dissolved honey samples and 
detected the ammonia production by using the indophenol method. During this reaction, 
known as Berthelot reaction, a phenol solution reacts with ammonia and sodium hypochlorite 
to form indophenol which can be detected photometrically at 625 nm. Both methods were 
tested in this study for their applicability. The Berthelot reaction in the presence of artificial 
honey was significantly suppressed (see Figure 25A). According to the results, the reducing 
sugars in honey, especially fructose, interfere with the oxidation of phenol to indophenol, thus 
leading to wrong positive inhibition values. Hence, the reducing nature of honey sugars 
makes this detection method unsuitable to study urease activity. Also the method used by 
Tanaka et al. (2004), based on the detection of ammonia via pH control with phenol red, was 
negatively influenced by reducing sugars (data not shown).  
Therefore, the first aim of this study was to develop a new method for reliable quantitation of 
ammonia production by urease in vitro, which is not influenced by honey sugars. Ammonia 
reacts with ninhydrin to form a purple dye, called Ruhemann purple (Ruhemann, 1910). 
Based on this knowledge, urea and urease with or without inhibitors were incubated and the 
resulting ammonia was separated via ion exchange chromatography and detected via post-
column derivatization with ninhydrin at 570 nm. The chromatographically quantitated amount 
of ammonia was depending on the presence or absence of an inhibitor (see Figure 26).  
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Figure 25: (A) Berthelot reaction in the presence of water (control) or artificial honey after 30 min 
incubation time with 280 mM ammonia, zoom figure: Berthelot reaction in the presence of water 
(control) or fructose and glucose after 30 min incubation time with 280 mM ammonia; (B) Reaction of 
ammonia with ninhydrin in the presence of water (control) or artificial honey after 30 min incubation 
time with 270 mM ammonia 
 
 
Figure 26: Amino acid analysis via ion-exchange chromatography and post-column ninhydrin 
detection (a) Amino acid standard solution with ammonia, (b) ammonia cleaved by urease from urea, 
(c) ammonia cleaved by urease from urea in the presence of 400 µM acetohydroxamic acid, (d) blank 
solvent 
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It was concluded that ammonia quantitation via ninhydrin reaction was suitable to analyse 
urease activity. To quantitate urease activity with high sample throughput, the assay was 
optimized by using a photometric approach instead of chromatographic separation. Hence, 
urea and urease with or without inhibitor was incubated in a microtiter plate and ninhydrin 
was directly added to the reaction. The incubation resulted in the formation of a yellow 
coloured product, with an absorption maximum at 440 nm (see Figure 27A). The absorption 
maximum at this wavelength was unexpected, since Ruhemann purple detected via post-
column derivatization of ammonia with ninhydrin absorbs at 570 nm. Nevertheless, the 
incubation of ammonia with ninhydrin in the microtiter plate resulted in the formation of a 
light-brown product with an absorption spectrum similar to the spectrum of the yellow 
product mentioned above. There was no increase at 440 nm when urease and urea were 
incubated without ninhydrin or ninhydrin was incubated with urease without urea. Moreover, 
the presence of artificial honey did not influence the reaction of ammonia with ninhydrin (see 
Figure 25B). 
 
Figure 27: (A) UV spectra after incubation of urea with urease and ninhydrin (■), urea with ammonia 
and ninhydrin (●), ninyhdrin and ammonia (“Ruhemann purple”) (▼) and urea with ammonia (▲), 
(B) Correlation between ammonia, which was quantitated chromatographically and the UV 
absorbance of the photometric assay at 440 nm. 
 
The absorbance measured using the photometric assay and the ammonia concentration as 
quantitated chromatographically correlated (see Figure 27B). That proves the hypothesis that 
the absorbance at 440 nm directly correlates with the ammonia concentration. The increase of 
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absorbance at 440 nm was therefore solely due to the formation of ammonia and subsequent 
reaction with ninhydrin. Moreover, Figure 27B illustrates the limit of detection of the 
microplate assay. At a concentration of 65 mM ammonia, no absorbance at 440 nm was 
detected. A minimum ammonia concentration of above 65 mM is necessary to detect 
ammonia photometrically. To ensure that a lack of absorption was not misinterpreted because 
of the limit of detection, the assay was incubated for 80 min. No increase of absorption after 
this time was observed, which was interpreted as complete inhibition of the enzyme. The 
inhibitor concentration, which inhibits 50 % of enzyme activity (IC50) was determined by 
plotting the percentage of urease inhibition against the logarithm of different concentrations 
of the inhibitor (see 1.4.13.2). The IC50 value of acetohydroxamic acid (AHA) was 
determined with the newly developed method to be 10.1 µM (see Annex-Figure 3 for dose-
response curves). In an earlier study an IC50 of 5 µM after 3 h pre-incubation time (current 
assay: 2 h) was determined (Tanaka et al., 2004). This proves that the assay is suitable to 
determine inhibition constants similar to those previously published. 
 
1.5.5.2. Inhibition of urease activity 
The aim of this study was to analyse urease inhibition by MGO and DHA and to evaluate the 
inhibitory potential of the carbonyl compounds in manuka honey. Therefore, aqueous 
solutions of MGO and DHA were studied for their urease inhibiting effect and the percentage 
of urease inhibition was plotted against the logarithm of the MGO and DHA concentrations. 
The fitting of the sigmoid dose-response curves resulted in IC50 values of 2.8 ± 0.2 mM for 
MGO and 5.0 ± 0.1 mM for DHA, what equals 202 mg/l and 450 mg/l, respectively (see 
Annex-Figure 3). Compared to other natural ingredients of food, which are known to inhibit 
urease like alkyl thiosulfinates in garlic or onion juice (IC50 values between 1-27 mM)(Olech 
et al., 2014), MGO and DHA are moderate inhibitors. Jack bean urease contains 15 cysteine 
residues per subunit, whereby Cys-592 is crucial for its enzymatic activity. It was proposed, 
that the interaction of α-hydroxyketones with the sulfhydryl group may be related to urease 
inhibition (Tanaka et al., 2004). Both MGO and DHA could interact with cysteine residues of 
urease and thereby decrease its enzymatic activity. Moreover, urease from jack bean contains 
50 lysine and 37 arginine residues, which accounts for 6 % and 4 % of total amino acids, 
respectively (according to jack bean urease amino acid sequence, UniProt database entry 
P07374). Both amino acids are known to react quickly with MGO and form glycation 
products, which could lead to a decrease of urease activity. To check, whether enzyme 
activity is non-specifically affected by MGO or DHA, pepsin and angiotensin converting 
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enzyme (ACE) activity was measured in the presence of MGO and DHA (see 1.4.13.6). Both 
enzymes contain lysine (pepsin: 3 %, ACE: 4 %) and arginine (pepsin: 1 %, ACE: 6 %) 
residues (according to pepsin and ACE amino acid sequence, UniProt database entry P00791 
and P12822, respectively). The hydrolytic activity of these physiologically relevant enzymes 
was not affected in the presence of MGO or DHA. The residual enzyme activity in the 
presence of 4 mM MGO or 7 mM DHA is presented in Figure 28.  
 
 
Figure 28: Residual enzyme activity of urease, pepsin and angiotensin-converting enzyme (ACE) in 
the presence of 4 mM MGO (grey) or 7 mM DHA (dark grey) 
 
Similar results for pepsin and pancreatin were recently published (Daglia et al., 2013). The 
authors concluded that glycation of digestive enzymes may occur, but it does not influence the 
three-dimensional structure and thus enzyme activity. These “protecting effects” may be a 
consequence of protein evolution, since MGO is present in different food, which is commonly 
consumed and physiologically relevant enzymes got adapted to incubation with carbonyls. In 
contrast, the enzyme urease has no protective effect and is specifically inhibited by MGO and 
DHA. Besides naturally present MGO and DHA, manuka honey contains mainly fructose and 
glucose. The effect of a sugar matrix on the urease inhibition was studied by preparing an 
artificial honey. No influence on urease activity was observed until concentrations of 10.9 % 
(w/v) and above, with maximum inhibition of 32 % at 27.3 % (w/v) (see Figure 29A). This 
effect might be due to the osmotic activity of the sugars and the limited availability of water 
for the enzymatic reaction. Hence, in high concentrations, the effect of honey on urease is a 
combination of inhibition caused by sugars and other honey compounds, e.g. MGO and DHA, 
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whereas in small concentrations of honey, sugars do not influence the enzyme activity. To 
prove whether MGO and DHA also inhibit urease activity when present in manuka honey, 
four different manuka honeys with varying MGO and DHA contents were tested. Figure 29B 
shows the urease inhibition of manuka honeys in concentrations ranging between 0.04 and 
27.3 % (w/v). The concentrations of MGO and DHA of the corresponding honeys are listed in 
Table 17. The results indicate that manuka honeys efficiently inhibit urease and that the effect 
is dose-dependent on the MGO and DHA content of the honeys. Figure 29A shows the 
inhibition of urease by non-manuka honeys, namely canola, lime and honeydew honey.  
 
 
Figure 29: Urease inhibition caused by honeys. (A) Artificial honey (white) and non-manuka honeys, 
namely canola (light grey), lime (grey) and honeydew honey (black). (B) Manuka honeys, MH 1 
(white), MH 2 (light grey), MH 3 (grey) and MH 4 (black). Results are expressed as mean values of 
three separate measurements and error bars indicate standard deviation. 
 
Table 17: MGO and DHA concentrations of manuka honeys MH1 to MH 4. Results are expressed as 
mean values of three separate measurements. 
Honey MH 1 MH 2 MH 3 MH 4 
MGO 
(mg/kg) 
73 284 595 435 
DHA (mg/kg) 350 722 1549 4342 
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Compared to manuka honeys, canola and lime honey showed significantly lower inhibitory 
activity on urease. This can be explained by the absence of MGO and DHA in these honeys 
(concentrations below 5 mg/kg). The inhibitory effect of the non-manuka honeys is mainly 
due to the effect of the sugars. A 27.3 % (w/v) solution of artificial honey resulted in 32 % 
inhibition of urease. For canola honey in the same concentration, 34 % and for lime honey 43 
% urease inhibition was observed. The honeydew honey showed a stronger effect compared 
to the other honeys with 62 % inhibition at 27.3 % honey (w/v). Honeydew honeys are known 
to be rich in phenolic compounds originating from the plant phloem which is absorbed and 
excreted by the insects. These compounds may be responsible for the increased inhibitory 
effect of honeydew honey. Earlier reports already showed that honeydew honeys cause 
significantly stronger urease inhibition than other monofloral honeys (Sahin, 2015). This was 
confirmed by the results of the current study. In contrast, a 5.5 % (w/v) solution of manuka 
honey MH 3 inhibited around 50 % of the enzyme. This solution contained 33 mg/l MGO and 
85 mg/l DHA. An aqueous solution of MGO and DHA in the same concentrations was 
prepared to study, if this effect found for honey MH 3 is solely due to these compounds. 
Figure 30 compares the inhibition of manuka honey MH 3 (S4) and the aqueous MGO and 
DHA sample (S3). Both solutions inhibited 50 % of the enzyme activity, thus demonstrating 
that the inhibition of manuka honey is exclusively caused by the effect of MGO and DHA. To 
test whether this inhibition is specific for manuka honey, MGO and DHA were artificially 
added to canola honey in concentrations similar to MH 3 (S2). After addition of MGO and 
DHA, the inhibitory effect of canola honey was higher than canola honey alone (S1), but not 
as strong as caused by manuka honey MH 3.  
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Figure 30: Urease inhibition caused by canola honey (sample S1), canola honey with added MGO and 
DHA (S2), a solution of MGO and DHA in water (S3), manuka honey MH 3 (S4) and manuka honey 
MH 3 after treatment with glyoxalase 1 and GSH (S5). All honeys were diluted to 5.5 % (w/v). MGO 
and DHA concentration was 33 mg/l and 87 mg/l, respectively, for the samples S2-S4. MGO and 
DHA concentration in S5 was not quantitated. Measurements were carried out in duplicate and error 
bars indicate standard deviation. Abbreviation: n.d., not detectable. 
 
This indicates that the strong urease inhibition is exclusive for manuka honey and cannot be 
achieved by adding MGO or DHA to non-manuka varieties. The decreased effect of 
artificially added MGO and DHA in the canola honey matrix could be due to trapping 
reactions caused by honey polyphenols. Benzene structures with hydroxyl groups can form 
MGO adducts (Lo et al., 2011). That reaction may reduce the apparent MGO concentration 
and its urease inhibition capacity. In manuka honey, MGO is naturally formed during honey 
maturation, thus an equilibrium between trapped and free MGO should exist. To elucidate 
whether MGO depletion from manuka honey results in decreased urease inhibition, 
glyoxalase I and glutathione (GSH) were added to MH 3. GSH forms a hemithioacetal adduct 
with MGO which is isomerized to S-2-hydroxyacylglutathione by glyoxalase I (Racker, 
1951). Thus, MGO should no longer be available for urease inhibition. After addition of 
glyoxalase I and GSH, the inhibitory effect of manuka honey MH 3 decreased by 23 %, but 
no complete decrease down to the level of a non-manuka honey was observed (see Figure 30, 
S5). The remaining inhibitory effect is due to DHA, which is not affected by glyoxalase or 
GSH. This unambiguously demonstrates that MGO and DHA are essentially responsible for 
urease inhibition with manuka honey.  
A manuka honey concentration of 0.4 % (w/v) is sufficient to achieve 20 % urease inhibition. 
That corresponds to a dose of 4 g manuka honey containing 595 mg MGO per kg and 1549 
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mg DHA per kg, solubilized in 1 litre of stomach fluid. Thus, an amount of manuka honey 
which causes significant urease inhibition can easily be achieved with the diet. Further studies 
are needed to clarify if the inhibition of jack bean urease can be transferred to urease present 
in Helicobacter pylori. There are several studies published in the literature, which use jack 
bean urease as a model to study potential urease inhibition in Helicobacter pylori (Krajewska, 
2011; Wu et al., 2013). Moreover, studies, which compared the inhibition of certain plant 
extracts on jack bean urease and urease from Helicobacter pylori did not find significant 
differences (Matsubara et al., 2003; Matongo and Nwodo, 2014). The results of this study are 
a contribution to explain the mechanism of the antibacterial activity of manuka honey against 
bacteria by inhibiting enzyme activity. According to our results, manuka honey might be a 
nutritional support for a treatment against Helicobacter pylori and might help to decrease the 
use of antibiotics. 
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1.6. Summary of Chapter A – The antibacterial effect of manuka honey 
 
Manuka honey is merchandised as an antibacterial food which helps to prevent and fight 
bacterial infections. The antibacterial effect is often associated with the methylgloyxal (MGO) 
content of manuka honey. Other honeys show an antibacterial effect which is mostly due to 
hydrogen peroxide. Regarding this, the question arises, how much stronger the antibacterial 
activity of MGO is compared to hydrogen peroxide. The aim of this study was to characterize 
the effect of MGO and hydrogen peroxide on four bacteria and give a quantitative statement 
on the effectiveness of these compounds in honey. Moreover, the molecular structure of 
manuka honey inclusion complexes formed with α-cyclodextrin were characterized and their 
antibacterial activity was studied. Furthermore, the mechanism of bacterial inhibition with 
manuka honey was studied by examining the inhibitory effect of MGO and dihydroxyacetone 
(DHA), present in manuka honey, on the enzyme urease. This enzyme ensures the survival of 
the bacterium Helicobacter pylori and, by decreasing its activity, bacterial growth may be 
inhibited. The results of chapter A can be summarized as follows: 
1 Methylglyoxal (MGO) in honey-relevant concentrations had a bacteriostatic effect on S. 
aureus, E. coli and B. subtilis, whereas P. aeruginosa was not inhibited by MGO. 
2 Hydrogen peroxide, which is formed in diluted honey, had a bacteriostatic effect on S. 
aureus, E. coli and P. aeruginosa, whereas B. subtilis was not inhibited by hydrogen 
peroxide. 
3 By comparing the slopes of the linearized dose-response curves, it was found that S. 
aureus, E. coli and P. aeruginosa are more sensitive to hydrogen peroxide than to MGO.  
4 Natural amounts of MGO in honey were higher than the formation of hydrogen peroxide. 
Although most bacteria were more sensitive to hydrogen peroxide, MGO was the 
predominant antibacterial compound in honey, because of its high concentrations 
compared to hydrogen peroxide formation. Certain bacterial species could be specifically 
inhibited by hydrogen peroxide and were insensitive to MGO (e.g. P. aeruginosa). 
5 Studies on the molecular structure of α-cyclodextrin inclusion complexes with MGO and 
DHA showed that protons inside the cone of α-cyclodextrin interact preferentially with 
MGO. An inclusion of MGO with α-cyclodextrin in the commercial product cyclopower 
is likely due to the excess of α-cyclodextrin compared to MGO (190:1). 
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6 Presumably, the inclusion has only minor consequences on bioavailability and 
antibacterial activity. Cyclopower did not enhance the antibacterial activity of manuka 
honey on S. aureus, E. coli and P. aeruginosa. 
7 The growth of B. subtilis was synergistically inhibited with cyclopower compared to 
manuka honey and α-cyclodextrin alone. 
8 Possible targets for bacterial inhibition with manuka honey are bacterial enzymes. It was 
shown that MGO and DHA inhibit jack bean urease, which was used as a model for 
Helicobacter pylori urease, with IC50 values of 2.8 and 5.0 mM, respectively. 
9 Urease inhibition of manuka honey correlated with its MGO and DHA content.  
10 Non-manuka honeys, which lack MGO and DHA, showed significantly less urease 
inhibition. MGO depletion from manuka honey with glyoxalase reduced urease 
inhibition. Therefore, urease inhibition by manuka honey was mainly due to MGO and 
DHA. 
 
The results of this chapter contribute to the understanding of the antibacterial activity of 
manuka honey and emphasize its unique effect compared to non-manuka honey. 
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2 Chapter B – Reactions of carbonyl compounds in honey 
 
2.1. Introduction 
 
Honey contains mostly mono- and disaccharides (80 g/100 g) and water (18 g/100 g). Minor 
compounds like polyphenols, melanoidins, free amino acids and proteins account for up to 2 
g/100 g. Based on its composition, honey is highly susceptible to the Maillard reaction. Louis-
Camille Maillard discovered that sugars react with amino acids to form brown compounds 
upon heating in 1912  (Maillard, 1912). Since then, the reaction has been studied intensively 
in vivo and in vitro (Hodge, 1953; Ledl and Schleicher, 1990; Tessier, 2010; Hellwig and 
Henle, 2014). The pattern of reaction products varies with the reaction conditions, whereby 
time, temperature and pH value have the strongest impact. The Maillard reaction is a complex 
of dehydration and fragmentation reactions and the irreversible binding of reaction products 
to amino compounds (gycation) can lead to advanced glycation end products (AGE). The 
reaction can have technological and biological consequences for proteins. It is widely 
accepted, that the Maillard reaction follows three main stages (early, advanced and final 
stage) and that dicarbonyl compounds are major reaction products (Ledl and Schleicher, 
1990). Earlier studies reported the occurrence of 3-deoxyglucosone, glyoxal and 
methylglyoxal in honey (Weigel et al., 2004; Mavric et al., 2008). It was found that manuka 
honey has a unique composition of dicabonyl compounds, whereby methylglyoxal (MGO) is 
present in concentrations up to 800 mg/kg (Mavric et al., 2008; Adams et al., 2009). 
Moreover, Kunze (2009) studied the protein and amino acid composition of honeys in her 
master thesis. Nevertheless, the extent of the Maillard reaction and its influence on proteins 
and amino acids in honey has not been studied yet. The focus of this chapter is based on the 
idea that the Maillard reaction also occurs in honey and that the pattern of reaction products 
differs between manuka and non-manuka honeys. The study focused on three reaction 
pathways, which are all part of the complex Maillard reaction system. Firstly, the occurrence 
of 2-acetyl-1-pyrroline, a product formed by the reaction of proline and MGO was studied. 
Secondly, proteins were isolated from honey and their fluorescence properties and molecular 
size were analysed. Thirdly, the isolated honey proteins were enzymatically hydrolysed and 
protein bound AGE were studied. The third part was a collaboration with Dr. Michael 
Hellwig (TU Dresden), who performed a study on the formation of AGE in honey. The 
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reactions were studied in model honeys with artificially added MGO and in commercial 
honey samples during storage. 
 
2.2. Background 
 
2.2.1 Carbonyl compounds in food 
The term carbonyl compounds refer to all organic compounds which contain carbonyl groups 
in their molecular structure. Examples for carbonyl compounds are aldehydes, ketones, and 
carboxylic acids or amides. In food, these compounds are mainly present in the form of 
carbohydrates or peptides and proteins. Especially the group of carbohydrates generates 
various structures, which are referred to as carbonyl compounds. These could either be of the 
aldehyde type, e.g. glucose or of the ketone type, e.g. fructose. Moreover, compounds can 
contain more than one carbonyl group. Compounds with two adjacent carbonyl groups, called 
1,2-dicarbonyls, are of particular interest for research. 1,2-Dicarbonyls are sugar degradation 
products, which occur in food after thermal treatment. They are preferentially formed at pH 
values below 3 or above 8. In fermented food 1,2-dicarbonyls can be formed by 
microorganisms and in plants they can occur during stress conditions (Yadav et al., 2005; 
Nemet et al., 2006). 1,2-Dicarbonyls are known to react with proteins and amino acids to form 
advanced glycation end products (AGE) (Brownlee et al., 1984). The effect of dietary AGE in 
vivo is discussed controversially (Henle, 2007). 3-Deoxyglucusone (3-DG), glyoxal (GO) and 
methylglyoxal (MGO) are quantitatively the most relevant dicarbonyl compounds in food 
(Gobert and Glomb, 2009). Figure 31 shows the molecular structures of 3-DG and MGO. 
 
 
Figure 31: Molecular structures of 3-deoxyglucosone and methylglyoxal 
Since 3-DG and MGO are also the most relevant 1,2-dicarbonyls in honey, these compounds 
will be discussed in detail. For 3-DG formation, an amino compound reacts with the aldehyde 
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group of glucose to form imines (Schiff base) in the early stage of the Maillard reaction. Via 
1,2-enolization, the stable 1-amino-1-deoxyketose (Amadori product) is formed (Ledl and 
Schleicher, 1990) (see Figure 32).  
 
 
 
Figure 32: Formation of 1-amino-1-deoxyketose (Amadori product) from glucose, R2 = C3O3H7 
 
During the advanced stage, the Amadori product can rearrange via 1,2-enolization or 2,3-
enolization and after water elimination and hydrolysis of the amino group, dicarbonyl 
compounds are formed. The formation of 3-DG is shown in Figure 33. 
 
 
 
 
Figure 33: Formation of 3-deoxyglucosone from the Amadori product of glucose, R2 = C3O3H7 
 
In contrast, the short dicarbonyl methylglyoxal is formed from deoxyosones or from the 
Amadori product of glucose via retro-aldol fragmentation. The fragmentation is enhanced 
under alkaline conditions (Kroh, 1994; Thornalley et al., 1999). 
 
 
78  Chapter B     
 
 
 
 
 
 
Figure 34: Formation of methylglyoxal from 3-DG, R2 = C3O3H7  
However, methylglyoxal and also 3-DG can be formed from other sources than glucose in 
food. For example caramelisation or lipid peroxidation can lead to an increase of 1,2-
dicarbonyls (Belitz, Grosch, 2008). Moreover, methylglyoxal is formed in living organisms in 
small amounts from the dephosphorylation of triose phosphates (Richard, 1993; Kalapos, 
1999). Triose phosphates like glyceraldehyde phosphate (GA3P) and dihydroxyacetone 
phosphate (DHAP) are metabolites of glycolysis. The enediol intermediate of the 
interconversion of DHAP and GA3P is a source of methylglyoxal. The reaction can occur in 
plants (Takagi et al., 2014; Bilova et al., 2016) and mammalian tissue (Allaman et al., 2015). 
Furthermore, MGO can arise directly from dihydroxyacetone (DHA). The occurrence of DHA 
is only insufficiently studied and it is not commonly found in food. Severin et al. (1984) 
reported that DHA occurs in pretzels, but they did not report quantitative data. The only 
exception where DHA is found in significant amounts is manuka honey. It was found that in 
honeys from the plant Leptospermum scoparium (manuka tree) the DHA level is significantly 
higher compared to other honeys and food. During storage, DHA is non-enzymatically 
dehydrated to MGO (Adams et al., 2009; Atrott et al., 2012). The quantitative data on the 
occurrence of 1,2-dicarbonyls in food is rather limited. Recent studies aimed to give a more 
accurate picture of the formation and distribution of 1,2-dicarbonyls in food. Table 18 
summarizes the relevant findings concerning MGO and 3-DG. 
 
Table 18: Concentrations of 1,2-dicarbonyls in food and their cause of formation 
Food 
Dicarbonyl 
mg/kg or mg/l Cause of formation 
3-DG MGO 
Vinegar 4.6-2622[1] 1.7-53[1] Microorganisms 
Soy sauce 32-832 [1] 
n.d.-12 [1] 
3.0-8.7 [2,3] 
Microorganisms 
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Beer (Pilsener) 
 
Malt beer 
18-54 [1] 
153-159 [4] 
19-136 [1] 
n.d.-1.0 [1] 
0.1-5.1[1,4,5] 
tr.-1.0 [1] 
Sugar, 
microorganisms 
Soft drink n.d.-28 [1] 
29-30 [6] 
n.d. [1] 
0.2-1.4 [2,3,6] 
Sugar 
Milk (UHT) n.d-1.4 [7] n.d. [7] Sugar 
Bread 13-619 [1] n.d.-28 [1] 
0.8-2.5 [3] 
Sugar 
Cookies 8-5-385 [1] 1.8-68 [1] 
3.7-82 [8] 
Sugar 
Honey 271-1641 [1] 
97-1266 [9] 
0.4-5.4 [9] 
 
Sugar 
Manuka honey 563-1060 [10] 38.4-761 [10] Sugar and DHA 
 
[1]Degen et al. (2012), [2] Hayashi & Shibamoto (1985), [3] Nagao et al. (1986), [4] Bravo et al. (2008), 
[5] Yamaguchi et al. (1994), [6] Lo et al. (2008), [7] Hellwig et al. (2010), [8] Arribas-Lorenzo & Morales 
(2010), [9] Weigel et al. (2004), [10]Mavric et al. (2008) 
 
Since 1,2-dicarbonyls are reactive compounds, it is likely that they are only intermediately 
present in food and can react with other compounds to form a variety of reaction products. 
The next section gives an overview of the most important reaction pathways of 1,2-dicarbonyl 
compounds in food. 
 
2.2.2 Reactions of carbonyl compounds in food 
In comparison to glucose, 1,2-dicarbonyls can be up to 20,000-fold more reactive 
(Thornalley, 2005). The α-oxoaldehydes can react with proteins to form protein-bound 
Maillard reaction products (MRP). The reactivity of individual proteins is dependent on the 
amino acid composition, the primary, secondary, and tertiary structure, and on the presence of 
cysteine (Ludwig, 1979; Hellwig and Henle, 2014). The amino acid derivatives resulting from 
the reaction with 1,2-dicarbonyls are called advanced glycation end-products (AGE). AGE 
can either be released from their protein linkage by enzymatic matters or can directly form at 
free, non-protein-bound amino acids. Table 19 summarizes some of the most important AGE 
formed in food. Besides modification of single amino acid residues, AGE formation can also 
lead to protein cross-linking when two dicarbonyl compounds react intramolecularly with two 
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amino acid residues. Popular representatives of this group are the lysine dimers MOLD and 
DOLD, which are formed by methylglyoxal and 3-DG respectively (Henle, 2005).  
 
Table 19: Structures and starting material of advanced glycation end-products 
AGE Structure 
Amino 
acid 
Dicar-
bonyl 
N-ε-Carboxyethyllysine 
(CEL) 
 
 
Lysine MGO 
Methylglyoxal-derived 
hydroimidazolone 
(MG-H1) 
 
 
Arginine MGO 
Pyrraline 
 
 
Lysine 3-DG 
3-Deoxyglucoson-derived 
hydroimidazolone 
(3-DGH) 
 
 
Arginine 3-DG 
N-ε-Carboxymethyllysine 
(CML) 
 
 
Lysine GO 
 
AGE formation can lead to the biochemical blockage of amino acids, since the modified 
amino acids are not available for digestive enzymes during gastrointestinal digestion. Thus, 
glycated proteins cannot be used as a source of essential amino acids (Finot, 1982). However, 
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during food processing, the Maillard reaction and especially the reaction of 1,2-dicarbonyls 
with amino acids can also have positive impact on food components. During Strecker 
degradation of amino acids with dicarbonyls, various aroma compounds are generated (Wang 
and Ho, 2012). In the initial phase of Strecker reaction a Schiff base is formed. Later during 
the reaction, the intermediate is cleaved via decarboxylation of the carboxyl group of the 
amino acid and subsequent formation of Strecker aldehyde and the corresponding amino 
ketone. Strecker aldehydes can be aroma active themselves and the amino ketones are key 
precursors for the formation of flavour compounds such as pyrazines, oxazoles and thiazoles 
(Wang and Ho, 2012). Moreover, intramolecular reactions of 1,2-dicarbonyls can lead to 
aroma active compounds. For example, MGO can form furaneol via the Cannizzaro reaction 
(Wang and Ho, 2008) and 3-DG can form 5-hydroxymethylfurfuraldehyde (HMF) via 
dehydration (Belitz, Grosch, 2008). Finally, the multiple interactions of MRP generate a wide 
pattern of advanced stage low molecular weight (LMW) products. The final stage of the 
Maillard reaction can also lead to high molecular weight (HMW) products, like melanoidins. 
To date neither the mechanism of formation nor the detailed structure of these partly dark 
brown coloured compounds are clarified completely (Kroh et al., 2008). It is assumed that 
covalent binding of low molecular weight compounds to form high molecular weight 
structures is one possible mechanism of melanoidin formation and of acquiring their 
antioxidant properties (Hofmann, 1998; Delgado-Andrade and Morales, 2005). Moreover, the 
incorporation of polyphenols into melanoidins and their influence on melanoidin functions 
was discussed (Brudzynski and Miotto, 2011).  
Concerning honey, reactions of carbonyls are rarely studied. Weigel et al. (2004) analysed the 
1,2-dicarbonyls 3-DG, glyoxal and MGO in honey for the first time and discussed the results 
in context to the HMF contents of the honeys. It was shown that most honeys predominately 
contain 3-DG in amounts between 80 to 1300 mg/kg, followed by smaller amounts of 0.2 to 
2.7 mg/kg of GO and 0.4 to 5.4 mg/kg of MGO. The HMF content of the honeys ranged 
between 0.6 and 44 mg/kg, which is predominantly in accordance with the European food 
regulation (Codex Alimentarius Commission, 2001). An exception of dicarbonyl content to 
honeys studied previously is manuka honey. It was found that manuka honey contains MGO 
in concentrations up to 100-fold higher than other commercial honeys (Adams et al., 2008; 
Mavric et al., 2008). MGO in manuka honey is non-enzymatically formed from 
dihydroxyacetone (DHA), which is present in the nectar of the manuka plant (Adams et al., 
2009; Atrott et al., 2012). Since then, there are various reports on the occurrence of DHA and 
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MGO in manuka nectar and honey (Windsor et al., 2012; Williams et al., 2014; Cokcetin et 
al., 2016; Grainger et al., 2016a). Moreover, HMF was studied intensively as a quality 
parameter of honey and the influence of storage parameters and heat treatment was shown 
previously (Singh and Bath, 1998; Karabournioti and Zervalaki, 2001; Windsor et al., 2013). 
Thus, the current situation gives a good picture of the formation of reactive carbonyl 
compounds in honey, especially manuka honeys. Nevertheless, there is only minor knowledge 
available about the reactions which occur in honey when 1,2-dicarbonyls further react with 
other honey compounds. Previous research showed, that MGO in manuka honey is not stable 
during storage (Grainger et al., 2016a). The fate of MGO and other honey carbonyls during 
honey processing and storage shall be addressed in this chapter. The following section should 
give a brief overview of methods to study carbonyl reactions in food matrices. 
 
2.2.3 Analysis of carbonyl reaction products 
As presented previously, the Maillard reaction leads to a diverse field of reaction products. 
The chemical and physical nature of the compounds can vary widely. Thus, the quantification 
of reaction products resulting from the reaction of carbonyls with proteins and amino acids is 
mainly achieved by measuring specific structures as representative compounds, which are 
formed during the complex reaction. During the early stage of the Maillard reaction, Amadori 
products are formed as the first stable intermediate. A popular method to study the early 
Maillard reaction is to analyse the furosine content of food via HPLC (Pompei and 
Spagnolello, 1997; Villamiel et al., 2000). Furosine is formed during the acid hydrolysis of 
protein-bound Amadori product of lysine. Depending on the sugar residue bound to lysine, 
the rate of furosine formation during hydrolysis differs (Krause et al., 2003). Therefore, 
conversion factors for the formation of furosine from Amadori products were calculated, thus 
enabling the evaluation of the progress of the early Maillard reaction (Krause et al., 2003). 
The advanced stage of the Maillard reaction can be analysed by measuring specific AGE 
structures. There are several methods published, which deal with sample preparation and 
product detection. The analysis of AGE in food and body fluids is most often performed by 
enzyme-linked immunosorbent assay (ELISA) or LC-MS (Sajithlal et al., 1998; Schmitt et al., 
2007; Poulsen et al., 2013; Thornalley and Rabbani, 2014). The ELISA method is often used 
by medical laboratories since no sophisticated instruments are required. However, the 
specifity of the antibodies for only one AGE structure is questionable (Poulsen et al., 2013). 
The ELISA method needs to be validated for different food matrices so that cross-reaction 
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with other AGE-modified structures can be prevented (Henle, 2008). In contrast the use of 
LC-MS/MS increases the sensitivity and in combination with isotopically labelled standards 
and the multiple reaction monitoring (MRM) mode the method is exact and suitable for 
quantification (Poulsen et al., 2013). Moreover, there are methods which do not measure 
specific glycation compounds but provide a more general view of the progress of the Maillard 
reaction. By measuring the colour of protein isolates from food matrices, statements 
concerning the extent of the Maillard reaction and the degree of cross-linking reactions can be 
given. As described in section 2.2.2, the final stage of the Maillard reaction provides complex 
reaction products, which are called melanoidins because of their colour properties (Hodge, 
1953). The products are mostly yellow or brown and can absorb light at the wavelength 405-
420 nm (De Marco et al., 2011). Moreover, the formation of fluorescent products during the 
Maillard reaction in milk is reported (Morales et al., 1996). For food stuff, the excitation 
wavelength studied were between 340 to 370 nm and the emission wavelength varied between 
420 to 450 nm (Sajithlal et al., 1998; Morales and Jiménez-Pérez, 2001; Bosch et al., 2007). It 
is known that dicarbonyls and amino acids can form specific, fluorescent AGE. One example 
is the formation of argpyrimidine which results from the reaction of MGO and arginine 
(Shipanova et al., 1997). However, the maximum fluorescence excitation and emission 
wavelengths of argpyrimidine are situated at shorter wavelengths (λex/em = 320/380 for 
argpyrimidine). Besides specific structures, protein fluorescence can be caused by protein 
crosslinking, reactions at the peptide backbone or changes in the tertiary structure (Sajithlal et 
al., 1998). It was initially assumed that fluorescent structures are a precursor of brown 
melanoidin pigments (Berrens, 1966; Adhikari and Tappel, 1973). Later on it was shown that 
under certain reaction conditions (low pH, retardant salts) brown pigments can be formed 
before fluorescent structures are present (Matiacevich and Pilar Buera, 2006). After the 
incubation of casein with lactose or glucose it was found that fluorescent compounds can 
either be formed protein-bound or to a lesser extent also in free form (Morales and Boekel, 
1997). The authors were able to show that fluorescence evolution was due to many different 
reactions products and that their formation was heat dependent. They concluded that the 
measurement of the sum of fluorescent AGE could be a valuable parameter to analyze the 
Maillard reaction in food matrices. Another rather unspecific method to pursue glycation 
reactions in food is size exclusion chromatography (SEC). SEC enables the user to 
differentiate molecules upon their molecular size. The detection of compounds is mostly 
based on UV or fluorescence. There exists a wide range of SEC columns which allow the 
84  Chapter B     
 
 
 
 
separation of proteins of various molecular sizes. It was recently shown, that the extent of 
browning reactions and the formation of fluorescent structures in bread crust and crumb can 
be followed by SEC (Helou et al., 2016). Moreover, SEC can also be used to distinguish 
between the precursors which are involved in the formation of HMW products. It was shown 
that the molecular size of melanoidins varies depending on the carbonyl compound which is 
involved in the formation (Fiedler et al., 2006). The authors were able to present that 
methylglyoxal is predominantly forming HMW products whereby 3-DG promotes the 
formation of lower molecular size domains. Besides, De Marco et al. (2011) showed that the 
increase of the molecular size of coffee melanoidins is an indicator for the progression of 
coffee bean roasting. The increase of the molecular size was explained by the incorporation of 
carbohydrates and phenolic compounds into a proteinaceous backbone. Taken together, both 
the analysis of concrete reaction products of the final stage of the Maillard reaction like AGE 
and the measurement of more general parameters like fluorescence or molecular size can be 
used to evaluate the extent of glycation reactions in food.  
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2.3. Aims 
Despite the high ratio of reducing sugars to proteins and amino acids, there is only limited 
information available dealing with the extent of glycation reactions in honey. Although it was 
shown that MGO in manuka honey slowly decreases over storage time, it is unknown which 
reaction products are formed up to the present day. Based on the hypothesis that honey in 
general and especially manuka honey with its unique high level of MGO is prone to glycation 
reactions, different honey-derived reactions shall be analyzed. The study was divided into two 
parts. Firstly, the reaction of MGO with small honey compounds to form LMW products was 
investigated. Therefore, a reaction product of MGO and the amino acid proline, namely 2-
acetyl-1-pyrroline (2-AP), was studied in honey and the concentrations were considered in 
relation to the MGO content of the honeys. Secondly, honey proteins were isolated and the 
formation of protein adducts was studied. Therefore, the molecular size and the fluorescence 
intensity of the HMW fraction of honey were analyzed. Moreover, a selection of protein-
bound Maillard reaction products was studied. This project was part of a study performed in 
cooperation with Dr. Michael Hellwig (TU Dresden). The aim of this chapter is to elucidate 
the formation of mainly MGO-derived reaction products in manuka honey compared to non-
manuka honey. The results of this study are supposed to contribute to the understanding of the 
unique reactions in manuka honey and could potentially be used to control honey authenticity 
and quality.  
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2.4. Methods 
 
2.4.1 Chemicals 
 
Table 20: Chemicals used for the studies presented in chapter B 
Chemical Specification Supplier 
1,3-Dihydroxyacetone dimer 97 % 
Sigma-Aldrich, Steinheim, 
Germany 
2,4,6-Trimethylpyridine > 99 % 
Sigma-Aldrich, Steinheim, 
Germany 
2-Acetyl-1-pyrroline 10% w/w in DCM 
Toronto Research Chemicals, 
Toronto, Canada 
3-[(3-cholamidopropyl)-
dimethylammonium]-1-
propanesulfonate, CHAPS 
99.3 % Molekula, Dorset, UK 
5-Hydroxymethylfurfuraldehyd 98+ % 
Alfa Aesar, Karlsruhe, 
Germany 
Acetic acid 100 %, p.a. 
Carl Roth, Karlsruhe, 
Germany 
Acetonitrile HPLC grade VWR, Darmstadt 
Amino acid mix 
2.5 mM each, in 0.1 M 
hodrochloric acid 
Sigma-Aldrich, Steinheim, 
Germany 
Ammonia 25 % Merck, Darmstadt, Germany 
Catalase 
from bovine liver, suspension in 
water, 15 000 000 U/15 ml 
Sigma-Aldrich, Steinheim, 
Germany 
Copper(II) sulfate pentahydrate  ≥99 %, Ph.Eur. 
Carl Roth, Karlsruhe, 
Germany 
D(-)Fructose > 99.5 %, for biochemistry 
Carl Roth, Karlsruhe, 
Germany 
D(+)-Glucose anhydrous, p.a. 
Carl Roth, Karlsruhe, 
Germany 
D(+)-Saccharose ≥ 99.5 %, p.a. 
Carl Roth, Karlsruhe, 
Germany 
Dichloromethane HPLC grade VWR, Darmstadt, Germany 
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Disodium hydrogenphosphate 99 %, p.a Grüssing, Filsum, Germany 
Dithiothreitol >99 % Molekula, Dorset, UK 
Dodium dodecyl sulfate min. 99.5 % Serva, Heidelberg, Germany 
Ferritin Part of gel filtration calibration kit 
GE Healthcare, Uppsala, 
Sweden 
Folin Ciocalteu’s phenol reagent  Fluka, Buchs, Switzerland 
Formyline 
Synthesis product, Michael 
Hellwig 
TU Dresden, Germany 
Glucose oxidase 
from Aspergillus niger, 10 kU, 
47200 U/g 
Sigma-Aldrich, Steinheim, 
Germany 
Helium 99.999 %, Alphagaz Air Liquide 
Hydrochloric acid 37 % 
Sigma-Aldrich, Steinheim, 
Germany 
Leucine aminopeptidase Type IV-S, 18 U/mg protein 
Sigma-Aldrich, Steinheim, 
Germany 
Lithium chloride p.a. Merck, Darmstadt, Germany 
Lithium citrate buffer 0.12 N, pH 2.2 
Sykam, 
Fuerstenfeldbruck, Germany 
Lithium citrate buffer 0.12 N, pH 2.9 
Sykam, 
Fuerstenfeldbruck, Germany 
Lithium citrate buffer 0.3 N, pH 4.2 
Sykam, 
Fuerstenfeldbruck, Germany 
Lithium citrate-/ borate buffer 0.3 N, pH 8.0 
Sykam, 
Fuerstenfeldbruck, Germany 
Lysozyme from chicken egg white 
Sigma-Aldrich, Steinheim, 
Germany 
Maltosine 
Synthesis product, Michael 
Hellwig 
TU Dresden, Germany 
Methanol HPLC grade VWR, Darmstadt, Germany 
Methylglyoxal  
~ 40 % (w/w), exact 
concentration was determined 
against 2-MQ 
Sigma-Aldrich, Steinheim, 
Germany 
Methylglyoxal-derived 
hydroimidazolone 
Synthesis product, Michael 
Hellwig 
TU Dresden, Germany 
Ninhydrin p.a., min. 99% Serva Feinbiochemica, 
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Heidelberg, Germany 
Nonafluoropentanoic acid 97 % 
Sigma-Aldrich, Steinheim, 
Germany 
N-ε-Carboxyethyllysine 
Synthesis product, Michael 
Hellwig 
TU Dresden, Germany 
N-ε-Carboxymethyllysine 
Synthesis product, Michael 
Hellwig 
TU Dresden, Germany 
N-ε-fructosyllysine 
Synthesis product, Michael 
Hellwig 
TU Dresden, Germany 
N-ε-maltulosyllysine 
Synthesis product, Michael 
Hellwig 
TU Dresden, Germany 
ortho-Phenylenediamine (oPD) ≥98 %, 
Sigma-Aldrich, Steinheim, 
Germany 
Ovalbumin from chicken egg white 
Sigma-Aldrich, Steinheim, 
Germany 
Pepsin 
from porcine gastric mucosa, 
3555 U/mg protein 
Sigma-Aldrich, Steinheim, 
Germany 
Potassium sodium tartrate 
tetrahydrate 
≥99 %, p.a. 
Carl Roth, Karlsruhe, 
Germany 
Prolidase 
from porcine kidney, 208 U/mg 
protein 
Sigma-Aldrich, Steinheim, 
Germany 
Pronase E 
from S. griseus, 4000 PU/mg 
protein 
Merck, Darmstadt, Germany 
Pyrraline 
Synthesis product, Michael 
Hellwig 
TU Dresden, Germany 
Sodium acetate 99 % Grüssing, Filsum, Germany 
Sodium carbonate 99.5 %, p.a. Grüssing, Filsum, Germany 
Sodium dihydrogenphosphate 99.5 %, p.a. Grüssing, Filsum, Germany 
Sodium hydroxide 98.56 % 
Fisher Scientific, 
Loughborough, UK 
Sigma-Aldrich, 
Sodium sulfate Anhydrous, p.a. Grüssing, Filsum, Germany 
Trichloroacetic acid > 99%; p.a. 
Carl Roth, Karlsruhe, 
Germany 
Tris(hydroxymethyl)- ≥99 %, p.a. Sigma-Aldrich, Steinheim, 
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aminomethan (TRIS) Germany 
Urea > 99.5 % Fluka AG, Basel, Switzerland 
γ-Globulin from bovine blood 
Sigma-Aldrich, Steinheim, 
Germany 
 
2.4.2 Materials 
 
Table 21: Materials used for the studies presented in chapter B 
Name Specification Supplier 
Amino acid analysator column Cation exchange LCA K07/Li 
Sykam, 
Fuerstenfeldbruck, Germany 
Centrifuge tube, Kimax® 
50 mL,  
O.D. × L 29 mm × 123 mm 
Sigma-Aldrich, Steinheim, 
Germany 
Dialysis tubings 
Cellulose, 33 mm, MWCO 14 
kDa 
Sigma-Aldrich, Steinheim, 
Germany 
GC column 
TR-FFAP capillary column,  
30.0 m × 0.25 mm inner diameter, 
with a 0.25 μm film thickness 
Thermo Scientific, Runcorn, 
U.K. 
GC vials with crimp caps 1.5 ml, glass VWR, Darmstadt, Germany 
Glass vessel 10-50 ml VWR, Darmstadt, Germany 
HPLC column 
Eurospher 100 RP18 material 
(250mm x 4.6 mm, 5 µm particle 
size with integrated pre-column 
Knauer, Berlin, Germany 
HPLC column 
Zorbax 100 SB-C18 column, 2.1 
× 50 mm, 3.5 μm 
Agilent Technologies, 
Böblingen, Germany 
HPLC vials with lit 1.5 ml, glass VWR, Darmstadt, Germany 
Ion-exchange resin Dowex 
50WX8 
100-200 mesh 
Sigma-Aldrich, Steinheim, 
Germany 
Membrane filter 
Regenerated cellulose, 45 µm, 26 
mm 
Phenomenex, Aschaffenburg, 
Germany 
Membrane filter for solvents 
GH Polypro 0,45 µm, 47 mm 
hydrophilic polypropylene 
Pall, Crailsheim, Germany 
Microtiter plate  
96 flat bottom, transparent, 
pureGrade, nonsterile 
Brand, Wertheim, Germany 
Microtiter plate UV-star Greiner Bio-One, 
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Kremsmuenster, Austria 
Microtiter plate 
96 flat bottom, black, pureGrade, 
nonsterile 
Brand, Wertheim, Germany 
Multichannel pipette 10-100 µl Brand, Wertheim, Germany 
Parafilm 4 in x 125 ft Bemis, Neenah, USA 
Pasteur pipettes 230 mm, glass 
VWR International, Leuven, 
Netherlands 
Pipette tips 1-1000 µl Brand, Wertheim, Germany 
Septa for HPLC vials 8*0.4 mm, PTFE coated VWR, Darmstadt, Germany 
Superdex 200 column 10/30 GL 
GE Healthcare Bio-Sciences 
AB, Uppsala, Sweden 
Syringe 1 ml 
B. Braun, Melsungen, 
Germany 
Tubes 1.5 ml, 2 ml 
Eppendorf, Hamburg, 
Germany 
 
2.4.3 Devices 
 
Table 22: Devices used for the studies presented in chapter B 
Device Specification Supplier 
Amino acid analysator 
S 4300, Software: Chromstar 6.3 
SCPA GmbH 
Sykam, 
Fuerstenfeldbruck, Germany 
Analytic balance 
BP 121 S, accuracy: 0.0001 g, 
max. 120 g 
Sartorius, Göttingen, 
Germany 
Centrifuge Eppendorf 5804-R 
Eppendorf AG, Hamburg, 
Germany 
CLN detector 8060 Antek, Houston, USA 
Freeze dryer Alpha 1 - 2 
Martin Christ, Osterode, 
Germany 
Freezer Comfort 
Liebherr, Bibrach an der Riss, 
Germany 
Fridge Econoic System, 5°C 
Liebherr, Bibrach an der Riss, 
Germany 
GC-MS 
GC 7890A system, 7683 Series 
injector with sample tray, 5975C 
Agilent Technologies, 
Böblingen, Germany 
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MS detector in electron ionization 
(EI) mode 
HPLC system 1 
Äkta basic system 
pump P-900 
auto sampler A-900 
UV detector UV-900 
online degasser K-5004 
Amersham Pharmacia 
Biotech, Uppsala, Sweden 
 
 
Knauer, Berlin, Germany 
HPLC system 2 
Smartline 1000 pump  
Dynamic mixing chamber 
solvent organizer K-1500 
online degasser K-5004 
Basic Marathon auto sampler 
Azura DAD detector 2.1 L 
Knauer , Berlin, Germany 
 
Knauer , Berlin, Germany 
Knauer , Berlin, Germany 
Sparks , Netherlands 
Knauer, Berlin, Germany 
HPLC system 3 (connected to 
CLN detector) 
Quarternary pump G1311A, 
Autosampler G1313A, 
Variable Wavelength Detector 
G1314A, Column Thermostat 
G1316A, Degasser G1322A 
Agilent Technologies, 
Böblingen, Germany 
HPLC-MS/MS 
binary pump (G1312A), online 
degasser (G1379B), autosampler 
(G1329A), column thermostat 
(G1316A), diode array detector 
(G1315D), triple-quadrupole 
mass spectrometer (G6410A) 
Agilent Technologies, 
Böblingen, Germany 
Incubator  BE 500 
Memmert, Schwabach, 
Germany 
Incubator  BE 400 
Memmert, Schwabach, 
Germany 
Incubator ULM 500 
Memmert, Schwabach, 
Germany 
Laboratory pipette 1-1000 µl 
Eppendorf AG, Hamburg, 
Germany 
LabWater Purelab Plus water 
system 
conductivity 0.055 µS/cm 
ELGA, Celle, Germany  
filter from 
USFilter, Ransbach-
Baumbach, Germany 
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Magnetic and heating stirrer 
 
RH basic 
IKA Labortechnik, Staufen, 
Germany 
 
Multimode reader Tecan infinite M200 Tecan, Mainz, Germany 
pH meter 
InoLab Level 1, electrode: InLab 
Semi-Micro 
Mettler-Toledo, Weilheim, 
Germany 
Photometer Spekol 1500 Analytik Jena, Jena, Germany 
Ultrasonic bath Sonorex RK 510 Super Bandelin, Berlin, Germany 
Viscotester iQ Peltier control 
Haake/Thermo Fisher 
Scientific, Waltham, USA 
Vortex Uniprep Gyrator Uniequip, Freital, Germany 
Vortex Minishaker MS-1 IKA 
IKA Labortechnik, Staufen, 
Germany 
 
 
2.4.4 Honey samples 
 
Table 23: List of commercial honey samples, Chapter B 
Honey Quantity Manufacturer, Best before 
Buckwheat honey 1 Bienenhonig R. Feldt, 03/18 
Chestnut honey 1 
Imkerauslese L.W.C. 
Michelsen, 03/14 
Cornflower honey 1 
Hans Grundner Imkermeister, 
01/17 
Honeydew honey 1 Biophar, Fürsten-Reform, 11/17 
Lime honey 1 Biophar, Fürsten-Reform, 12/17 
Manuka honey active 10 1 Wellbeing, 07/2015 
Manuka honey active 20 1 Wellbeing, 09/2016 
Manuka honey active 5 1 Wellbeing, 03/2016 
Manuka honey Bio  1 Hoyer GmbH, 08/2011 
Manuka honey MGO 250 2 Manuka Health NZ Ltd 
Manuka honey MGO 30 3 Manuka Health NZ Ltd 
Manuka honey MGO 400 2 Manuka Health NZ Ltd 
Manuka honey MGO 550 2 Manuka Health NZ Ltd 
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Manuka honey Miel de Manuka IAA 15 + 1 
Compoirs & Compagnies, 
05/18 
Manuka honey Miel de Manuka IAA 18 + 1 
Compoirs & Compagnies, 
05/18 
Manuka honey Miel de Manuka IAA 5 + 1 
Compoirs & Compagnies, 
05/18 
Manuka honey Pure Gold 18 1 Pure Gold, 08/16 
Manuka honey Pure Gold 8 1 Pure Gold, 09/16 
Manuka honey UMF 15 1 Comvita, 10/2016 
Manuka honey UMF 20 1 Comvita, 05/2016 
Manuka honey UMF 5 1 Comvita, 09/2016 
Manuka honey, Queen Bee active 15 1 Queen Bee, 04/16 
Manuka honey, Steen Raw 25 1 Steens limited, 11/15 
Polyfloral honey 1 Dr. Krieger, 08/17 
Polyfloral honey 1 
Nektarquell, Ulis Hongimarkt 
04/14 
Canola honey 1 
Bienen Wirtschaft Meißen, 
06/16 
Scottish heather honey 1 John Mellies’Apiaries, 10/14 
Thyme honey 1 
Imkerauslese L.W.C. 
Michelsen, 03/14 
Ulmo honey 1 Bienenhonig R. Feldt, 08/15 
 
Table 24: List of spiked honey samples, Chapter B 
Honey Specification Manufacturer 
Manuka honey MGO 30 + 
MGO/DHA for MRP 
studies 
A: spiked with MGO 500 mg/kg and DHA 
1000 mg/kg, stored at 30°C 
Manuka Health NZ Ltd 
Polyfloral honey 
+/- MGO/DHA for 2-AP 
studies 
A: spiked with MGO 100 mg/kg, stored at 
room temp. 
B: spiked with MGO 100 mg/kg stored at 37 
°C 
C: spiked with MGO 500 mg/kg, stored at 
room temp. 
D: spiked with MGO 500 mg/kg stored at 37 
Nektarquell 
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°C 
E: spiked with MGO 100 mg/kg and DHA 
200 mg/kg, stored at room temp. 
F: spiked with MGO 100 mg/kg and DHA 
200 mg/kg, stored at 37°C 
G: spiked with MGO 500 mg/kg and DHA 
1000 mg/kg, stored at room temp. 
H: spiked with MGO 500 mg/kg and DHA 
1000 mg/kg, stored at 37°C 
Polyfloral honey 
+/- MGO/DHA for 
fluorescence and SEC 
studies 
A: spiked with MGO 100 mg/kg and DHA 
200 mg/kg, stored at room temp. 
B: spiked with MGO 100 mg/kg and DHA 
200 mg/kg, stored at 37°C 
C: spiked with MGO 500 mg/kg and DHA 
1000 mg/kg, stored at room temp. 
D: spiked with MGO 500 mg/kg and DHA 
1000 mg/kg, stored at 37°C 
Dr. Krieger 
 
 
2.4.5 Quantification of methylglyoxal and dihydroxyacetone via RP-HPLC-UV 
The quantification of methylglyoxal and dihydroxyacetone is described in section 1.4.5. All 
honey samples were analysed following the same procedure as mentioned above. 
 
2.4.6 Quantification of hydroxymethylfurfural 
The determination of HMF was performed according to the literature (Jeuring and Kuppers, 
1980) with some modifications. Briefly, 1 mL aliquots of 10% honey solutions in ultrapure 
water were membrane-filtered (0.45 μm) and subsequently analyzed via HPLC-UV. 
Separation was achieved by using HPLC system 1 (see Table 22) connected to a stainless 
steel column filled with Eurospher 100 RP18 material (250mm x 4.6 mm, 5 µm particle size 
with integrated pre-column; Knauer, Berlin, Germany). The mobile phase consisted of 0.05 M 
phosphate buffer at pH 5.5 (solvent A) and HPLC-grade methanol (solvent B). The elution 
was carried out isocratically with 15% solvent B over 30 min. The flow rate was 1.0 mL/min 
at ambient temperature; 50 μL sample solution was injected; and peaks were detected by 
measurement of UV absorbance at 283 nm. Quantitation was achieved by external calibration 
with freshly prepared HMF standard solution. 
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2.4.7 Isolation and quantification of 2-acetyl-1-pyrroline  
A total of 10 g of honey was dissolved in 10 mL of ultrapure water. A total of 50 μL of the 
internal standard 2,4,6-trimethylpyridine (TMP) solution (195 mg/L) was added, and the pH 
was adjusted to 8 with 1 M sodium hydroxide solution. The alkaline honey solution was 
mixed with 5 mL of dichloromethane, agitated vigorously for 60 s, and centrifuged 
afterwards. The organic layer was collected, and extraction with dichloromethane was 
repeated once. The collected organic layer was washed with 5 mL of water and dried with 
anhydrous sodium sulfate. An aliquot of 1 mL was transferred to a GC vial and subjected to 
GC-MS analysis. Matrix calibration was achieved by adding known amounts of 2-AP to an 
artificial honey, which was then extracted as described above. The artificial honey was 
prepared following Wahdan (1997). Briefly, 46.5 g of fructose, 35 g of glucose, 1.5 g of 
saccharose, and 17 g of water were mixed and stirred until a fine crystalline suspension was 
formed. The artificial honey/2-AP mixture was diluted with pure artificial honey, and 10 g of 
each mixture was analyzed according to the extraction procedure above. The actual 2-AP 
concentration of the commercial standard was determined by RP-HPLC with a 
chemiluminescent nitrogen detector (CLND) according to Penndorf et al. (2007). GC−MS 
analysis of 2-AP was performed using the GC-MS system described in Table 22. The GC 
system was equipped with a TR-FFAP capillary column (30.0 m × 0.25 mm inner diameter, 
with a 0.25 μm film thickness) from Thermo Scientific (Runcorn, U.K.). Helium was used as 
the carrier gas with a constant flow of 1 mL/min. The injector temperature was set to 250 °C, 
and a 1 μL sample was injected using the pulsed splitless mode. The auxiliary temperature 
was set to 235 °C, and the ion source and quadrupole temperatures were set to 230 and 150 
°C, respectively. The initial oven temperature was set to 40 °C and held for 2 min, then raised 
at 2.25 °C/min to 80 °C, finally raised at 30 °C/min to 235 °C, and held for 5 min. The mass 
spectrometer was working in EI mode at 70 eV in the scan (mass range of m/z 40.0−300.0) 
and selected ion monitoring (SIM) mode. For quantitation, the SIM mode was used with the 
monitoring of the following ions: m/z 111 and 83 (2-AP) and m/z 121 and 79 (TMP). The 
ions underlined were used for quantitation. The retention time of the analytes was 15.0 min 
for 2-AP and 17.9 min for TMP, respectively. Data acquisition and evaluation were 
performed with MSD ChemStation software (Agilent, Germany). Results are expressed as 
mean values of two separate measurements, except otherwise indicated. Hypothesis testing 
was performed via a two sample t test with a significance level of 0.01. Intraday variation of 
2-AP analysis was investigated using five replicate injections of a 2-AP standard solution. 
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Interday precision was determined using four calibration standards, which were analyzed 
during 8 months. 
 
2.4.8 Protein isolation from honey 
High molecular-weight (HMW) fractions were isolated from honey either by dialysis or by 
precipitation with trichloroacetic acid (TCA). For the former approach, ca. 10 g of honey was 
dissolved in 10 mL of water and transferred to a dialysis tube (MWCO, 14 kDa, Sigma). The 
samples were dialyzed against distilled water for 2 days with the water changed twice per day. 
The retentates were then lyophilized and stored at -18 °C. For TCA precipitation, 10 mL of 
TCA (20%, w/v) was added to 10 g of honey, and the suspension was stored at -20 °C for 30 
min after mixing. Following centrifugation (4 °C, 5000 rpm, 10 min), the supernatant was 
decanted and discarded, and the precipitate was suspended in water (10 mL). After 
centrifugation (4 °C, 5000 rpm, 10 min), the supernatant was discarded, and the precipitate 
was washed once more in the same way. Finally, the precipitate was suspended in 5 ml of 
water lyophilized and stored at -18 °C. 
 
2.4.9 Protein determination 
Acid precipitates 
Proteins extracted via TCA precipitation are denatured and therefore only soluble in detergent 
buffers. To analyze the protein content of TCA precipitates, a modification (Harrington, 1990) 
of the Lowry assay (Lowry et al., 1951) was used. Briefly, precipitates were solubilized in 
sodium dodecyl sulfate solution (1 %) in ultrapure water with a final concentration of 0.3 
mg/mL. In a microtiter plate, 50 µL of the diluted samples were incubated with 150 µL dye 
solution for 10 min at room temperature. The dye solution consisted of 1 mL CuSO4 x 5 H2O 
(0.16 M) and 10 mL of an aqueous solution containing Na2CO3 (0.2 M), NaOH (0.1 M), 
potassium sodium tartrate (5.6 mM) and SDS (1 %). After 10 min, 15 µL of Folin Ciocalteu’s 
phenol reagent (1:1 with ultrapure water) was added and the mixture was incubated for 45 
min at room temperature. Absorbance at 700 nm was measured using a multimode reader 
Tecan Infinite M200 (Mainz, Germany). Calibration was achieved using γ-globulin, which 
was precipitated with TCA and thus denatured prior to analysis (according to protein 
extraction mentioned in section 2.4.8). The denatured γ-globulin was solubilized in SDS (1 
%) and the calibration range was 0.08 to 0.8 mg/L. 50 µL of calibration solutions were treated 
like samples described above. 
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Dialysis retentates 
The protein content of the retentates was calculated as the sum of amino acids measured by 
amino acid analysis after acid hydrolysis. The amino acid analysis and acid hydrolysis is 
described in section 2.4.10. 
 
2.4.10 Amino acid determination 
Free proline 
A total of 1 g of honey was dissolved in 10 mL of phosphate buffer (0.1 M, pH 2) and 
subjected to a column (25×110 mm) filled with ion-exchange resin Dowex 50WX8, 100-200 
mesh. The ion-exchange resin was previously activated with 50 mL of HCl (2 mol/L). The 
amino acids were eluted with 100 mL of a solution of ammoniac (7 mol/L). The eluate was 
evaporated to dryness, and the dry residue was dissolved in ultrapure water. After 
lyophilization, the sample was dissolved in 1 mL of lithium citrate buffer (0.12 M, pH 2.2), 
diluted (1:10), and subjected to amino acid analysis. The analyses were performed using a 
SYKAM S4300 amino acid analyzer (Fuerstenfeldbruck, Germany) with conditions according 
to the instructions of the manufacturer. The ninhydrin derivate of proline was detected at 
440 nm. 
 
Protein-bound amino acids 
Acid hydrolysis of protein isolates was performed by adding 2 mL of 6 M HCl to 2-3 mg of 
the fractions and heating of the mixture at 110 °C for 23 h in a pre-heated oven. Then, 500 µL 
of the hydrolyzate was evaporated to dryness in a vacuum concentrator (SPD Speed Vac; 
Thermo Fisher Scientific, Karlsruhe, Germany). The residue was reconstituted in 1 mL of 
sample buffer for amino acid analysis (0.12 N lithium citrate, pH 2.2). Proteinogenic amino 
acids were quantitated with a SYKAM S4300 amino acid analyser (Fuerstenfeldbruck, 
Germany). The effluent was derivatized with ninhydrin, and detection of products was 
performed with an integrated two-channel photometer (λ = 440 nm, 570 nm). External 
calibration was performed with an amino acid mixture (Sigma-Aldrich, Steinheim, Germany). 
The injection volume was between 50 and 100 µL. Leucine was taken as an internal reference 
for the evaluation of amino acid concentrations due to its abundance in the honey protein. 
Amino acid analysis was also used to calculate the protein content of HMW isolates obtained 
by dialysis and the efficiency of enzymatic hydrolysis. The release of amino acids during 
enzymatic hydrolysis was calculated by regarding the release during acid hydrolysis as 100%. 
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2.4.11 Fluorescence measurement of honey proteins 
To analyze fluorescence characteristics, 1 mg of protein precipitate was solubilized in 1 mL of 
0.1 M sodium phosphate buffer, pH 6.8, containing 6 M urea, 0.1 M sodium chloride, and 
0.1% 3-[(3-cholamidopropyl)-dimethylammonium]-1-propanesulfonate. Ultra-sonication for 
15 min was used to completely solubilize the precipitates. The solutions were diluted 1:10 
with buffer and 200 µL were transferred to a black microtiter plate (Brand, Germany). The 
hydrolyzed precipitates were directly diluted 1:10 with ultrapure water and subsequently 
analyzed. Fluorescence intensities were measured at λex = 350 and λem = 450 nm using a 
multimode reader Tecan Infinite M200 (Mainz, Germany). 
 
2.4.12 Size exclusion chromatography of honey proteins 
Size exclusion chromatography was performed using the HPLC system 1 (see Table 22). 
Separation of the samples was achieved using a Superdex 200 10/300 GL column (GE 
Healthcare Bio-Sciences AB, Uppsala, Sweden). Analysis was carried out at room 
temperature and flow rate was set to 0.5 mL/min. The elution was performed isocratically for 
60 min with the 0.1 M phosphate buffer system which was also used for fluorescence 
measurement. 50 µL of the samples were injected with a protein concentration of 5 mg/mL. 
Prior to analysis, samples were either solubilized in elution buffer only or incubated at 6 °C in 
phosphate buffer with 1% dithiothreitol (DTT) over night. Detection was achieved by 
monitoring UV absorbance at 220 nm. The relative peak areas were calculated by relating the 
respective peak area to the total area under the curve. Calibration of molecular size was 
achieved by comparing the elution volume of protein standards with the elution volume of the 
samples. Protein standards used for calibration were ferritin (440 kDa), catalase (240 kDa), 
glucose oxidase (160 kDa), ovalbumin (43 kDa) and lysozyme (15 kDa).  
 
2.4.13 Enzymatic hydrolysis of proteins 
This was performed according to Hellwig et al. (2015). Briefly, 2-3 mg of the precipitates 
were suspended in 1 mL HCl (0.02 M) and 50 µL pepsin (1 U/sample) in 0.02 M HCl were 
added. After 24 h, 250 µL of TRIS buffer (2 M, pH 8.2) and 50 µL of pronase E (400 
U/sample) were added. After 24 h, 5 µL aminopeptidase (0.4 U/sample) and 10 µL prolidase 
(1 U/sample) were added. The samples were further incubated for 24 h. All incubations were 
performed at 37 °C. A blank, containing only digestive enzymes but no honey proteins, was 
included. 
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2.4.14 Analysis of Maillard reaction products via HPLC-MS/MS 
Protein-bound MRPs were quantitated on an HPLC-MS/MS system consisting of a binary 
pump (G1312A), an online degasser (G1379B), an autosampler (G1329A), a column 
thermostat (G1316A), a diode array detector (G1315D), and a triple-quadrupol mass 
spectrometer (G6410A; all from Agilent Technologies, Böblingen, Germany). At the ESI 
source, nitrogen was utilized as the nebulizing gas (gas flow, 11 L/min; gas temperature, 350 
°C; nebulizer pressure, 35 psi), and the capillary voltage was at 4000 V. 
For chromatographic separation, the column Zorbax 100 SB-C18 (2.1 × 50 mm, 3.5 µm; 
Agilent) was used at a column temperature of 35 °C. HPLC solvent A was a solution of 10 
mM nonafluoropentanoic acid (NFPA) in water, and solvent B was a solution of 10 mM 
NFPA in acetonitrile. The solvents were pumped at a flow rate of 0.25 mL/min in the gradient 
mode (0 min, 5% B; 15 min, 32% B; 16 min, 85% B; 20 min, 85% B; 21 min, 5% B; 27 min, 
5% B). The injection volume was 5 µL. Data were acquired and evaluated with the software 
Mass Hunter B.02.00 (Agilent). 
The standard addition method was used for quantitation of MRPs. All samples were analyzed 
at least in duplicate. In the sample without addition, 100 µL of enzymatic hydrolyzate was 
mixed with 20 µL of water. In the second run, 100 µL of hydrolyzate was mixed with 10 µL 
of water and 10 µL of a standard solution. In the last run, 100 µL of hydrolyzate was mixed 
with 20 µL of standard solution. All samples were centrifuged before injection (10,000 rpm, 
10 min). In the standard solution added to Manuka honeys, N-ε-fructosyllysine (87.5 µg/mL), 
N-ε-maltulosyllysine (35.2 µg/mL), CML (13.4 µg/mL), CEL (19.9 µg/mL), formyline (0.4 
µg/mL), MG-H1 (5.0 µg/mL), maltosine (0.11 µg/mL), and pyrraline (2.0 µg/mL) were 
dissolved in water. In the standard solution added to non-Manuka honeys, the same 
concentrations were used, except for CEL (1.0 µg/mL), and MG-H1 (0.25 µg/mL). 
 
2.4.15 Model studies on 2-acetyl-1-pyrroline formation in honey 
A commercial non-manuka multifloral honey from Germany was mixed with MGO alone 
(100 mg/kg, labeled as “low”, or 500 mg/kg, labeled as “high”, respectively) or MGO and 
DHA in a 1:2 ratio (100 and 200 mg/kg, labeled as “low”, or 500 and 1000 mg/kg, labeled as 
“high”, respectively). The samples were stirred vigorously and stored in the dark at room 
temperature and 37 °C. The storage temperature of 37 °C was chosen to simulate accelerated 
ripening and to study chemical reactions that occur during longer storage. Samples were taken 
after 0, 2, 4, 8, and 12 weeks of storage. A control (multifloral honey without added MGO) 
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was stored under the same conditions, and samples were taken after 0, 4, and 12 weeks of 
storage. The samples were analyzed according to the extraction procedure mentioned in 
section 2.4.7.  
 
2.4.16 Model studies on protein reactions in honey 
Commercial non-manuka honey (multifloral honey from Germany) was spiked with MGO 
and DHA in a 1:2 ratio (100 and 200 mg/kg labeled as “low” and 500 and 1000 mg/kg labeled 
as “high”). The samples were stirred vigorously and stored at room temperature and 37 °C. 
The elevated temperature was chosen to simulate accelerated ripening and to study chemical 
reactions occurring during longer storage. Samples were taken after 1, 14, 35, 56 and 84 days. 
Protein extraction and fluorescence measurement of the samples were performed according to 
the procedure mentioned above. 
 
2.4.17 Model studies on Maillard reactions in honey 
Commercial manuka honey (Manuka Health MGO 30) was spiked with MGO and DHA in a 
1:2 ratio (500 and 1000 mg/kg). The sample was stirred vigorously and stored at 30 °C. The 
elevated temperature was chosen to simulate accelerated ripening and to study chemical 
reactions occurring during longer storage. Samples were taken after 0, 14, 42, 70 and 112 
days. A control (manuka honey MGO 30 without added MGO and DHA) was stored under 
the same conditions, and samples were taken after 0, 4, 14, 42, 70 and 112 days of storage. 
The proteins were extracted according to 2.4.8, enzymatically hydrolyzed according to 2.4.13 
and MRP were analyzed according to 2.4.14. 
 
2.4.18 Rheological studies 
Thixotropy loop 
Prior to analysis the honey samples were kept at room temperature over night to warm up. 
The rheological properties were studied by Haake Viscotester iQ (Thermo Scientific) 
rheometer using a parallel plate system (35mm diameter) at a gap of 1 mm. The rheological 
measurement data were analysed with rheometer software RheoWin. The honey samples were 
placed in the rheometer measuring system, then relaxed and equilibrated for 2 min to obtain 
required temperature. The temperature was set at 20 °C and kept constant during the 
measurement. The curves were obtained in CR mode with shear rate increasing from 1 to 100 
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s-1 in 180 s, followed by a plateau at 100 s-1 for 180 s and finally decreasing the shear rate 
from 100 to 1 s-1 in 180 s.  
 
Creep recovery 
The same rheometer instrument was used as described in the section above. The honey 
samples were placed in the rheometer measuring system, then relaxed and equilibrated for 
2 min to obtain required temperature. The temperature was set at 20 °C and kept constant 
during the measurement. The curves were obtained in CR mode with shear rate kept at 0.5 s-1 
for 60 s, followed by an increase to a plateau at 50 s-1 for 30 s and finally decreasing the shear 
rate back to 0.5 to 1 s-1 and keeping it for 300 s.  
 
  
102  Chapter B     
 
 
 
 
2.5. Results and discussion 
 
Manuka honey contains the carbonyl compounds methylglyoxal (MGO) and 
dihydroxyacetone (DHA) in amounts up to 700 and 1600 mg/kg, respectively, wheras 
conventional honeys contain only 5 to 10 mg/kg of MGO and DHA (Atrott et al., 2012). 
MGO and DHA are highly reactive substances, leading to a variety of unique chemical 
reactions during honey maturation and storage. This chapter deals with MGO-derived 
reactions in manuka honey and the possibility to use this reaction to distinguish manuka 
honey from other honey varieties.  
 
2.5.1 Identification and quantification of 2-acetyl-1-pyrroline in manuka honey 
Besides MGO and DHA, manuka honey also contains amino compounds like amino acids. 
Proline is the most abundant amino acid in honey, accounting for 260−890 mg/kg, which 
represents 70% of the total free amino acids (Bernal et al., 2005). Despite the unusual ratio of 
highly reactive carbonyls and amino acids, there are no studies available concerning Strecker 
reactions in manuka honey. Therefore, the aim of this study was to investigate the possible 
occurrence of 2-acetyl-1-pyrroline (2-AP), a direct reaction product of proline and MGO, in 
manuka honey and its dependency upon the MGO content. The studies presented here were 
published in the Journal of Agricultural and Food Chemistry (Rückriemen et al., 2015). The 
volatile molecule 2-acetyl-1-pyrroline (2-AP) originates from the reaction of MGO with the 
amino acids ornithine or proline (Hofmann and Schieberle, 1998) and is the main aroma 
compound in aromatic rice varieties and bread crust (Buttery et al., 1986; Schieberle and 
Grosch, 1987; Grimm et al., 2011). Its smell is described as “popcorn-like” or “roasted”, with 
an odor threshold of 0.1 μg/ kg (Belitz H.-D., Grosch W., 2008). Reactive carbonyl species, 
such as MGO, play an important role in flavor chemistry (Wang and Ho, 2012). This process 
is affected by water activity, temperature, and pH value (Hellwig and Henle, 2014). The aim 
of this study was to investigate whether 2-AP, a specific flavor compound formed from MGO 
and proline, is present in manuka honeys from New Zealand. Identification and quantitation 
of 2-AP in manuka honey was achieved using GC-MS based on a method recently described 
in the literature for 2-AP analysis (Wu et al., 2009). For sample preparation, a crucial step for 
reliable quantitation of 2-AP, solid-phase microextraction (SPME), or solvent extraction 
methods are reported (Schieberle and Grosch, 1987; Wu et al., 2009; Grimm et al., 2011). 
Because 2-AP formation in manuka honey is probably enhanced by a high temperature, an 
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extraction procedure using dichloromethane without heating was chosen (see 2.4.7). 
Furthermore, concentration steps like drying with nitrogen were avoided to prevent a loss of 
2-AP during sample preparation. 2,4,6-Trimethylpyrindine (TMP) was used as an internal 
standard to check the recovery during the extraction procedure. Comparing peak areas for 2- 
AP standard samples extracted from aqueous solutions or from an artificial honey matrix, the 
mean recovery of 2-AP resulted in an estimated 60%. Therefore, quantitation was carried out 
via external matrix calibration, using a synthetic 2-AP standard in artificial honey. The actual 
2-AP concentration of the commercial standard was checked with RP-HPLC and 
chemiluminescent nitrogen detection (CLND) to be 83.3% of the specification given by the 
supplier. The actual concentration of the standard was used for calculation. A regression 
coefficient R2 of 0.998 was calculated for the linear calibration range from 0.1 to 2.0 mg/ kg. 
The limit of detection (LOD) was 0.04 mg/kg, and the limit of quantitation (LOQ) was 0.09 
mg/kg. LOD and LOQ were calculated on the basis of the signal-to-noise-ratio. Inter- and 
intraday precisions were 3.1 and 6.1%, respectively (see 2.4.7 for validation parameters). 
2-AP was unequivocally identified in commercial samples of manuka honey by comparing 
retention time and corresponding mass spectra of honey samples and standard solutions 
(panels A and C of Figure 35). The comparison of the fragmentation pattern and the 
characteristic ratio of the quantifier ion to the qualifier ion (m/z 83 and 111, respectively) of 
the 2-AP standard and the 2-AP peak in honey yields identical relative intensity ratios.  
 
 
Figure 35: GC-MS data for identification and quantitation of 2-AP. (A) synthetic standard solution, 
(B) manuka honey, (C) lime honey, (D) artificial honey spiked with proline and MGO (black line) and 
DHA (grey line) incubated for 20 weeks at 37 °C (D) 
 
The hypothesis, that 2-AP in manuka honey results from the reaction of MGO and proline 
was confirmed by significantly smaller signals of 2-AP in non-manuka honeys without MGO 
(Figure 35B) and the detection of 2-AP in an artificial honey containing MGO and proline 
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after 20 weeks of incubation (Figure 35D). For 11 commercially available manuka honeys, 
amounts of 2-AP ranging from 0.08 to 0.45 mg/kg were measured (Figure 36A). In contrast to 
this, the majority of non-manuka honeys analyzed in this study contained 2-AP only in very 
small amounts between 0.08 and 0.11 mg/kg. However, some aromatic non-manuka honeys, 
namely, buckwheat, lime, and thyme honey, contained 2-AP in concentrations ranging 
between 0.20 and 0.31 mg/kg. According to the literature, 2-AP has been found in different 
sorts of food as an aroma active compound. The concentrations vary between 78 μg/kg for 
white-bread crust and 0.8 mg/kg for cooked rice (Buttery et al., 1986; Schieberle and Grosch, 
1987). Concerning honey, 2-AP has already been detected in lime honey from the linden tree 
(Blank et al., 1989). The authors pointed out that 2-AP is an important odorant of linden 
honey but did not report on quantitative amounts of 2-AP. Interestingly, no 2-AP was detected 
in the blossoms of the linden tree, what supports the hypothesis that 2-AP originates from 
reactions in the honey matrix. The 2-AP concentration of manuka honey with a MGO 
concentration below 250 mg/kg is comparable to the non- manuka honeys (see Figure 36A, 
manuka group 1). However, the concentration of 2-AP in manuka honeys with a MGO 
concentration above 250 mg/kg was significantly increased in comparison to the non-manuka 
group (Figure 36A, manuka group 2). The average amount of 2-AP in manuka honeys with 
MGO contents above 250 mg/kg was 0.36 mg/kg, and the average amount of 2-AP in non-
manuka honeys was 0.16 mg/kg.  
 
Figure 36: (A) 2-AP concentration of commercial samples of non-manuka honey (n=8), manuka honey 
with MGO below 250 mg/kg (manuka 1) ( n=4) and above 250 mg/kg (manuka 2) ( n=7), stars 
indicate average value for each group, (B) correlation of 2-AP concentration and MGO content of 
manuka honeys (group 1 and 2) 
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For the manuka honey samples, the 2-AP content increased with increasing MGO 
concentrations up to a MGO value of approximately 500 mg/kg honey (see Figure 36B). For 
concentrations of 600−1000 mg of MGO/kg of honey, no further increase of 2-AP was found. 
Proline is the most abundant amino acid in honey, accounting for 260−890 mg/kg, which 
represents 70% of the total free amino acids. The analysis of the proline concentration of the 
studied honeys showed no significant difference between the non-manuka and manuka honeys 
with varying MGO contents. The proline concentration ranged between 200 and 540 mg/kg 
and did not correlate with the MGO content. In fact, MGO appears to be the crucial factor for 
2-AP formation. The observation that MGO contents between 600 and 1000 mg/kg do not 
lead to a further increase of 2-AP in manuka honeys could be explained by competitive 
reactions. MGO can react with other honey compounds or with another MGO molecule to 
form adducts or aroma-active compounds, such as furaneol, respectively. To assess whether 
storage of non-manuka honey containing artificially added MGO or DHA results in the 
formation of 2-AP, a commercial multifloral honey was spiked with MGO alone or a 1:2 
mixture of MGO and DHA, respectively, and stored at room temperature and 37 °C for 12 
weeks.  
 
 
Figure 37: 2-AP formation in a non-manuka multifloral honey with (A) added MGO stored at 37 °C, 
(B) added MGO and DHA stored at 37°C and (C) added MGO and DHA stored at room temperature 
(n=2 for each time point and sample). 
 
Panel A and B of Figure 37 show the 2-AP concentration depending upon the incubation time. 
When high amounts of MGO (500 mg/kg) were added to the honey, 2-AP significantly 
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increased after 4 weeks of storage at 37 °C. After 12 weeks, the 2-AP concentration reached 
the amount that was quantitated in the commercial manuka honey samples with high MGO 
contents, followed by no further increase. No increase of 2-AP was found during storage of 
non-manuka honey with artificially added MGO and DHA at ambient temperature (Figure 
37C) and non-manuka honey without MGO (ambient temperature and 37 °C; data not shown). 
There was also no increase in 2-AP when low MGO concentrations (100 mg/kg) were added 
to non-manuka honey and stored at an elevated temperature for 12 weeks (see Figure 37 A 
and B). This is in accordance with the 2-AP amounts of commercial manuka honeys 
containing MGO below 250 mg/kg. The average 2-AP content of these samples was 0.14 
mg/kg. The non-manuka honey with artificially added low amounts of MGO had 
approximately the same amount of 2-AP, which did not increase after storage. This indicates 
that a “threshold level” of MGO of approximately 250 mg/kg is necessary to initiate a 
reaction of proline and MGO and significantly increase the 2-AP content in manuka honey. 
Competitive reactions as a possible reason for the disproportionate conversion of MGO and 
proline to 2-AP were discussed above. The 2-AP concentration in non-manuka honey was not 
influenced by the addition of DHA and subsequent storage (Figure 37A and B). This indicates 
that DHA is a not a promoter of 2-AP formation. For the spiked honey samples, which were 
stored for 8 weeks or longer at 37 °C, a significant increase in the concentration of HMF in 
addition to the formation of 2-AP was observed. At the first day of storage, the honeys had a 
mean HMF value of 10 mg/kg. Storage at 37 °C for 12 weeks resulted in a HMF increase up 
to 80 mg/kg, whereas samples stored at room temperature contained a maximum HMF level 
of 13 mg/kg after 12 weeks. HMF is used as a quality parameter of honey and should not 
exceed 40 mg/kg (Codex Alimentarius Commission, 2001). All commercial manuka honeys 
in this study were below this threshold level. This result points to the fact, that following 
“artificial” spiking of a non-manuka honey with MGO, 2-AP concentrations do only increase 
during storage at elevated temperatures, which also leads to increasing amounts of HMF. 
Therefore, 2-AP might be an interesting indicator to control the storage conditions and the 
quality of manuka honey. High amounts of 2-AP, as a result of high MGO levels, together 
with an increased concentration of HMF may point to a fraudulent addition of MGO and 
storage at increased temperatures for “artificially” producing high-price manuka honey 
products. A manuka honey with a high MGO content together with a high 2-AP concentration 
and a low HMF level has likely been stored at low temperatures over a longer time period. 
This “natural” ripening process cannot be simulated by MGO addition followed by high 
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temperature storage. Thus, in addition to MGO and DHA, 2-AP as a direct reaction product of 
MGO and proline could be a suitable parameter to characterize the quality of manuka honey. 
 According to the literature, the storage of manuka honey initially leads to MGO increase as a 
result of continuous formation from DHA, followed by a MGO decrease, probably as a result 
of reactions of MGO with other honey components (Atrott et al., 2012; Grainger et al., 
2016a).  
This study demonstrates that 2-AP is one of the reaction products which can be formed from 
MGO during storage. Nevertheless, the conversion rate from MGO to 2-AP is very low and 
the reaction of MGO with the amino acid proline can only explain a small percentage of 
MGO loss. Hence, other reactions leading to unique MGO-derived reactions products could 
be mainly responsible for MGO decrease during storage. In proteins, many amino groups are 
available for the reaction with the electrophile carbonyl compounds. The next section will 
focus on reactions of MGO with honey proteins.  
 
2.5.2 Reactions of carbonyl compounds with honey proteins 
Proteins are minor compounds in honey and can be plant-derived like catalase (Weston, 2000) 
or bee-derived like major royal jelly protein 1 (MRJP1) (Won et al., 2008). Proteins can 
quickly react with reducing sugars or dicarbonyl compounds to form Maillard reaction 
products. Previous reports have shown that MGO in manuka honey can modify honey 
proteins and influence its bioactive effect (Majtan et al., 2012). From a chemical point of 
view, these reactions are interesting, because they might explain the fate of MGO during 
honey storage. The unique chemical reactions of MGO may be useful to differentiate manuka 
honey from non-manuka honey. This section will deal with MGO mediated reactions with 
proteins and will focus on unspecific cross-linking reactions on the one hand (2.5.2.1 and 
2.5.2.2) and specific protein-bound amino acid side chain modifications on the other hand 
(2.5.2.3). 
 
2.5.2.1 Cross linking of honey proteins 
The results of the following sections 2.5.2.1 and 2.5.2.2 are partly originating from the 
experimental work of master student Christoph Hohmann and were primarily published in his 
master thesis (Hohmann, 2015) and in Food Research International (Rückriemen, Hohmann, 
et al., 2017). Proteins from food matrices can be extracted with various techniques such as 
ultracentrifugation or dialysis. The aim of this study was to analyze the molecular size of 
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honey proteins. Therefore it was important that the isolates where rich in protein and do not 
contain high amounts of other honey-derived compounds such as polyphenols or sugars. As 
methods for protein isolation from honey, dialysis and acid precipitation were tested in this 
study. Due to the simplicity and the time saving when acid precipitation was performed, the 
studies dealing with the molecular size and the fluorescence properties of honey proteins were 
conducted using TCA precipitates of honey. The obtained isolates were analyzed for their 
protein content, which was ≥ 92% (data not shown). To assess the molecular size of honey 
proteins, honey precipitates were analyzed with size exclusion chromatography with 
subsequent UV detection at 220 nm. A typical chromatogram of manuka proteins and non-
manuka proteins is shown in Figure 38A. Manuka honey proteins were shifted towards higher 
molecular weights (> 510 kDa) compared to the non-manuka honey proteins, which were 
distributed mainly between 510 to 100 kDa. For this study, the high molecular weight fraction 
(HMW) with a molecular size > 510 kDa was of special interest since it is probably formed 
by cross-linking reactions. To rule out that the absorption increase of manuka honey protein 
was caused by hyperchromic effects, UV absorption of the protein precipitates was measured 
without chromatographic separation and no correlation of total UV absorption and MGO 
content of the honeys was found (data not shown). The shift of manuka honey proteins to 
higher molecular weights was described earlier. Majtan et al. (2012) reported that the 
antibacterial peptide bee defensin 1 experiences a molecular shift from 55 kDa to around 60 
kDa in manuka honey. Nevertheless, the authors studied single protein structures. The high 
molecular weight fraction presented in the current work is more likely caused by cross-linking 
reactions of more than one protein. The principle of separation for size exclusion 
chromatography is based on the hydrodynamic diameter of molecules. For polymers of the 
same type (e.g. fibrous or globular proteins), the hydrodynamic diameter is proportional to 
their molecular mass. For calibration, only globular proteins were used, since the molecular 
structure of honey protein complexes was expected to be globular as well. Nevertheless, 
calibration with natural proteins provides an appropriate estimation for the molecular size of 
the analyzed proteins, but cannot be considered as accurate. Besides, proteins were extracted 
from honey by acid precipitation. During acid treatment of proteins, amino acid chains are 
protonated, which triggers protein unfolding by disrupting the electrostatic interactions that 
stabilize the native conformation of proteins. Thereby, protein oligomers can form which may 
not recover their natural conformation after solubilisation (Rajalingam et al., 2009). To 
enhance solubilisation of polymerised proteins to prevent overestimation of protein size, a 
Chapter B  109 
 
 
 
 
buffer containing 6 M urea was used (see 2.4.11). More precise statements concerning the size 
of honey protein complexes could be made with electron microscopy. The distribution of the 
relative amount of high molecular weight protein compared to total protein is shown in Figure 
38B. Manuka honey proteins have an average amount of HMW fraction to total protein of 34 
%. Most of the honeys without MGO (non-manuka) did not exhibit a large signal at high 
molecular weights. Nevertheless, some non-manuka honeys have an amount of high 
molecular weight fractions similar to the manuka honeys. The average amount of HMW 
fraction of all non-manuka proteins was 28 %. Besides of MGO-induced reactions, proteins 
can aggregate due to disulfide bonds. Thiol groups in honey proteins can be oxidized, e.g. 
with oxidizing reagents such as hydrogen peroxide present in honey, and form disulfide 
bonds. Therefore, honey proteins were incubated with dithiothreitol (DTT) prior to SEC. 
Dithiothreitol reduces disulfide bonds to thiol groups, thus reversing disulfide-derived 
crosslinking in proteins. With DTT, non-manuka honey proteins had an average amount of 
HMW fraction of 21 %, whereas manuka honey proteins contained 36 % of HMW fraction. 
The HMW fraction of non-manuka honey proteins decreased by 7% after incubation with 
DTT since disulfide crosslinks were reduced. The remaining HMW fraction could be 
originated from the reaction of honey proteins and carbonyl compounds, e.g. 3-
deoxyglucosone, which are present in different types of honeys (Weigel et al., 2004).  
 
Figure 38: (A) Size exclusion chromatography with UV detection at 220 nm of proteins isolated from 
manuka honey with high MGO content (MGO 900 mg/kg; black line), low MGO content (MGO 118 
mg/kg; blue line) and canola honey (MGO 10 mg/kg; grey line). Calibration was achieved by 
analyzing natural proteins with defined molecular weights. Grey box indicates high molecular weight 
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protein. (B) Relative amount of high molecular weight protein fraction in non-manuka honey (NMH) 
and manuka honey (MH) without addition of DTT (black) and after addition of DTT (grey). Stars 
indicate the average value of each group. 
In contrast, HMW fraction of manuka honey protein apparently increased after incubation 
with DTT. This could be due to the loss of low molecular weight fragments with disulfide 
bonds, which contributed to the total amount of protein. A decrease of the total area under the 
curve, but a stable signal of the HMW fraction would result in an apparent increase of HMW 
fraction. Moreover, it is possible that thiol groups in the manuka honey protein are directly 
involved in formation of high-molecular weight fragments. Thus, the incubation with DTT 
does not influence manuka honey protein, since thiols did not form disulfide bonds, but might 
have reacted with MGO. The results lead to the conclusion that HMW fraction in manuka 
honey is mainly caused by MGO-derived reactions, whereas HMW fraction in non-manuka 
honey is a result of disulfide bonds. The formation of HMW proteins can lead to characteristic 
changes in their absorption properties. Therefore, the next section will focus on the influence 
of protein cross-linking on the fluorescence properties of honey proteins. 
 
2.5.2.2 Fluorescence properties of honey proteins 
During the advanced stage of Maillard reaction, proteins are modified into colored and 
fluorescent compounds. Typical fluorescence excitation and emission wavelength to study 
these changes in food are λex = 340-370 and λem = 420-450 (Morales and Jiménez-Pérez, 
2001; Schmitt et al., 2005; Matiacevich and Pilar Buera, 2006). To detect the wavelength with 
the highest intensity for the honey protein matrix, the purified honey proteins (acid 
precipitates) were dissolved in phosphate buffer containing 6 M urea and the fluorescence 
excitation spectra were recorded at emission wavelength 440 nm with excitation wavelengths 
between 230 to 420 nm (2 nm step size). A maximum excitation wavelength of 350 nm was 
observed. With the excitation wavelength set at 350 nm, emission spectra were recorded 
between 380 to 600 nm (2 nm step size) and an emission maximum was found to be at 450 
nm (see Figure 39). According to these results, the wavelength pair λex = 350 and λem = 450 
nm was used for further studies. 
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Figure 39: (A) Fluorescence excitation spectrum of manuka honey protein (MH) and non-manuka 
honey protein (NMH), recorded at emission wavelength 440 nm with excitation wavelengths between 
230 to 420 nm, (B) Fluorescence emission spectrum of manuka honey protein (MH) and non-manuka 
honey protein (NMH), recorded at excitation wavelength 350 nm with emission wavelength between 
380 to 600 nm 
 
Non-manuka and manuka honey proteins were extracted and screened for their fluorescence 
intensities at λex = 350 and λem = 450 nm. Non-manuka honey protein displayed fluorescence 
intensities between 23 000 to 71 000 AFU per mg precipitate. The highest AFU values were 
obtained for heather or chestnut honey protein. Isolated manuka honey protein gave 
fluorescence intensities from 24 000 to 145 000 AFU per mg precipitate. For proteins isolated 
from manuka honey, AFU correlated with the corresponding MGO contents of the honeys 
(see Figure 40A). The dicarbonyl compound MGO can react with proteins or amino acids to 
form fluorescent products (Riley and Harding, 1995), such as argpyrimidine, which results 
from the reaction of MGO and the amino acid arginine (Shipanova et al., 1997). However, the 
maximum fluorescence excitation and emission wavelengths of argpyrimidine are situated at 
shorter wavelengths as compared to the fluorescence maxima in our study (λex/em = 320/380 
for argpyrimidine). Nevertheless, specific AGE could potentially be formed in manuka honey 
and will be discussed in section 2.5.2.3. Besides specific structures, protein fluorescence can 
be caused by protein crosslinking, reactions at the peptide backbone or changes in the tertiary 
structure (Sajithlal et al., 1998). To assess how much of the honey protein fluorescence was 
caused by protein-protein interactions compared to single fluorophore structures, honey 
proteins were enzymatically hydrolyzed. Fluorescence measurement of the hydrolyzed honey 
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protein precipitates resulted in a decrease of the slope of the regression equation by 50% (see 
Figure 40B).  
 
 
Figure 40: Fluorescence intensities before (A) and after (B) enzymatic hydrolysis of non-manuka 
honey protein precipitate (■) and manuka honey protein precipitate (○) against honey MGO 
concentration. Fluorescence of the precipitates was recorded at an excitation wavelength of 350 nm 
and an emission wavelength of 450 nm. MGO content was analyzed via RP-HPLC-UV. 
 
This points to the fact that fluorescence of intact honey proteins is equally caused by specific 
fluorophores, such as glycated amino acids on the one hand, and interactions in the protein 
network on the other hand. When manuka honey proteins were treated with DTT, which 
reduces disulfide bonds, no decrease of HMW fraction was detectable (see Figure 38 in 
section 2.5.2.1). This might be due to the formation of thiol-MGO adducts, which may be 
fluorescent or form transient fluorophores due to the interaction with peptide bonds. 
Enzymatic cleavage of the protein and breakup of the network, could lead to the decrease 
which was observed for the hydrolyzed protein. The higher fluorescence intensities of manuka 
honey protein compared to non-manuka honey protein is not only dependent on MGO 
content, but also on storage conditions. The extent of Maillard reaction depends on incubation 
time and water content and it occurs preferentially at elevated temperatures. The honeys used 
in this study were commercial samples and stored at 6 °C in our lab. There is no information 
available about storage conditions prior to purchase. Variations in storage conditions could 
lead to higher variances in the fluorescence to MGO plot. To elucidate whether protein 
fluorescence in the range observed for manuka honeys can be induced by adding synthetic 
MGO and DHA to honey, a non-manuka honey was spiked with low or high amounts of 
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MGO and DHA (MGO/DHA 100/200 and 500/1000 mg/kg respectively) and stored at room 
temperature and 37 °C for 84 days. At certain time points, samples were taken and proteins 
were extracted. Fluorescence measurements were performed and the results are shown in 
Figure 41.  
 
 
Figure 41: Fluorescence intensities of protein isolated from honey samples with added MGO and DHA 
stored at room temperature and 37 °C for 84 days. The label “low” corresponds to 100 and 200 mg/kg 
of MGO and DHA and “high” to 500 and 1000 mg/kg of MGO and DHA, respectively. 
 
The storage experiment showed that fluorescence intensity increases from 20 000 to 40 000 
AFU per mg precipitate only when high amounts of MGO and DHA are added to the honey 
and the honey is stored at 37 °C. In contrast, manuka honey protein with similar MGO 
concentrations as measured for the original honey yielded approximately 80 000 AFU/mg 
precipitate. Chemical reactions in the honey matrix are rather slow, because of its low water 
activity. Hence, the formation of fluorescent proteins takes either long time or requires 
elevated temperatures. This leads to the conclusion that protein fluorescence of manuka honey 
is uniquely formed during honey maturation from the nectar and cannot be achieved by 
artificially spiking a matured honey with MGO and DHA and subsequent storage.  
A recent study which analyzed fluorescence properties of manuka honey, reported manuka-
specific fluorescence at λex = 330 and λem = 470 nm (Bong et al., 2016). The same research 
group claimed that 3,6,7-trimethyllumazine, also called lepteridine, is responsible for this 
honey-derived fluorescence (Lin et al., 2017). According to our results, since fluorescence 
reading is performed with the original, non-extracted honey, the fluorescence measured by the 
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authors is also at least partially caused by MGO-derived reactions in honey proteins. A more 
accurate picture of the progress of Maillard reaction at honey proteins can be achieved when 
proteins are extracted from honey and are subsequently analyzed with fluorescence reading. 
Moreover, the Maillard reaction can be studied by analyzing representative compounds which 
are formed during glycation of proteins, which will be discussed in section 2.5.2.3. 
 
2.5.2.3 Maillard reaction products in honey proteins 
After fluorescence measurement and detection of an HMW fraction in manuka honey 
proteins, it is likely that the abundance of MGO in manuka honey also results in the formation 
of specific protein-bound Maillard reaction products (MRP). Therefore, proteins from twelve 
manuka and eight non-manuka honeys were isolated by dialysis (see 2.4.8). The proteins were 
enzymatically hydrolysed and subsequently analysed with LC-MS/MS for eight Maillard 
reaction products. The study was initiated by Dr. Michael Hellwig and his master student 
Daniel Sandner and was expanded in cooperation with me later on. The results of the study 
were published in Journal of Agricultural and Food Chemistry (Hellwig et al., 2017). 
The Maillard reaction products which were analysed during the investigation were the 
Amadori products N-ε-fructosyllysine and N-ε-maltulosyllysine, which arise from the reaction 
of the ε-amino group of lysine with glucose and maltose, respectively. Moreover, the 
advanced stage Maillard reaction products carboxymethyllysine (CML), carboxyethyllysine 
(CEL), pyrraline, formyline, maltosine, and methylglyoxal-derived hydroimidazolone 1 
(MG-H1) were quantified, which arise from the reaction of amino or guanidine groups of 
proteins and 1,2-dicarbonyl compounds. The summary of the study presented here will focus 
on protein-bound MRP, which are remarkably increased in manuka honeys compared to non-
manuka honeys, namely MG-H1 and CEL. Concentrations of all other quantified MRP can be 
found in the published paper (Hellwig et al., 2017). Also, for method validation parameters 
and synthesis of reference compounds please refer to the published manuscript. 
The mean 5-hydroxymethylfurfural (HMF) concentration of the non-manuka honeys was 6 
mg/kg, whereas the average HMF value of manuka honey was 16 mg/kg. The higher HMF 
value of manuka honey is in accordance with earlier studies, which showed that DHA, which 
is only present in manuka honey, has an influence on HMF levels (Atrott, 2013). The 
chemical pathway for the increased HMF formation is not studied yet. The MGO 
concentration of all non-manuka honeys was below 7 mg/kg, whereas the manuka honeys had 
a mean MGO level of 358 mg/kg. To assess the level of protein-bound MRP in food protein, 
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enzymatic hydrolysis is required. The efficiency of the enzymatic hydrolysis procedure was 
assessed by comparing the concentrations of amino acids in enzymatic hydrolyzates with 
those in acid hydrolyzates. The mean concentration of serine, alanine, valine, isoleucine, 
leucine, and phenylalanine in the enzymatic hydrolyzated was slightly lower for manuka (77-
93%) than for non-manuka honeys (88-97%), with the release of individual amino acids being 
reduced by 3-12%. It was shown in previous reports that the release of certain amino acids 
can be decreased depending on the progress of glycation reactions in proteins (Hellwig et al., 
2016). To overcome the limitations of enzymatic realease of amino acids and to prevent an 
underestimation of MRP in manuka honey because of a decreased hydrolysis rate, the 
concentrations of MRP are calculated on the basis of the leucine content of the protein. 
Leucine is not modified during the Maillard reaction and thus can be used as an internal 
reference. Moreover, leucine concentration is not significantly different in manuka and non-
manuka honey proteins. The quantification of protein-bound MRP in honey was achieved by 
HPLC-MS/MS with the standard addition method. The pattern of protein-bound MRP in 
honey revealed that CEL and MG-H1 are present in particularly high levels in manuka honey 
protein hydrolyzates (see Figure 42). Non-manuka honey proteins contain CEL and MG-H1 
only in levels below the limit of quantification. Manuka honey proteins contain CEL and MG-
H1 in concentrations up to 102.8 and 24.2 µmol/mmol leucine, respectively.  
 
 
Figure 42: Concentrations of protein-bound MRP MG-H1 and CEL in enzymatically hydrolyzed 
HMW fractions (dialysis retentates) of 8 non-Manuka honeys (NMH) and 12 Manuka honeys (MH). 
Dotted lines indicate the medians. Significance of differences between MH and NMH medians was 
assessed by the Mann-Whitney U test. Figure taken from Hellwig et al. (2017). 
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CEL and MG-H1, which are formed during modification of the amino side chain of lysine or 
the guanidine group of arginine with MGO, are almost exclusively formed in manuka honeys. 
Compared to the reaction product of the free amino acid proline and MGO, namely 2-acetyl-
1-pyrroline, the differences of non-manuka and manuka honey are more pronounced (see 
section 1). The CEL and MG-H1 concentrations correlated with the MGO content of the 
honeys (see Figure 43) and the CEL to MG-H1 ratio was approximately 5:1 (determined for 
the manuka honeys were both compounds were detected (n=11)). Moreover protein-bound 
CEL is the most abundant MRP in manuka honey with even higher concentrations than CML 
or N-ε-fructosyllysine, which are normally described as the MRP with the highest 
concentrations in food stuff (He et al., 2014; Scheijen et al., 2016). Based on the CEL and 
MG-H1 concentrations in the protein fractions of manuka honey, it can be assumed that 
approximately 1 % of total MGO has reacted with honey proteins.  
 
Figure 43: (A) Correlation of MGO with protein-bound MG-H1 concentrations and (B) CEL 
concentrations in manuka honey (n=11). (C)Correlation of protein-bound MG-H1 and CEL in manuka 
honey (black squares) and in artificially spiked honey with MGO (500 mg/kg) and DHA (1000 mg/kg) 
(red stars) after storage at 30 °C. Number of storage days is given in red. Figures taken from Hellwig 
et al. (2017) and partly modified. 
Chapter B  117 
 
 
 
 
Taken together, protein-bound MRP in Manuka honey show a unique pattern compared to 
other food stuff and especially in contrast to non-manuka honey proteins. The pathways and 
the kinetic of the formation of CEL and MG-H1 in Manuka honey are not studied yet. Besides 
MGO, also DHA could play an interesting role in the formation of protein-bound MRP during 
honey maturation. DHA is present in very high concentrations not only in the honey, but also 
in nectar, where MGO only plays a minor role (Adams et al., 2009; Williams et al., 2014). 
Nectar is derived from the plant phloem, which has a pH value of 7.4-8.7 (Vreugdenhil and 
Koot-Gronsveld, 1989; Schopfer and Brennicke, 2005). Moreover, the water content of honey 
nectar can vary between 50 to 90 % since it is mostly depending on floral microclimate and is 
affected by evaporation in the exposed flowers (Nicolson et al., 2007; Heil, 2011). Bees 
incorporate specific enzymes into the nectar matrix and during honey maturation in the 
beehive the pH value decreases through the enzymatic formation of organic acids to a pH 
value of approximately 4 (Molan, 1992a; Bogdanov, 1997). The water content slowly 
decreases and the aw-value of the final honey reaches 0.5-0.65 (Gleiter et al., 2006). Under 
these circumstances, it is more likely that the conditions in the nectar or even the plant phloem 
favour the Maillard reaction. Nevertheless, the increase of protein by the addition of bee-
derived enzymes to the honey could also lead to an increase of MRP, although the reaction 
conditions in the honey matrix (low pH and water activity) are less favourable. More 
profound knowledge about formation pathways of glycation compounds is necessary to 
determine if CEL and MG-H1 are convenient compounds to study the fraudulent addition of 
MGO and DHA to a less valuable honey. To study whether the formation of CEL and MG-H1 
can be simulated by the addition of MGO and DHA to a honey matrix, a manuka honey was 
spiked with MGO and DHA and stored for 17 weeks at 30 °C. The manuka honey chosen for 
this experiment contained 96 mg MGO/kg and 464 mg DHA/kg. Thus, based on the recently 
quantified amounts of protein-bound CEL and MG-H1 in commercial manuka honeys, only 
low amounts of CEL and MG-H1 were expected to be present in this honey (3 µmol 
MG-H1/mmol leucine and 19 µmol CEL/mmol leucine as calculated from the regression 
curve presented in Figure 43. The aim of the storage experiment was to elucidate whether a 
fraudulent addition of MGO and DHA to a ripened honey leads to an increase of CEL and 
MG-H1. The concentrations of MGO, DHA and HMF in the storage samples are presented in 
Figure 44. During 17 weeks of storage at 30 °C, the MGO content in the natural honey 
increased by 2.4 % and the sample spiked with MGO increased by 36.2 % during storage. In 
contrast, DHA decreased slightly in the natural honey and the spiked sample. The smaller 
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DHA content at day 0 compared to day 4 is probably due to limited solubility of solid DHA in 
the honey matrix. Thus, DHA might not be dispersed thoroughly in the honey matrix at day 0. 
The HMF concentration of the commercial honey and the spiked honey increases over 17 
weeks of storage at 30 °C. Again, HMF increases more quickly when DHA is present in high 
amounts. This was described previously in the PhD thesis of Atrott (2013) and leads to the 
conclusion that honeys with high levels of DHA need to be stored at especially mild 
conditions to prevent violation of the regulatory limit of HMF of 40 mg/kg (Codex 
Alimentarius Commission, 2001). The commercial sample exceeds the HMF limit at approx. 
75 d and the spiked honey at 30 d of storage. 
 
Figure 44: Concentration of MGO (A), DHA (B) and HMF (C) in commercial manuka honey 
MGO30+ (■) and in manuka honey MGO30+ with added MGO and DHA (●) over 17 weeks of 
storage at 30 °C. Dotted line marks regulatory limit of HMF in commercial honey (40 mg/kg). 
 
The results for the protein-bound Maillard reaction products CEL and MG-H1 are shown in 
Figure 45. 
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Figure 45: Concentration of protein-bound MG-H1 (A) and CEL (B) in commercial manuka honey 
MGO30+ (■) and in manuka honey MGO30+ with added MGO and DHA (●) over 17 weeks of 
storage at 30 °C. 
The concentration of MG-H1 in the commercial manuka honey sample without added MGO 
and DHA increased from 3.2 to 4.2 µmol/mmol leucine over 17 weeks. The concentration of 
the sample, which was spiked with MGO and DHA quadruples after 42 d up to 11.9 
µmol/mmol leucine. The quick increase is followed by a decrease of MG-H1, which resulted 
in a concentration of 8.3 µmol/mmol leucine after 17 weeks. For CEL, the concentration of 
the commercial sample increased from 14.2 to 26.6 µmol/mmol leucine. In contrast, the CEL 
concentration of the spiked sample increased up to 60.4 µmol/mmol leucine on day 42, 
followed by slight decrease and reaches a concentration of 92.3 µmol/mmol leucine after 17 
weeks of storage. Both protein-bound Maillard reaction products, MG-H1 and CEL, 
significantly increased in honey, when artificial MGO and DHA were spiked to the 
commercial sample. On the one hand that demonstrates the unambiguous role of MGO and 
DHA in the formation of protein-bound Maillard reaction products. On the other hand this 
questions the application of CEL and MG-H1 as parameters to study the fraudulent addition 
of MGO and DHA to natural honey. For commercial, natural manuka honeys a constant CEL 
to MG-H1 ratio of 5:1 was found (see Figure 43). The increase of CEL and MG-H1 in the 
spiked manuka honey also led to a median CEL to MG-H1 ratio of 5:1. However, since MG-
H1 started declining after day 42 whereas CEL increased further, the final CEL to MG-H1 
ratio after 17 weeks of storage is 11:1 (see red stars in Figure 43). The decrease of MG-H1 
might be due to consecutive reactions, such as protein cross linking. For example, protein-
bound MG-H1 could react with amino groups of lysine residues and form methylglyoxal-
derived imidazolium cross-links (MODIC).  Moreover, the decrease of MG-H1 and a further 
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increase of CEL at the same time confirmed that the reactivity of MGO in manuka honey 
towards lysine residues appeared to be higher compared to arginine residues. When MGO is 
added to a honey without natural MGO, it will primarily react with lysine residues and 
arginine residues, which are easily accessible. When all available argine residues reacted with 
with MGO, the formation of MG-H1 will stagnate, whereas the formation of lysine-derived 
CEL further increased. This could be either due to the reactivity of MGO towards the amino 
acid residues or depend on the steric accessibility of the amino or guanidine groups. However, 
the role of DHA in the formation of glycation compounds in manuka honey should be further 
elucidated for a better understanding of the unique pattern of MRP in manuka honey.  
In manuka honey, a discrepancy of the CEL to MG-H1 ratio of 5:1 together with an increased 
concentration of HMF might be an indicator for fraudulent addition of MGO and storage at 
increased temperatures for “artificially” producing high-price manuka honey products. 
Kinetic studies of the Maillard reaction in manuka honey at different temperatures should be 
continued to gain a more detailed insight in the spectrum of reaction products, which might 
prove useful for manuka honey authentication.  
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2.6. Summary of Chapter B - Reactions of carbonyl compounds in honey 
 
Chapter B deals with unique chemical reactions which occur in manuka honey during storage. 
The aim is to identify exceptional reactions arising in manuka honey and evaluate their 
suitability to control quality and authenticity of manuka honey. Honey mainly consists of 
sugars and water accounting for 98 % of honey constituents. The key compounds for honey 
identification may be found in the missing 2 %. Therefore, the low molecular weight fraction 
of manuka honey is studied to identify the reaction product of MGO and the amino acid 
proline, namely 2-acetyl-1-pyrroline. Moreover, the extent of glycation reactions in manuka 
honey proteins is studied by the means of fluorescence measurement and size exclusion 
chromatography. Additionally, specific protein-bound Maillard reaction products derived 
from MGO and lysine and arginine, namely CEL and MG-H1, respectively, are studied. The 
results of chapter B can be summarized as follows: 
1 In honey, methylglyoxal (MGO) reacted with proline to form 2-acetyl-1-pyrroline (2-
AP). In manuka honey containing ≥ 250 mg/kg MGO, the 2-AP concentration was 0.3 to 
0.5 mg/kg and was significantly increased compared to non-manuka honey, which 
contained ≤ 0.1 mg 2-AP/kg.  
2 The addition of high amounts of MGO and DHA (500 and 1000 mg/kg, respectively) to a 
non-manuka honey and subsequent storage at room temperature did not lead to an 
increase of 2-AP. Storing the spiked honey at 37 °C led to a 2-AP increase to the same 
level present in commercial manuka honeys. However, 5-hydroxymethylfurfural (HMF) 
level also rose and exceeded the regulatory limit of 40 mg/kg, making this honey 
nonsalable. 
3 The molecular size of manuka honey proteins was significantly shifted to high molecular 
weights (HMW) with a size above 510 kDa. The amount of HMW protein in manuka 
honey compared to non-manuka honey was significantly increased and cannot be 
decreased by cleavage of disulphide bonds. It was hypothesized that MGO cross-linking 
of proteins is mainly responsible for the formation of HMW adducts in manuka honey. 
4 HMW proteins of manuka honey showed higher fluorescence intensities at λex=350 nm 
and λem=450 nm compared to non-manuka honeys. The fluorescence intensity of manuka 
honey proteins depended on the MGO content of the honey. 
5 The artificial addition of MGO and DHA to a non-manuka honey did not lead to an 
increase of fluorescence to the level of commercial manuka honeys. Thus protein 
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fluorescence could be used as an indicator for the Maillard reaction in honey and to 
control natural origin of MGO and DHA. 
6 The protein-bound Maillard reaction products N-ε-carboxyethyllysine (CEL) and 
methylglyoxal-derived hydroimidazolone 1 (MG-H1) were quantified in manuka honey. 
Their amount was significantly higher in manuka compared to non-manuka honey, where 
the concentrations were mostly below LOQ. CEL and MG-H1 concentrations correlated 
with the MGO content of the honey. 
7 The addition of MGO and DHA to a manuka honey with naturally low amounts of MGO, 
DHA and the Maillard reaction marker CEL and MG-H1, led to an increase of CEL and 
MG-H1 up to the level of commercial manuka honeys after 17 weeks of storage at 30 °C. 
In this sample, HMF exceeded the regulatory limit after 30 days of storage, leaving it 
nonsalable.  
 
Taken together, unique MGO-derived reactions in manuka honey could be useful for 
analyzing the genuineness of manuka honey. To evaluate fraudulent addition of MGO or 
DHA to manuka honey, a combination of parameters like MGO, DHA, HMF, 2-AP, MRP 
and physicochemical parameters like pH and water content should be taken into account, 
since the consideration of only a single compound may lead to wrong conclusions. The 
reactions between MGO and honey proteins cannot be fully induced by artificial spiking of a 
ripened non-manuka honey with MGO and DHA, which is probably due to the low water 
activity of honey. The results contribute to the understanding of the unique chemistry of 
MGO in manuka honey and its role in manuka honey characterization. 
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3 Chapter C – Metabolic transit of carbonyl compounds 
 
3.1. Introduction 
 
Carbonyl compounds, especially 1,2-dicarbonyls compounds are discussed to pose a risk to 
human health when ingested with food. This discussion is based on in vitro studies, which 
indicated cytotoxic effects of 1,2-dicarbonyl compounds (Lee et al., 2009; Amoroso et al., 
2013; Daglia, Amoroso, et al., 2013). This discussion poses two difficulties: The 
concentrations used for testing cytotoxicity are usually much higher than concentrations found 
in the human body and thus results are not directly transferable to the human system. 
Moreover, a distinction between endogenously formed 1,2-dicarbonyl compounds, which can 
be elevated under certain metabolic conditions (e.g. diabetes) and 1,2-dicrabonyl compounds 
which are taken up with the diet is necessary. Until now, there is only minor knowledge about 
the dietary influence of the endogenous “1,2-dicarbonyl load”. The background of this chapter 
focuses on studies revealing sources and concentrations of 1,2-dicarbonyl compounds in the 
human body and explaining important reaction pathways and the formation of by-products 
with potential adverse side effects.  
 
3.2. Background 
 
3.2.1 Carbonyl compounds in living organisms 
Since 1,2-dicarbonyl compounds are important intermediates of sugar degradation, their 
formation pathways and concentrations in body fluids were studied increasingly during recent 
years (see Table 25 for concentrations and corresponding literature). Since glucose is 
frequently regarded as the precursor compound for the formation of 1,2-dicarbonyls (in food 
and endogenously), its concentrations in body fluids and the impact of the diet is well 
documented. Despite the fact, that fructose can be converted into glucose in vivo, the interest 
in this precursor compound for dicarbonyl formation was rather low so far. The 
concentrations of 1,2-dicarbonyls in vivo, with 3-DG and MGO as the most important 
representatives, are presented s in Table 25. For 3-DG and MGO a dietary influence after the 
consumption of food was shown (Degen et al., 2013; Degen et al., 2014; Maessen et al., 
2015). Nevertheless, there appears to exist a certain base level of dicarbonyl compounds in 
vivo, which can either be explained by endogenous formation or by incomplete metabolism 
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after dietary intake. The next section will focus on endogenous formation pathways of 3-DG 
and MGO.   
 
Table 25: Concentrations of glucose, fructose, 3-deoxyglucosone and methylglyoxal in body fluids of 
healthy subjects before (F: fasting) and after (P: postprandial) ingestion of compounds. 
Compound Body fluid Concentration 
Glucose Blood plasma[1] 
 
Urine[2] 
Saliva[3] 
F: 5 mmol/l 
P: 6-8 mmol/l (consumption of 75 g glucose) 
0.1-0.8 mmol/l (24 h urine) 
F: 80 µmol/l 
P: 160-200 µmol/l 
Fructose Blood serum[4]  
 
Blood serum[5] 
Cardiac blood 
(murine)[6] 
Urine[7],[8] 
Saliva[9] 
F: 100 µmol/l 
P: 200-300 µmol/l (consumption of 10 g fructose) 
8 µmol/l 
F: 20 µmol/l 
P: 150-250 µmol/l (consumption of sucrose 2g/kg) 
11-110 µmol/d (24 h urine) 
F: < 1.8 µmol/l 
3-Deoxyglucosone Blood plasma[1] 
 
Blood serum[10] 
 
Urine[10], [11] 
F: 1000 nmol/l 
P: 1500 nmol/l (consumption of 75 g glucose) 
F: 500 nmol/l 
P: 700-1100 nmol/l (consumption of 125 g honey) 
1.8-7.6 µmol/d (24 h urine) 
Methylglyoxal Blood plasma[1] 
 
Urine[10], [12] 
F: 350 nmol /l 
P: 420 nmol/l (consumption of 75 g glucose) 
0.1-0.7 µmol/d (24 h urine) 
 
[1]Maessen et al. (2015), [2]Burtis et al. (2013), [3]Jurysta et al. (2009) [4]Anderstam et al. (2013), 
[5]Kawasaki et al. (2002), [6]Sugimoto et al. (2010), [7]Johner et al. (2010), [8]Tasevska et al. (2005), 
[9]Luke et al. (1999) [10]master thesis Stephanie Schultes (2016), [11]Degen et al. (2014) ,[12] Degen et al. 
(2013) 
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Formation of 3-deoxyglucosone 
The reaction of reducing sugars with proteins leads to glycated amino groups of protein side 
chains. During the early stage of the Maillard reaction, Amadori products, also called 
ketoamine compounds, are formed. Depending on the chemical nature of the reacting sugar, 
fructosamines and ribulosamines from glucose and ribose, respectively, can be formed (Van 
Schaftingen et al., 2012). Amadori products can be enzymatically repaired by the enzymes 
fructoseamine-3-kinase (FN3K) and fructoseamine-3-kinase-related protein (FN3KRP). Both 
enzymes lead to phosphorylation of the Amadori compound, which results due to instability 
of the intermediate in the release of the native protein, anorganic phosphate and a 1,2-
dicarbonyl compound (see Figure 46) (Delpierre et al., 2000, 2002). The enzymes FN3K and 
FN3KRP are ubiquitously present in all human tissues and are regenerating native proteins 
and forming new glycating agents at the same time (Collard et al., 2004). 3-DG, which is 
released after the reaction of FN3K and fructosamine, is considered to be the main metabolite 
of protein repair in vivo (Kato et al., 1987). 
 
Figure 46: Formation of 1,2-dicarbonyl compounds from enzymatic repair of glycated proteins 
 
Besides enzymatic protein repair, 1,2-dicarbonyl compounds can be formed via the polyol 
pathway. Under hyperglycaemic conditions, an excess of glucose can be converted to sorbitol 
by aldose reductase. Sorbitol can be further converted into fructose, which either leads to 3-
DG via enolization and oxidation or via enzymatic phosphorylation and subsequent 
hydrolysis (see Figure 47) (Niwa, 1999). The phosphorylating enzyme for this conversion was 
identified to be fructose-3-kinase or 3-phosphokinase in rat and mammalian lenses (Lal et al., 
1993, 1995). However, when Delpierre et al. (2000) studied human erythrocytes, they found a 
300-fold lower affinity of the enzyme to fructose compared to fructosamines. These results 
indicated that the physiological function of the enzyme that is able to convert fructose into 
fructose 3-phosphate in erythrocytes is probably to phosphorylate fructosamines. Therefore, it 
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is assumed that the earlier discovered 3-phosphokinase and FN3K, which was studied later, 
are the same enzymes. 
 
Figure 47: Formation of 3-DG from the polyol pathway 
 
Under normoglycaemic conditions, the intracellular concentration of sorbitol is very low due 
to a low affinity of aldose reductase for glucose (Schalkwijk et al., 2004). The polyol pathway 
is indirectly linked to oxidative stress by decreasing the concentration of NADPH. NADPH 
serves as a cofactor for glutathione reductase, which restores glutathione levels in tissues. A 
decrease of NAPH via the polyol pathway may also lead to decreased levels of GSH, which 
results in enhanced oxidative stress (Schalkwijk et al., 2004). Moreover, 3-DG can be formed 
non-enzymatically via the advanced stage of the Maillard reaction, which is discussed in 
chapter 1. However, the formation of the 1,2-enaminol is enhanced under acidic conditions. 
The slightly basic conditions in vivo make the enzymatic formation more likely. Under 
healthy conditions, endogenously formed 3-DG can be metabolized enzymatically and 
eliminated by renal clearance. These reactions will be further discussed in section 3.2.2. 
 
Formation of methylglyoxal 
There are several pathways known, which can lead to endogenous formation of methylglyoxal 
making it a normal by-product of metabolic processes in vivo. It can be formed during 
glycolysis from the triose phosphates dihydroxyacetone phosphate and glyceraldehyd 
phosphate (Phillips and Thornalley, 1993). This can occur enzymatically via methylglyoxal 
synthase or non-enzymatically via fragmentation and dephosphorylation (Ray and Ray, 1981; 
Thornalley, 1996). Moreover, acetone, which is released during metabolism of ketone bodies, 
can be converted by cytochrom P450 monooxygenase into methylglyoxal via hydroxyacetone 
(Thornalley, 1996). During catabolism of threonine the compound aminoacetone is formed, 
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which can also lead to MGO via an enzymatic oxidation. The potential pathways of MGO 
formation in vivo are summed up in Figure 48. 
 
 
Figure 48: Formation of methylglyoxal in vivo (dashed arrows: non-enzymatic pathway) 
 
Besides endogenous formation of 3-DG and MGO, carbonyl compounds can be taken up with 
the diet. The next section explains how the human body handles carbonyl compounds during 
digestion.   
 
Dietary uptake of carbonyl compounds  
Based on the concentration of 3-DG and MGO in commonly consumed foods, Degen et al. 
(2012) estimated the daily dietary intake of 3-DG to 0.1 to 1 mmol, whereas MGO is taken up 
in significantly lower amounts ranging from 0.1 to 0.3 mmol/day. There is only a limited 
number of food known, which contains very high amounts of 1,2-dicarbonyl compounds. One 
popular example is New Zealand manuka honey. Its MGO concentration can reach up to 800 
mg/kg (Mavric et al., 2008). Moreover, honey is known to contain 3-DG in amounts up to 
1300 mg/kg (Weigel et al., 2004). Thus, the alimentary levels of 3-DG and MGO are 
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exceeding the levels found in vivo by factor 100 to 1000 (see Table 25). This indicates that 
dietary dicarbonyl compounds are either not absorbed in the gastrointestinal tract or can be 
rapidly metabolized by the human body. The presence of dicarbonyl compounds in vivo is of 
special interest, since their reactivity towards proteins is increased by factor 10000 (for MGO) 
compared to glucose (Thornalley, 2005). Until now, there exists only minor knowledge about 
the resorption mechanisms of dicarbonyl compounds. It is not clear whether 3-DG and MGO 
are actively transported into the blood stream or can pass intestinal cells by diffusion. It was 
assumed that MGO and glyoxal (GO) can cross cell membranes, possibly by passive diffusion 
(Abordo et al., 1999). Hoffmann (2012) studied in her master thesis the 3-DG absorption and 
metabolism by Caco-2-cells. She found that a small proportion of 3-DG can cross the cell 
membrane (presumably passively) and can be recovered intracellularly. A further indication 
for potential transportation systems of dicarbonyl compounds into cells and the blood stream 
might be the increase of dicarbonyl compounds in body fluids after food consumption (see 
Table 25, fasting (F) versus postprandial (P) concentrations). Nevertheless, it is also possible 
that glucose and fructose, which are ingested with carbohydrate rich food, are precursor 
compounds leading to the endogenous formation of dicarbonyl compounds. According to the 
HELENA study (Healthy Lifestyle in Europe by Nutrition in Adolescence) European 
adolescents are consuming approximately 138 g sugars per day (defined as mono- and 
disaccharides), whereby 110 g of sugars are consumed as “free” sugars, which were added 
during processing or preparation of food (Mesana et al., 2016). This free sugar is also called 
extrinsic sugar, whereas intrinsic sugar describes sugars which are naturally incorporated into 
the cellular structure of foods, such as sugars in intact fruits and vegetables. The average 
consumption of fructose in the United States of America was 49 g per day, whereby 41 g were 
extrinsic fructose and only 8 g per day occurred naturally in food (Marriott et al., 2009). 
Tasevska et al. (2009) estimated that extrinsic sugars account for 60 % of the total sugar 
consumption. The authors also reported on the analysis of sucrose and fructose in urine as a 
good biomarker for the consumption of extrinsic sugar. According to the World Health 
Organization (WHO), the daily sugar intake should not be above 50 g, whereby extrinsic 
sugars should only contribute with 25 g (World Health Organization 2015). After dietary 
intake, the monosaccharide glucose is actively transported into mucosa cells by the sodium-
dependent SLGT1 transporter and passed to the blood stream via the GLUT2 transporter. The 
uptake by tissue cells and the metabolism of glucose is strictly regulated since higher levels of 
free, circulating glucose can lead to protein damage (Cerami, 1986). In contrast to glucose, 
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the monosaccharide fructose is transported via the GLUT5 and facilitated diffusion into the 
mucosa cell and passed through the GLUT2 transporter to the blood stream (Löffler et al., 
2007). Fructose is quickly resorbed by the liver and subsequently metabolized. Thus, the 
resorption and metabolism of glucose and fructose in healthy individuals leads to human 
plasma levels below 5 mmol/l and 1 mmol/l, respectively (Schalkwijk et al., 2004; Teichert et 
al., 2015). 
 
3.2.2 Reactions of carbonyl compounds in vivo 
When tissue levels of carbonyl compounds are rising due to dietary uptake or bad health 
conditions, enzymatic control mechanisms will lead to the turning-on of metabolic reactions. 
The following section will deal with the enzymatic metabolism of 3-DG and MGO as 
representatives of dicarbonyl compounds and glucose and fructose as the main 
monosaccharides commonly consumed with the diet.   
 
Metabolism of 3-DG 
The reactive intermediate 3-DG is rapidly metabolized to its reduced form 3-deoxyfructose 
(3-DF) via the enzymes aldose reductase (EC 1.1.1.21) and aldehyde reductase (EC 1.1.1.2), 
which belong to the enzyme family of aldo-keto-reductases (Kato et al., 1990; Hayase et al., 
1991; Knecht et al., 1992). 3-DF is less reactive than 3-DG and can be excreted via the urine. 
The reductive enzymes are present in all tissues with high expression in the kidneys, the small 
intestine and the human colon (Cao et al., 1998; Zhong et al., 2009). 3-DG can also be 
oxidized to 3-deoxy-2-ketogluconic acid (3-DGA) via aldehyde dehydrogenase ALDH1A1 
and 2-oxoaldehyde dehydrogenase (Fujii et al., 1995; Collard et al., 2007) (see Figure 49). 
The enzymes are mainly present in erythrocytes, but also in liver and lung tissue (Vander Jagt 
and Hunsaker, 2003; Collard et al., 2007).  
 
Figure 49: Metabolic degradation of 3-DG to 3-DF (reductive pathway) and 3-DGA (oxidative 
pathway), grey arrows represent approximate ratio of degradation 
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3-DF was found in the urine of healthy individuals in a concentration of 32 µmol/g creatinine 
(Knecht et al., 1992), whereas 3-DGA was only found in amounts of 17 µmol/g creatinine 
(Collard et al., 2007). This indicates that the metabolism of 3-DG to 3-DF is the main route of 
degradation, whereas the detoxification of 3-DG via the formation of 3-DGA may be an 
important pathway for tissues which miss the reductive enzymes (e.g. erythrocytes) (Fujii et 
al., 1995). 
Degen et al. (2014) studied the dietary influence on the urinary excretion of 3-DF and 3-DG. 
It was shown that a diet, which avoids 3-DG and other Maillard products followed by a dose 
of honey containing 505 µmol of 3-DG, significantly increases the urinary level of 3-DG and 
3-DF by factor 10 and 20, respectively. In total, 6-25 % of the dietary 3-DG could be 
recovered as urinary 3-DG and 3-DF. These data demonstrated for the first time, that dietary 
3-DG might be bioavailable and is rapidly metabolized to 3-DF. Until now, there are no data 
available for the dietary influence on the oxidative metabolite 3-DGA. 
 
Metabolism of MGO 
The 1,2-dicarbonyl compound MGO is even more reactive towards amino and thiol groups 
and thus might be a risk factor in altering protein structures in vivo. Thus, the human system 
detoxifies MGO via an enzymatic cascade, which is called the glyoxalase system (Thornalley, 
1993). The enzymes of the glyoxalase pathway are found in the cytosol of all eukaryotic and 
prokaryotic cells. The glyoxalase system consists of glyoxalase I, which catalyzes the 
glutathione-dependent formation of the intermediate S- D-lactoylglutathione, and glyoxalase 
II, which hydrolyzes the glutathione-MGO adduct to D-lactate and glutathion. D-Lactate is 
subsequently excreted with the urine, but might also be converted into pyruvate via D-lactate 
dehydrogenase (Ewaschuk et al., 2005). The glyoxalase system is shown in Figure 50. 
 
 
Figure 50: Metabolic degradation of MGO to D-lactate via the glyoxalase system, dashed arrow 
indicates non-enzymatic reaction 
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Besides the conversion to D-lactate, MGO can be enzymatically reduced to acetol with aldose 
reductase or oxidized to pyruvate with methylglyoxal dehydrogenase. Moreover, adehyde 
dehydrogenase can convert MGO into lactaldehyde, which is further metabolized to pyruvate 
(Ko et al., 2005; Chakraborty et al., 2014). 
The disposal of MGO by the glyoxalase system or other metabolic enzymes depends on the 
cellular pool of reduced glutathione. Finally, MGO is either converted to lactate or pyruvate, 
which are intermediates in several metabolic processes. Recently, it was concluded, that 
tissues with high energy requirements and high glycolytic fluxes (e.g. the brain) also produce 
higher amounts of the by-product MGO (Allaman et al., 2015). The authors hypothesized that 
the glyoxalase defence mechanism of the cells in these tissues evolutionary adapted to the 
energetic differences by up-regulating glyoxalase activity and thus protecting against high 
levels of MGO. However, most studies dealing with MGO elimination pathways are 
analysing endogenously formed MGO. The available data for dietary MGO and its 
metabolism is rather limited by now. 
 
Metabolism of glucose and fructose 
Glucose is metabolized in nearly all living organisms via the glycolysis pathway indicating 
that this is one of the most ancient known metabolic pathways (Romano and Conway, 1996). 
The uptake of glucose into cells is regulated by insulin. Via enzymatic cascades, the C6-sugar 
glucose is degraded into two molecules of pyruvate (C3-sugar). The aim of the glycolytic 
pathway is the production of the high-energy molecule adenosine triphosphate (ATP) and 
reduced nicotinamide adenine dinucleotide (NADH+H+). Under normal conditions the 
cellular uptake of glucose and its metabolic degradation is strictly enzymatically regulated, so 
that glucose plasma concentration remains in a narrow range between 4 to 7 mmol/l (Löffler 
et al., 2007). However, under diabetic conditions, which are caused by insulin deficiency or 
resistance, higher levels of glucose are present in the blood stream. The subsequent 
dysregulation of glycolysis is due to inappropriate amount and/or activities of metabolic and 
regulatory enzymes of glycolysis (Guo et al., 2012). Additionally, glucose can enter the 
polyol pathway and is reduced to sorbitol via aldose reductase. Sorbitol can either be 
converted to fructose with sorbitol dehydrogenase or it can accumulate and can cause cellular 
osmotic stress and damage cellular proteins.  
Fructose is metabolized via entering the glycolytic pathway and also delivers ATP. In 
enterocytes but mainly in the liver, fructose can be phosphorylated with fructokinase to 
fructose-1-phosphate which is cleaved by aldolase B to glyceraldehyde and dihydroxyacetone 
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phosphate (DHAP). Glyceraldehyd is phosphorylated to glyceraldehyde phosphate (GAP) and 
both, GAP and DHAP pass glycolysis. Fructose metabolism is independent from the enzyme 
phosphofructokinase, which is regulated by insulin. Thus, fructose is metabolized even under 
diabetic conditions (Löffler et al., 2007). Moreover, fructose can also be converted into 
glucose via the vice-versa polyol pathway and is then metabolized insulin-dependent via 
glycolysis. In contrast to the elimination of glucose, the cellular uptake and metabolism of 
fructose is less regulated. Thus, under diabetic conditions, the production of fructose via the 
polyol pathway combined with the kinetically less controlled metabolism, can pose a risk for 
side reactions of fructose.   
 
Beyond metabolism: Reactions of carbonyl compounds in vivo 
Among the reactions of carbonyl compounds, the Maillard reaction is one of the most 
important pathways. Some details concerning the Maillard reaction in food were discussed in 
chapter 2.2.2. Therefore, this section will focus on reaction products which are present in 
body fluids. Under physiological conditions (pH 7.4, 37 °C), 1,2-dicarbonyl compounds 
preferentially react with the nucleophilic ε-amino group of lysine, the guanidine group of 
arginine and the thiol group of cysteine. Under physiological conditions the initial reversible 
reactions form hemithioacetals from cysteine and glycosylamine derivatives from arginine 
and lysine (Thornalley, 1996). Further irreversible reactions may form more stable products 
like methylglyoxal-derived hydroimidazolones or N-ε-carboxyethyllysine. The analogue 
reaction products from 3-DG are 3-deoxyglucosone-derived hydroimidazolone and pyrraline 
(Thornalley et al., 2003). The hydroimidazolones derived from arginine and 3-DG or MGO 
together with the lysine modification with glyoxal, N-ε-carboxymethyllysine, respectively, 
are the most important glycation products in vivo (Ahmed et al., 2005). Further reactions of 
lysine and arginine with 1,2-dicarbonyl compounds include the formation of protein cross-
linking, whereby two lysine or argine side chains react with two molecules of the respective 
1,2-dicarbonyl compound. Since these cross-linked structures can cause fluorescence, their 
analysis is used in clinical biochemistry as a marker for the Maillard reaction in vivo (Münch 
et al., 1997). In general, the formation and accumulation of AGEs in tissues is discussed as a 
risk to overall health. It was found to be related to the development of retinopathy, neuropathy 
and nephropathy as complication of diabetes (McCance et al., 1993). Moreover, also 
individuals with unimpaired glucose metabolism can be affected by the impact of AGEs 
through the development of age-related diseases like Alzheimer’s and cataract (Lyons et al., 
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1991; Vitek et al., 1994; Sell et al., 1996). More recently, a novel Maillard reaction compound 
formed from the reaction of creatine and MGO, namely N‑ (4-Methyl-5-oxo-1-imidazolin-2- 
yl)sarcosine (MG-HCr), was discovered (Löbner et al., 2015). The incubation of creatine and 
MGO under pyhsiolgical conditions resulted in a rapid decrease of MGO to only 13 % of the 
initial concentration after 1 h at 37 °C. This indicates a “scavenging” role of creatine in 
trapping MGO, which may delay the formation of AGEs in vivo (Löbner et al., 2015). 
Moreover, with the analysis of the urinary MG-HCr concentration of non-vegetarians (0.4-3.8 
µmol/24 h urine) and vegetarian volunteers (0.1-0.3 µmol/24 h urine), it was shown that MG-
HCr excretion is influenced by the dietary uptake of creatine. The unique role of scavenging 
compounds in the human body and their mechanism to protect physiological proteins from 
glycation reactions is only rarely studied until now. Whether creatine reacts also with other 
1,2-dicarbonyl compounds is currently studied in our group. The formation of AGEs and MG-
HCr are important reactions of 1,2-dicarbonyl compounds which are formed endogenously 
under physiological conditions. However, the question whether dietary carbonyl compounds 
are absorbed during gastrointestinal digestion and increases “carbonyl stress” is discussed 
controversially. In our group, the stability of 3-DG and MGO during a simulated in vitro 
digestion was studied. Degen (2013) studied in her PhD thesis the stability of 3-DG during 
gastrointestinal digestion (incubation for 2 h at pH 2 with pepsin) and ileal digestion 
(incubation for 6 h at pH 7.5 with trypsin and pancreatin). She found that 3-DG was stable 
during gastrointestinal digestion and that 70 % of the initial 3-DG concentration can be 
recovered after 6 h of simulated ileal digestion. The missing 30 % were assumed to have 
reacted with digestive enzymes. The results demonstrate that 3-DG is rather stable under 
physiological conditions. However, when MGO was incubated under the same conditions it 
was stable under gastric conditions but showed a rapid decrease to 15 % of the initial 
concentration in the presence of ileal conditions (Degen et al., 2013). If these results can be 
transferred to human digestion, it is assumed that 3-DG might be bioavailable, whereby the 
resorption of MGO is unlikely because its concentration in vivo is quickly decreased by the 
reaction with physiological proteins or other food components. However, this assumption 
needs further research to elucidate the distinct role of dietary carbonyl compounds and their 
contribution to the “1,2-dicarbonyl load” of the human body. Since 1,2-dicarbonyl 
compounds are generally regarded as harmful and were related to severe diseases like multi-
organ failure (van Bussel et al., 2017) or cardiovascular diseases (Maessen et al., 2017) very 
recently, the fate of dietary carbonyl compounds deserves reinforced research. 
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3.3. Aims 
The modern western diet leads to an uptake of millimolar amounts of carbonyl compounds 
every day. Although the metabolism of the energy delivering monosaccharide glucose is well 
studied, the metabolism of fructose and of sugar fragmentation products like 1,2-dicarbonyl 
compounds is understood poorly. A previous study of our group showed that healthy 
individuals are capable of metabolising 3-deoxyglucosone (3-DG) to the less reactive 3-
deoxyfrutose (3-DF) and that dietary methylglyoxal (MGO) is probably not absorbed during 
digestion. However, especially the simultaneous uptake of a combination of carbonyl 
compounds and its impact on individual metabolic pathways needs further research. Since 
1,2-dicarbonyl compounds are discussed as a risk to human health because of their increased 
reactivity towards endogenous proteins, the current work will focus on the recovery of dietary 
carbonyl compounds and the quantification of their metabolites. Manuka honey served as a 
model food to study the metabolic transit of carbonyl compounds. The main carbonyl 
compounds of honey are fructose, glucose and 3-DG. Moreover, manuka honey is 
characterised by additional high amounts of MGO and its precursor dihydroxyacetone (DHA). 
During the first part of the study, the gastrointestinal stability of carbonyl compounds was 
studied under simulated, physiological conditions. The loss of MGO and its reaction partners 
during simulated digestion, which were described in previous reports, should be considered in 
detail. The stability of MGO in manuka honey, which was complexed with α-cyclodextrin 
(cyclopower) shall be studied for the first time. Moreover, a dietary intervention study was 
performed to evaluate the fate of carbonyl compounds during digestion. Therefore, two 
different approaches were used: By analysing the 24 h urine, the excretion of the initial 
carbonyl compounds and also their metabolites was studied (transit to the urine). Furthermore, 
the release of carbonyl compounds into the blood stream was studied by monitoring carbonyl 
compounds in plasma from fasting state until two hours after dietary intervention (transit to 
blood). The aim of this study was to achieve a better understanding of the influence of dietary 
carbonyl compounds on the endogenous level of sugar fragments and the clearance 
mechanism of the human body. Finally, a possible “risk” posed by the uptake of manuka 
honey and therefore high amounts of carbonyl compounds should be assessed.  
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3.4. Methods 
 
3.4.1. Chemicals 
 
Table 26: Chemicals used for the studies presented in chapter C 
Chemical Specification Supplier 
[13C]-MGO 
Synthesis product 2016 (T. 
Hofmann) 
TU Dresden, Germany 
[13C6]3-DG 
Synthesis product 2014 (master 
thesis F. Hahne) 
TU Dresden, Germany 
[13C6]3-DGA 
Synthesis product 2014 (master 
thesis F. Hahne) 
TU Dresden, Germany 
1,3-Dihydroxyacetone dimer 97 % 
Sigma-Aldrich, Steinheim, 
Germany 
3-DF 
Synthesis product 2010 (master 
thesis H.Beyer) 
TU Dresden, Germany 
3-DG 
Synthesis product 2011 (PhD 
thesis M. Hellwig) and 2014 
(master thesis F. Hahne) 
TU Dresden, Germany 
3-DGA 
Synthesis product 2014 (master 
thesis F. Hahne) 
TU Dresden, Germany 
Acetic acid 100 %, p.a. 
Carl Roth, Karlsruhe, 
Germany 
Acetonitrile HPLC grade VWR, Darmstadt 
Amino acid mix 
2.5 mM each, in 0.1 M 
hodrochloric acid 
Sigma-Aldrich, Steinheim, 
Germany 
Bile extract from porcine 
Sigma-Aldrich, Steinheim, 
Germany 
Calcium chloride dihydrate 99.5 % Grüssing, Filsum, Germany 
D(-)Fructose > 99.5 %, for biochemistry 
Carl Roth, Karlsruhe, 
Germany 
D(+)-Glucose anhydrous, p.a. 
Carl Roth, Karlsruhe, 
Germany 
D(+)-Saccharose ≥ 99.5 %, p.a. 
Carl Roth, Karlsruhe, 
Germany 
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Dihydroxyacetone phosphate Lithium salt, ≥95.0 % (TLC) 
Sigma-Aldrich, Steinheim, 
Germany 
Disodium hydrogenphosphate 99 %, p.a Grüssing, Filsum, Germany 
Ethanol 
96%, denatured with light 
petroleum 
Berkel, Berlin, Germany 
Helium 99.999 %, Alphagaz Air Liquide 
Hydrochloric acid 37 % 
Sigma-Aldrich, Steinheim, 
Germany 
Hydroxylamine hydrochloride 99 %, p.a. Grüssing, Filsum, Germany 
Leucine aminopeptidase 
19 U/mg protein, 3.7 mg 
protein/mg 
Sigma-Aldrich, Steinheim, 
Germany 
Lithium chloride p.a. Merck, Darmstadt, Germany 
Lithium citrate buffer 0.12 N, pH 2.2 
Sykam, 
Fuerstenfeldbruck, Germany 
Lithium citrate buffer 0.12 N, pH 2.9 
Sykam, 
Fuerstenfeldbruck, Germany 
Lithium citrate buffer 0.3 N, pH 4.2 
Sykam, 
Fuerstenfeldbruck, Germany 
Lithium citrate-/ borate buffer 0.3 N, pH 8.0 
Sykam, 
Fuerstenfeldbruck, Germany 
Magnesium chloride hexahydrate p.a. Merck, Darmstadt, Germany 
Methanol HPLC grade VWR, Darmstadt, Germany 
Methylglyoxal  
~ 40 % (w/w), exact 
concentration was determined 
against 2-MQ 
Sigma-Aldrich, Steinheim, 
Germany 
Mucin from porcine stomach; Type III 
Sigma-Aldrich, Steinheim, 
Germany 
N,O-
bis(trimethylsilyl)trifluoroacetamide 
(BSTFA + TCMS) 
99:1 
Sigma-Aldrich, Steinheim, 
Germany 
n-Hexane HPLC grade VWR, Darmstadt, Germany 
Ninhydrin p.a., min. 99 % 
Serva Feinbiochemica, 
Heidelberg, Germany 
O-(2,3,4,5,6-
Pentafluorobenzyl)hydroxylamine) 
≥ 99.0 % 
Sigma-Aldrich, Steinheim, 
Germany 
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hydrochloride (PFBOA) 
o-Chlorobenzaldehyde N/A N/A 
ortho-Phenylenediamine (oPD) ≥98 %, 
Sigma-Aldrich, Steinheim, 
Germany 
Pancreatin from porcine pancreas 
Sigma-Aldrich, Steinheim, 
Germany 
Pepsin 
from porcine gastric mucosa, 
3555 U/mg protein 
Sigma-Aldrich, Steinheim, 
Germany 
Potassium chloride 99.5 %, p.a. Grüssing, Filsum, Germany 
Potassium dihydrogenphosphate p.a. 
VEB Laborchemie, Apolda, 
Germany 
Potassium hydroxide 85 % Grüssing, Filsum, Germany 
Prolidase 
from porcine kidney, 208 U/mg 
protein 
Sigma-Aldrich, Steinheim, 
Germany 
Pronase E 
from S. griseus, 4000 PU/mg 
protein 
Merck, Darmstadt, Germany 
Pyridine anhydrous VWR, Darmstadt, Germany 
Sodium acetate 99 % Grüssing, Filsum, Germany 
Sodium chloride p.a. VWR, Darmstadt, Germany 
Sodium dihydrogenphosphate 99.5 %, p.a. Grüssing, Filsum, Germany 
Sodium hydrogencarbonate 99.5 %, p.a. Grüssing, Filsum, Germany 
Trypsin 
from porcine pancreas; Type 
IX- S, 1500 U/mg protein 
Sigma-Aldrich, Steinheim, 
Germany 
Urea > 99.5 % 
Fluka AG, Basel, 
Switzerland 
Urease from Canavalia ensiformis 
(Jack bean) 
Type III; 34310 U/g solid 
Sigma-Aldrich, Steinheim, 
Germany 
α-Cyclodextrin 
≥98 %, CAVAMAX® W6 
FOOD 
Wacker Chemicals AG, 
Supplied by Manuka Health 
NZ Ltd. 
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3.4.2. Materials 
 
Table 27: Materials used for the studies presented in chapter C 
Name Specification Supplier 
Amino acid analysator column Cation exchange LCA K07/Li 
Sykam, 
Fuerstenfeldbruck, Germany 
Blood collection system 
BD Vacutainer SST II Advance 
containing clot activator 
Becton Dickinson, Franklin 
Lakes, USA 
Dialysis tubings 
Cellulose, 33 mm, MWCO 14 
kDa 
Sigma-Aldrich, Steinheim, 
Germany 
GC column 
ZB-5 capillary column, 30 m x 
0.25 mm i.d., 1.0 μm film 
thickness and a Zebron Z-guard 
guard column, deactivated, 5 m x 
0.25 mm i.d. 
Phenomenex, Aschaffenburg, 
Germany 
GC vials with crimp caps 1.5 ml, glass VWR, Darmstadt, Germany 
Glass vessel 10-50 ml VWR, Darmstadt, Germany 
HPLC column 
Eurospher 100 RP18 material 
(250mm x 4.6 mm, 5 µm particle 
size with integrated pre-column 
Knauer, Berlin, Germany 
HPLC vials with lit 1.5 ml, glass VWR, Darmstadt, Germany 
Hydrolysis tubes 12 mm x 100 mm, glas Schott AG, Mainz, Germany 
Membrane filter 
Regenerated cellulose, 45 µm, 26 
mm 
Phenomenex, Aschaffenburg, 
Germany 
Membrane filter for solvents 
GH Polypro 0,45 µm, 47 mm 
hydrophilic polypropylene 
Pall, Crailsheim, Germany 
Parafilm 4 in x 125 ft Bemis, Neenah, USA 
Pasteur pipettes 230 mm, glass 
VWR International, Leuven, 
Netherlands 
Pipette tips 1-1000 µl Brand, Wertheim, Germany 
Plastic containers 5 l N/A 
Septa for HPLC vials 8*0.4 mm, PTFE coated VWR, Darmstadt, Germany 
Syringe 1 ml 
B. Braun, Melsungen, 
Germany 
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Tooth brush soft Various suppliers 
Tubes 1.5 ml, 2 ml 
Eppendorf, Hamburg, 
Germany 
 
 
3.4.3. Devices 
 
Table 28: Devices used for the studies presented in chapter C 
Device Specification Supplier 
Amino acid analysator 
S 4300, Software: Chromstar 6.3 
SCPA GmbH 
Sykam, 
Fuerstenfeldbruck, Germany 
Analytic balance 
BP 121 S, accuracy: 0.0001 g, 
max. 120 g 
Sartorius, Göttingen, 
Germany 
Blood glucose meter ACCU CHEK aviva Roche, Mannheim Zymark, 
Centrifuge Eppendorf 5804-R 
Eppendorf AG, Hamburg, 
Germany 
Freeze dryer Alpha 1 - 2 
Martin Christ, Osterode, 
Germany 
Freezer Comfort 
Liebherr, Bibrach an der Riss, 
Germany 
Fridge Econoic System, 5°C 
Liebherr, Bibrach an der Riss, 
Germany 
GC-MS 
GC 7890A system, 7683 Series 
injector with sample tray, 5975C 
MS detector in electron ionization 
(EI) mode 
Agilent Technologies, 
Böblingen, Germany 
HPLC system 1 
Äkta basic system 
pump P-900 
auto sampler A-900 
UV detector UV-900 
online degasser K-5004 
Amersham Pharmacia 
Biotech, Uppsala, Sweden 
 
 
Knauer, Berlin, Germany 
HPLC system 2 
Smartline 1000 pump  
Dynamic mixing chamber 
solvent organizer K-1500 
online degasser K-5004 
Knauer , Berlin, Germany 
 
Knauer , Berlin, Germany 
Knauer , Berlin, Germany 
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Basic Marathon auto sampler 
Azura DAD detector 2.1 L 
Sparks , Netherlands 
Knauer, Berlin, Germany 
Incubator  BE 500 
Memmert, Schwabach, 
Germany 
Incubator  BE 400 
Memmert, Schwabach, 
Germany 
Incubator ULM 500 
Memmert, Schwabach, 
Germany 
Laboratory pipette 1-1000 µl 
Eppendorf AG, Hamburg, 
Germany 
LabWater Purelab Plus water 
system 
conductivity 0.055 µS/cm 
ELGA, Celle, Germany  
filter from 
USFilter, Ransbach-
Baumbach, Germany 
Magnetic and heating stirrer 
 
RH basic 
IKA Labortechnik, Staufen, 
Germany 
 
pH meter 
InoLab Level 1, electrode: InLab 
Semi-Micro 
Mettler-Toledo, Weilheim, 
Germany 
Ultrasonic bath Sonorex RK 510 Super Bandelin, Berlin, Germany 
Vacuum concentrator 
Thermo Savant SPD SpeedVac, 
Kühlfalle RVT 4104, 
Vakuumpumpe OFP 400 
ThermoSavant, Holbrook, 
USA 
Vortex Uniprep Gyrator Uniequip, Freital, Germany 
Vortex Minishaker MS-1 IKA 
IKA Labortechnik, Staufen, 
Germany 
 
 
3.4.4. Honey samples 
 
Table 29: List of commercial honey samples, Chapter C 
Honey Quantity Manufacturer, Best before 
Artificial honey (AH) 
100g AH contain 
46.5g fructose + 34g glucose + 
1.5g sucrose + 18g ultrapure 
- 
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water 
Cyclopower capsules, Manuka 
honey 400+ with α-cyclodextrin 
0.05 mg/capsule 
Batch: G4189 
Manuka Health, 07/2017 
Manuka honey MGO 550 + 2 Manuka Health NZ Ltd 
Polyfloral honey Batch: C080331 Dr. Krieger`s, 08/2017 
RewaRewa honey 1 
Manuka Health NZ Ltd, 
03/2019 
 
Table 30: List of food used for intervention studies (except honey), Chapter C 
Honey Specification Manufacturer, Best before 
Fructose 99.8 % 
Lorenz & Lihn GmbH & Co. 
KG, Zarrentin, Germany, 
07/2019 
Glucose 91 %  
Dextro Energy GmbH & Co. 
KG, Krefeld, Germany, 
02/2020 
α-Cyclodextrin 
≥98 %, CAVAMAX® W6 
FOOD 
Wacker Chemicals AG, 
Supplied by Manuka Health NZ 
Ltd. 
 
 
3.4.5. Simulated gastrointestinal digestion 
The in vitro digestion model was performed according to Hellwig et al. (2014). In brief, the 
synthetic gastric juice contains NaCl (2.9 g/l), KCl (0.7 g/l) and KH2PO4 (0.27 g/l) and the 
synthetic pancreatic juice contains KCl (0.3 g/l), CaCl2 * 2 H2O (0.5 g/l), urea (0.3 g/l), 
MgCl2 * 6 H2O (0.2 g/l), NaHCO3 (1 g/l) and lyophilized porcine bile (9 g/l). Directly before 
the incubation, the digestive enzymes pepsin (2.5 mg) and mucin (7.5 mg) were solubilized in 
4 ml of the gastric juice and trypsin (1 mg) and pancreatin (24 mg) were homogenized in 3 ml 
pancreatic juice. The gastric phase was started by mixing 2 ml sample solution with 4 ml of 
gastric juice. The samples solutions were prepared by solubilizing the samples in 5 ml 
ultrapure water (see Table 31). The pH value was adjusted to pH 2 ± 0.1 with HCl (3 N) and 
the samples were incubated in a water bath at 37 °C for two hours. After the stomach phase, 3 
ml of pancreatic juice were added to the samples and the pH value was adjusted with solid 
NaHCO3 to 7.5 ± 0.1. The samples were further incubated for six hours at 37 °C. The pH 
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value was controlled every hour and adjusted to pH 7.5 ± 0.1 with HCl (3 N) if necessary. For 
the analysis of DHA in the samples, a higher sample volume was required. Therefore, the 
simulated digestion was performed with 3-times higher volume of sample solution, gastric 
juice and pancreatic juice. During incubation, samples were taken at 0, 1 and 2 hour of 
simulated gastric digestion and 0, 2, 4 and 6 hours of simulated ileal digestion. For HPLC-UV 
analysis the sample volume was 0.5 ml for MGO and 1.5 ml for DHA analysis, respectively. 
For amino acid analysis, 2 ml samples were taken. A blank, containing the MGO standard 
solution, but no digestive juices was included in the sample set. 
 
Table 31: Preparation of sample solutions for the simulated gastrointestinal digestion 
Sample 
MGO in sample 
(mg/kg) 
Sample weight 
(g) 
MGO in sample 
solution (mg/l) 
MGO in 
simulated gastric 
digestion (mg/l) 
MGO standard 
solution (436.7 g/l) 
- - 174.7 58.2 
Manuka honey 488.5 1.8 175.9 58.6 
Cyclopower 221.3 1.8 79.7 26.6 
CD-complex 1 437.5 1.4 122.5 53.3* 
CD-complex 2 74377.9 0.012 178.5 59.5 
CD-complex 3 221.0 1.8 79.6 26.5 
* 3 ml of sample solution was mixed with 4 ml gastric juice 
 
The CD-complexes containing MGO and α-cyclodextrin were prepared according to the 
protocol for the pilot scale production of “MGO 400+ Manuka Honey with CyclopowerTM” 
(Manuka Health NZ Ltd., 2013) with slight modifications. Briefly, ultrapure water was heated 
to 50 °C and α-CD was added. The turbid solution was stirred for 10 min and cooled down to 
40 °C. MGO and artificial honey were added and the solution was stirred for exactly ten 
minutes. The sample volumes and concentrations are presented in Table 32. The mixture was 
subsequently frozen and lyophilized. The lyophilized complexes were stored at -20 °C. 
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Table 32: Preparation of model CD-complexes for the simulated gastrointestinal digestion 
Sample 
Molar ratio 
CD:MGO 
Ultarpure 
water (ml) 
α-CD (g) 
MGO (ml), 
concentration given 
in parentheses 
Artificial 
honey (g) 
CD-complex 1 190:1 100 15 0.015 (436.7 g/l) - 
CD-complex 2 1:1 50 5 0.85 (436.7 g/l) - 
CD-complex 3 190:1 50 14.4 1 (5.76 g/l) 11.6* 
* preparation of artificial honey see 3.4.4. 
 
Influence of the pH value on the simulated gastrointestinal digestion 
To check the influence of the pH value on the stability of the MGO standard solution, the pH 
value was adjusted according to Table 33. The gastric pH was adjusted to 7.5 directly after the 
sample after 1 h incubation was taken and the sample was further incubated for one hour. The 
ileal pH was initially kept at 2.0 and a sample was taken after 0 min of incubation. Then, the 
pH was adjusted to 7.5 and a sample was taken directly. The sample was further incubated at 
pH 7.5 for 2 hours and the final sample was taken and analysed for its MGO concentration. 
 
Table 33: Modifications of pH value during simulated gastrointestinal digestion 
Digestion 
Time point (h) pH of sample in 
standard digestion 
pH of sample 
variation 
Gastric  
0 
1 
2 
2.0 
2.0 
2.0 
2.0 
2.0 
7.5 
Ileal 
0 
0 
2 
7.5 
7.5 
7.5 
2.0 
7.5 
7.5 
 
Influence of human saliva on MGO stability 
The samples were solubilized in human saliva instead of ultrapure water and incubated for 5 
min at 37 °C. The human saliva was obtained according to (Hu et al., 2013). Briefly, a healthy 
volunteer rinsed the mouth with water for 30 s. After starting spitting, saliva which was 
obtained in the first 30 s was discarded. The saliva obtained after following 2 min of spitting 
was stored and the procedure was repeated until enough saliva was available. The collected 
saliva was centrifuged at 5000 rpm for 10 min and the supernatant was used as the salivary 
digestive fluid. The MGO standard solution, manuka honey and CD-complex 1 were studied 
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for their MGO stability towards human saliva. The samples were solubilised in human saliva 
instead of water in concentrations according to Table 31 (column 3). For simulated digestion, 
3 ml of saliva with solubilized sample were incubated at 37 °C for 5 min and after taking 
samples at t = 0 min and t = 5 min (0.5 ml each), the residual 2 ml were used for 
gastrointestinal digestion. 
 
3.4.6. Quantification of methylglyoxal and dihydroxyacetone via RP-HPLC-UV 
The quantification of methylglyoxal and dihydroxyacetone is described in section 1.4.5. All 
honey samples were treated as described in the mentioned section. The samples of the 
simulated gastrointestinal digestion taken at each time point were directly mixed with 1 ml of 
methanol and kept at -18 °C for 1 h to precipitate proteins. After centrifugation at 10,000 rpm 
for 10 min at 4 °C, 500 µl of the supernatant was used for MGO and DHA analysis. The 
volume of the derivatization reagent and the phosphate buffer were adjusted to the reduced 
sample volume (150 µl of each solution instead of 300 µl). 
 
3.4.7. Sample preparation of simulated digestion samples for amino acid analysis 
Based on the results from the master thesis of Zeitz (2013), the recovery of amino acids from 
the digestive proteins after enzymatic hydrolysis of the simulated digestion samples is rather 
limited. Therefore, proteins were supposed to be extracted from the residual sample matrix 
before subjecting them to enzymatic hydrolysis. The results of the enzymatic hydrolysis with 
previous protein extraction were compared to the amino acid yield after acid hydrolysis of the 
digestion samples. 
 
Protein isolation 
The proteins of the simulated digestion samples were either isolated by protein precipitation 
with methanol or by dialysis. For protein precipitation, 2 ml of the digestion samples were 
mixed with 4 ml methanol and kept at -18 °C for 1 h. After centrifugation (10,000 rpm, 10 
min) the supernatant was discarded and the protein pellet was washed with 2 ml aceton and 
centrifuged again (10,000 rpm, 10 min). The supernatant was discarded and the protein pellet 
was dried under a nitrogen stream. For dialysis, the digestion samples were transferred to 
dialysis tubings (MWCO 14 kDa) and were dialyzed against distilled water for 3 days at 6 °C 
with the water changed twice per day. The retentates were then lyophilized and stored at 
-18 °C. 
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Enzymatic hydrolysis 
For enzymatic hydrolysis, 2-3 mg of the protein retentate or precipitate was solubilized in 1 
mL of 0.02 M hydrochloric acid and 50 µl pepsin solution (14 kU in 2 ml 0.02 N HCl) was 
added. After incubation (37 °C, 24 h), 250 µl of potassium phosphate buffer (0.05 M, pH 7.4), 
50 µl KOH (260 mM) and 50 µl of pronase E solution (16 kU Pronase E in 2 ml 0.05 M 
potassium phosphate buffer, pH 7.4) were added. After further incubation (37 °C, 24 h), 4 µl 
of aminopeptidase solution (ready to use, Sigma) and 20 µl prolidase (98.5 U in 1 ml 
ultrapure water) were added. After incubation (37 °C, 24 h), the samples were lyophilized and 
reconstituted in 1 ml lithium citrate buffer (0.12 M, pH 2.2) and membrane filtered (0.45 µm) 
prior to analysis. 
 
Acid hydrolysis 
The acid hydrolyisis was performed according to Förster (2006) with the protein retentates 
and precipitates and with the digestion samples without previous protein extraction. For acid 
hydrolysis of protein isolates and digestion samples, 3 mg of the solid samples were dissolved 
in 3 ml 6 N HCl and 2 ml of the liquid digestion samples were mixed with 2 ml 12 N HCL.  
The mixture was heated at 110 °C for 23 h in a preheated oven. Then, 1 ml of the hydrolysate 
was evaporated to dryness in a vacuum concentrator (SPD Speed Vac; Thermo Fisher 
Scientific, Karlsruhe, Germany). The residue was reconstituted in 1 mL of sample buffer for 
amino acid analysis (0.12 N lithium citrate, pH 2.2) and membrane filtered (0.45 µm) prior to 
analysis. 
 
3.4.8. Amino acid determination 
Proteinogenic amino acids were quantitated with a SYKAM S4300 amino acid analyser 
(Fuerstenfeldbruck, Germany). The effluent was derivatized with ninhydrin at 130 °C and 
detection of products was performed with an integrated two-channel photometer (λ = 440 nm, 
570 nm). External calibration was performed with an amino acid mixture (Sigma-Aldrich, 
Steinheim, Germany). The injection volume was between 10 and 90 µL. The parameters of 
the amino acid analysis are summarized in Table 34. 
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Table 34: Parameters of amino acid analysis 
Eluent 
 
A: Lithium citrate buffer, 0.12 M, pH 2.9 
B: Lithium citrate buffer, 0.3 M, pH 4.2 
C: Lithium citrate/borate buffer, 0.3 M, pH 8.0 
D: Lithium hydroxide, 0.5 N 
Flow rate 0.45 ml/min 
column Cation exchange LCA K07/Li 
G
ra
d
ie
n
t 
E
lu
ti
o
n
 
Time (min) A % B % C % D % 
0 85 15 0 0 
3.0 85 15 0 0 
4.0 79 21 0 0 
21.0 43 57 0 0 
25.0 43 57 0 0 
33.0 0 100 0 0 
39.0 0 0 100 0 
43.0 0 0 77 23 
61.0 0 0 77 23 
61.1 0 0 0 100 
64.1 0 0 0 100 
64.2 85 15 0 0 
77.2 85 15 0 0 
P
o
st
 C
o
lu
m
n
 D
er
iv
a
ti
za
ti
o
n
 
Tim (min) Valve Temperature (°C) 
0 30 % Isopropanol in water 42 
0.1 SYKAM Ninhydrin 42 
25.0 SYKAM Ninhydrin 42 
40.4 SYKAM Ninhydrin 60 
46.0 SYKAM Ninhydrin 74 
61.0 SYKAM Ninhydrin 74 
69.0 30 % Isopropanol in water 74 
71.0 30 % Isopropanol in water 42 
81.0 30 % Isopropanol in water 42 
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3.4.9. Determination of carbonyl compounds via GC-MS 
The sample preparation and analysis parameters of the GC-MS method depend on the sample 
matrix and will be described in detail for the physiological samples urine, blood and saliva. 
 
3.4.9.1. In urine 
MGO 
The analysis of MGO was performed according to Degen et al. (2013). After the urine had 
been thawed and centrifuged at 10,000 rpm for 10 min, an aliquot of 400 μl was mixed with 
400 μl of acetic acid-acetate buffer (0.5 M, pH 5.0) and spiked with 50 μl of the internal 
standard o-chlorobenzaldehyde (17.8 μM in ethanol/water (1:1, v/v)). For derivatization, 100 
μl of a freshly prepared O-(2,3,4,5,6-pentafluorobenzyl)hydroxylamine) hydrochloride 
(PFBOA) solution (15 mg/l in water) was added to the sample solution and vigorously mixed 
by vortex. After 6 h of derivatization at room temperature, the samples were extracted with 
250 μl of n-hexane for 5 min. An aliquot of 100 μL of the organic layer was transferred to a 
GC vial and then analyzed. GC-MS analysis was performed using an HP7890A gas 
chromatograph, coupled with an HP7683 automatic liquid sampler and an HP5975C mass 
spectrometer equipped with an ZB-5 capillary column (30 m, 0.25 mm i.d., 1.0 μm film 
thickness; Phenomenex, USA) and a Zebron Z-guard guard column (deactivated, 5 m, 0.25 
mm i.d.; Phenomenex, Germany). The carrier gas was helium with a constant flow at 1.0 
ml/min, the injector temperature was 250 °C, and 1 μl of sample was injected using the pulsed 
splitless injection mode. MS quadrupole temperature was set at 150 °C and MS source 
temperature at 230 °C. The oven temperature program started at 120 °C (hold time of 1 min) 
elevated to 230 °C at a rate of 25 °C/min (hold time of 2 min), and finally heated to 300 °C at 
30 °C/min with a subsequent post run at 300 °C for 3 min, resulting in a complete run time of 
13 min. The mass spectrometer was used with electron impact ionization (70 eV) in SCAN 
and SIM modes. In SIM mode, the dwell time of the analytes was 80 ms and the quantifier 
and qualifier ions for o-chlorobenzaldehyde were 335 and 300, respectively, and for 
methylglyoxal 265 and 462, respectively. Data acquisition and evaluation were performed 
with MSD ChemStation software (Agilent, Germany). For external calibration, stock 
solutions of MGO in water (0.1-1.9 μM) were prepared, and 100 μl of each stock solution was 
mixed with 400 μl of acetic acid-acetate buffer (0.5 M, pH 5.0) and spiked with 50 μl of the 
internal standard o-chlorobenzaldehyde (17.8 μM in ethanol/water (1:1, v/v)). For 
derivatization, 100 μl of a freshly prepared O-(2,3,4,5,6-pentafluorobenzyl)hydroxylamine 
hydrochloride (PFBOA) solution (15 mg/l in water) was added to each standard solution and 
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vigorously mixed by vortex. After 6 h of derivatization at room temperature, the samples were 
extracted with 250 μl of n-hexane for 5 min. An aliquot of 100 μl of the organic layer was 
transferred to a GC vial and then analyzed. The procedure resulted in a calibration range of 
0.010−0.19 nmol MGO per derivatization assay. Due to the formation of stereoisomers with 
PFBOA, MGO and o-chlorobenzaldehyde were quantified on the basis of the sum of their 
signals. Quantitative evaluation was then carried out by the use of the ratio of the area of 
summarized analyte peaks and the summarized internal standard peaks. The limits of 
detection (LOD) and quantification (LOQ) in urine were calculated as the concentrations of 
the analyte necessary to show a peak at a signal-to-noise ratio of 3 and 10, respectively.  
 
3-Deoxyglucosone, 3-deoxyfructose and 3-deoxy-2-ketogluconic acid 
The analysis of 3-DG, 3-DF and 3-DGA was performed according to Degen et al. (2014). An 
aliquot of 100 μl of the thawed urine was spiked with 10 μl of internal standard solution 
(containing 45 µM [13C6]3-DG and 170 µM [
13C6]3-DGA in water) and was then treated with 
30 μl of urease (1 mg/mL in 0.2M sodium phosphate buffer, pH 7.0) for 10 min at 37 °C in a 
water bath. Termination of the enzymatic reaction was realized by addition of 900 μl of ice-
cold ethanol. After centrifugation (10,000g rpm for 15 min), the resulting supernatant was 
transferred to a new tube and evaporated to dryness under a nitrogen stream. The dry residue 
was incubated with 50 μl of hydroxylamine hydrochloride solution (10 mg/mL in anhydrous 
pyridine) for 30 min at 80 °C followed by evaporation to dryness. Then 50 μl of N,O-
bis(trimethylsilyl)trifluoroacetamide (BSTFA + TCMS) was added to the residue and 
vigorously mixed by vortex and incubated at room temperature for another 2 h. Subsequently, 
50 μl of n-hexane was added and an aliquot of 80 μl was transferred to a vial. The GC-MS 
system used for analysis was the same mentioned above for MGO analysis. The carrier gas 
was helium with a constant flow at 1.0 mL/ min, the injector temperature was 250 °C, and 
injection mode was 1 μL pulsed splitless. The oven temperature program started at 80 °C 
(hold time of 2 min) elevated to 260 °C at 7 °C/min and finally heated to 300 °Cat 20 °C/min, 
resulting in a complete run time of 31 min. Mass spectrometer was used with electron 
ionization (70 eV) in scan and SIM modes. In SIM mode, the dwell time of the analytes was 
100 ms and the quantifier and qualifier ions of the analytes are presented in Table 35. 
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Table 35: SIM mode parameters for the GC-MS analysis of 3-DG, 3-DF and 3-DGA in urine and 
blood 
Analyte Quantifier ion (m/z) Qualifier ion (m/z) 
3-DF 214 524 
3-DG 347 537 
[13C6]3-DG 351 543 
3-DGA 348 538 
[13C6]3-DGA 352 544 
 
For quantification, stock solutions of the analytes in water (0.1 µM to 1.1 mM) were pipetted 
(10-150 μl) to yield concentrations between 0.003 to 1.5 nmol per derivatization assay for 3-
DG, 0.6 to 69.5 for 3-DF and 0.01 to 6.9 for 3-DGA. Each calibration sample was mixed with 
10 µl internal standard and subjected to the derivatization procedure after evaporation to 
dryness (see above). The analytes formed syn- and anti-stereoisomers, but for quantification 
only the ratio of the area of the most prominent analyte peak and the internal standard peak of 
the corresponding quantifier ions were used. For quantification of 3-DF, the internal standard 
[13C6]3-DG was used. The limits of detection (LOD) and quantitation (LOQ) in standard 
solution and urine were calculated as the concentrations of the analyte necessary to show a 
peak at signal-to-noise ratios of 3 and 10, respectively.  
 
3.4.9.2. In blood 
MGO 
The blood samples were centrifuged (6,000 rpm, 12 min) in the hospital and 60 µl aliquots of 
the supernatant blood serum were stored at -80 °C. Prior to analysis, the serum samples were 
thawed and homogenized by gentle vortexing. After the addition of 240 µl ultrapure water 
and 600 µl ice-cold acetonitrile/methanol solution (v/v 70:30), the samples were stored at -18 
°C for 1 h. Then, the samples were centrifuged (6,500 rpm, 10 min) and 600 µl of the 
supernatant was transferred in a fresh 1.5 ml tube and subsequently evaporated to dryness 
under a nitrogen stream. Then, 50 µl of the internal standard ([13C]-MGO, 5.6 µM in 0.5 M 
acetic acid-acetate buffer, pH 5.0) and 50 µl of acetic acid-acetate buffer (0.5 M, pH 5.0) were 
added. For derivatization, 300 µl of a freshly prepared O-(2,3,4,5,6- 
pentafluorobenzyl)hydroxylamine hydrochloride (PFBOA) solution (15 mg/l in water) was 
added and vigorously mixed by vortex. After 6 h of derivatization at room temperature, the 
samples were extracted with 150 μl of n-hexane for 5 min. An aliquot of 100 μl of the organic 
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layer was transferred to a GC vial for GC-MS analysis. The GC-MS parameters were the 
same mentiones in section 3.4.9.1 and in SIM mode, the quantifier and qualifier ions for 
[13C]-MGO were 266 and 463, respectively, and for ([12C]-MGO 265 and 462, respectively. 
For quantification of MGO, a matrix calibration was used. Therefore, different volumina of a 
stock solution in water (91 µM) were diluted in 10 ml acetic acid-acetate buffer (0.5 M, pH 
5.0) to yield concentrations between 0.9 to 27.3 µM. Then, eight blood serum samples (from a 
healthy volunteer in fastened state) was prepared as mentioned above. To the dried serum 
samples, 50 µl of the internal standard solution ([13C]-MGO, 5.6 µM in 0.5 M acetic acid-
acetate buffer, pH 5.0) and 50 µl of the corresponding standard solutions were added. The 
derivatization procedure was performed according to the serum samples. 
 
3-Deoxyglucosone, 3-deoxyfructose and 3-deoxy-2-ketogluconic acid 
The blood samples were centrifuged (6,000 rpm, 12 min) and 60 µl aliquots of the supernatant 
blood serum were stored at -80 °C. Prior to analysis, the serum samples were thawed and 
homogenized by gentle vortexing. After the addition of 10 µl internal standard (containing 45 
µM [13C6]3-DG and 170 µM [
13C6]3-DGA in water), 240 µl ultrapure water and 600 µl ice-
cold acetonitrile/methanol solution (v/v 70:30), the samples were stored at -18 °C for 1 h. 
Then, the samples were centrifuged (6,500 rpm, 10 min) and 600 µl of the supernatant was 
transferred in a fresh 1.5 ml tube and subsequently evaporated to dryness under a nitrogen 
stream. The derivatization procedure was performed according to 3.4.9.1. The GC-MS SIM 
parameters were also described in the previous mentioned section. Moreover, 
dihydroxyacetone phosphate (DHAP) was included in the SIM mode with the quantifier ion 
315 and the qualifier ions 299 and 458. The internal standard [13C6]3-DG was used for the 
evaluation of peak areas of DHAP. Since DHAP and 3-DG are physically and chemically 
different, there were no absolute amounts of DHAP quantified. However, the ratio of the peak 
area of DHAP to the peak area of [13C6]3-DG was calculated and the ratio of the fastened state 
was defined as 100 %. For quantification of 3-DG, 3-DF and 3-DGA, a matrix calibration was 
used. Therefore, stock solutions of the analytes in water (9.8 nM to 4.5 µM) were pipetted 
(10-300 μl) to yield concentrations between 0.0005 to 0.12 nmol per derivatization assay for 
3-DG, 0.001 to 1.0 for 3-DF and 0.002 to 0.55 for 3-DGA. The calibration standards were 
mixed with 10 µl internal standard solution and were evaporated to dryness. Then, 60 µl of 
blood serum (from a healthy volunteer in fastened state) were added and the samples were 
treated according to the blood serum samples.   
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3.4.9.3. In saliva 
The freshly collected saliva (see 0 for collection protocol) was stored on ice and subsequently 
membrane filtered (0.45 µm). After the addition of 100 µl saliva filtrate to 40 µl of MGP 
solution (6.3 mg/l) and 30 µl of [13C]MGO solution (4.2 mg/l), the samples were frozen and 
lyophilized. The dry residue was incubated with 50 μl of hydroxylamine hydrochloride 
solution (10 mg/mL in anhydrous pyridine) for 30 min at 80 °C followed by evaporation to 
dryness. Then 50 μl of N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA + TCMS) was 
added to the residue and vigorously mixed by vortex and incubated at room temperature for 
another 2 h. Subsequently, 70 μl of n-hexane was added and after centrifugation (10,000 rpm, 
10 min) an aliquot of 50 μl was transferred to a vial. The GC-MS system used for analysis 
was the same mentioned above (see Table 28). The carrier gas was helium with a constant 
flow at 1.0 mL/ min, the injector temperature was 250 °C, and injection mode was 1 μL 
pulsed splitless. The oven temperature program started at 70 °C (hold time of 1 min) elevated 
to 130 °C at 4 °C/min, followed by an increase of 10 °C/min to 162 °C, elevated to 184 °C at 
2 °C/min and finally heated to 254 °Cat 7 °C/min, resulting in a complete run time of 40.2 
min. A post run at 320 °C for 7 min was subsequently performed. Mass spectrometer was 
used with electron ionization (70 eV) in scan and SIM modes. In SIM mode, the dwell time of 
the analytes was 50 ms and the quantifier and qualifier ions of the analytes are presented in 
Table 36. 
 
Table 36: SIM mode parameters for the GC-MS analysis of MGO, DHA, DHAP, 3-DG, 3-DF, 3-
DGA, fructose and glucose in saliva, *internal standard 
Analyte Quantifier ion (m/z) Qualifier ion (m/z) 
[13C]MGO* 232 247 
MGP* 204 217 
MGO 231 246 
DHA 221 158 
DHAP 315 299 
Fructose 217 307 
Glucose 319 205 
3-DG 347 537 
3-DF 214 524 
3-DGA 348 538 
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For quantification, an external matrix calibration with 100 µl freshly collected and filtered 
saliva was used. Stock solutions of the analytes in water were pipetted to yield concentrations 
between 0.0005 to 0.03 nmol per 100 µl saliva for MGO, 0.03 to 0.3 for DHA, 0.3 to 11.8 for 
DHAP, 0.0009 to 0.4 for 3-DG, 0.006 to 0.12 for 3-DF, 0.0002 to 0.2 for 3-DGA, 0.005 to 50 
for fructose and 0.05 to 40 nmol/100 µl saliva for glucose. Each calibration sample was mixed 
with the same internal standards like the samples (MGP and [13C]MGO) and was subjected to 
the derivatization procedure after evaporation to dryness (see above). The analytes formed 
syn- and anti-stereoisomers, but for quantification only the ratio of the area of the most 
prominent analyte peak and the internal standard peak of the corresponding quantifier ions 
were used. For quantification of MGO and DHA, the internal standard [13C]MGO was used. 
For all other analytes, MGP was used as internal standard.  
 
3.4.10. Conception of nutrition studies  
Within the scope of the master thesis of Stephanie Schultes (Schultes, 2016) and Lisa-Marie 
Blasse (Blasse, 2017), the metabolic transit of carbonyl compounds was studied. On this 
occasion, two approaches to study human carbohydrate metabolism were used. By collecting 
the 24 h urine of healthy individuals, which followed a dietary protocol, the daily urinary 
excretion rate of carbonyl compounds and their metabolites was studied over 5 days (long-
term metabolic transit) (Schultes, 2016). Moreover, by taking blood (Schultes, 2016) or saliva 
samples (Blasse, 2017) from healthy volunteers in fastened state and at certain time points 
after a dietary intervention, the current metabolic state of the individuals was studied (short-
term metabolic transit). 
 
3.4.10.1. Metabolic transit in urine 
The group of subjects comprised 18 volunteers (see Table 38 for characterisation of study 
subjects), which were divided into five groups. The intervention study lasted for five days, 
whereby on day 1 and 5 the individuals had no dietary restrictions, on day 2-4 they followed a 
diet consisting solely of raw fruits and vegetables, avoiding heated and fermented food such 
as dairy and bakery products, coffee, juices, and beer to ensure a diet virtually free of 
dicarbonyl compounds (“raw-food” diet). In the morning of day 3 the subjects were 
administered their intervention food. The diet on intervention day for the five groups is 
described in Table 37. Prior to the intervention study, a control group followed the dietary 
protocol without intervention, whereby day 1 had no dietary restrictions, day 2-6 consisted of 
 Chapter C  153   
 
 
 
a raw-food diet and on day 7 the subjects went back to no dietary restrictions again. The 
results of the control group showed that one day for the wash-out of residual dicarbonyl 
compounds in the urine is sufficient, so the intervention study was shortened to 5 days in 
total. The subjects were asked to collect their 24 h urine in plastic containers, which were 
stored at 6 °C during the collection time. On the following morning of each day, the total 
volume of the 24 h urine was measured and a aliquot of the 24 h urine was subsequently 
stored at -80 °C until analysis of MGO, 3-DG, 3-DF and 3-DGA was performed (see section 
3.4.9.1). The subjects were further asked to keep records of the kind and amount of the daily 
ingested food, their physical activity and the amount of cigarettes smoked during each study 
day.  
 
Table 37: Dietary restrictions during the intervention study 
Day Diet Number of subjects 
1 Raw-food 15 
2 Raw-food 15 
3 
Group 2: Raw-food + 125 g manuka honey  4 
Group 3: Raw-food + 12 cyclopower capsules  4 
Group 4: Raw-food + 2.7 g cyclodextrin powder 4 
Group 5: Raw-food + 125 g non-manuka honey 3 
4 Raw-food 15 
5 Raw-food 15 
 
The subjects of group 3 and 4 were administered the dose of 6 capsules or 1.35 g α-
cyclodextrin powder in the morning of day 3 and further 6 capsules or 1.35 g α-cyclodextrin 
powder during mid-day. This was done to prevent digestion complications like flatulence. 
Based on a voluntarily questionnaire, the subjects were classified as healthy individuals with 
an average body mass index (BMI) of 23 kg/m2 and fastened-state glucose level of 4.8 
mmol/l. Table 38 gives an overview of the study subjects. In total, 18 subjects took part in the 
study, whereby two subjects participated two times. 
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Table 38: Characterisation of study subjects for metabolic transit in urine 
Parameter Subjects 
n 18 
Sex 14 female, 4 male 
Age (years) 25.6 ± 4.8 (range: 21-41) 
BMI (kg/m2) 23.0 ± 3.7 (range: 20.8-36.3) 
Fastened-state 
glucose (mmol/l) 
4.8 ± 0.4 (range: 4.1-5.8) 
Vegetarians 4 
Smokers 2 
 
3.4.10.2. Metabolic transit in blood 
Two subjects participated in a short-term intervention study, which was designed in the style 
of an oral glucose tolerance test (OGTT). Venous blood was withdrawn from the subjects via 
a vascular access and after the subjects gave a fastened-state blood sample, they orally 
administered either 125 g manuka honey (subject 1) or 125 g artificial honey (subject 2). The 
subjects were asked to consume the samples within 10 min and blood was withdrawn after 30, 
60 and 120 min of administration. Parallel to the blood withdrawal, the blood glucose level 
was detected with a blood glucose meter. The venous blood was stored in the BD Vacutainer 
SST II Advance containing clot activator for 30-60 min and was centrifuged after complete 
coagulation at 6,000 rpm for 12 min. Aliquots of the blood serum were stored at -80 °C until 
analysis of MGO, 3-DG, 3-DF, 3-DGA and DHAP (see section 3.4.9.2). The subjects are 
characterised in Table 39. 
 
Table 39: Characterisation of study subjects for metabolic transit in blood 
Parameter 
Subject 1 
(manuka honey) 
Subject 2 
(artificial honey) 
Sex female male 
Age (years) 24 31 
BMI (kg/m2) 20.5 26.8 
Fastened-state glucose 
(mmol/l) 
4.9 4.3 
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Vegetarian yes yes 
Smoker no no 
  
3.4.10.3. Metabolic transit in saliva 
The study subjects were divided into five groups, which were administered five different food 
products. Group 1 was administered 75 g of glucose, group 2 had 40 g of fructose, group 3 
had a fructose/glucose mix (34.7/30.3), which resembled the honey sugar matrix, group 4 had 
65 g of manuka honey (MGO 550+) and group 5 had 65 g of rewarewa honey. The study was 
performed in the morning of the according day and the participants were asked to be in 
fastened state. The food stuff was weighed in a plastic beaker and dissolved in 150 ml water. 
The administration was performed in a time period of 1 min and the subjects were allowed to 
drink water afterwards. Saliva samples were collected prior to the food administration (0 min) 
and 15, 30, 60 and 120 min after. Prior to each saliva sample collection, the subjects rinsed 
their mouth with 30 ml water for 10 s, brushed their teeth for 60 s without toothpaste and 
rinsed again with 30 ml water for 10 s. After the cleaning procedure, the subjects waited 5 
min and then swallowed the residual saliva in their oral cavity. For the following 3 min, the 
subjects collected the saliva, which pooled in their mouth, into a 10 ml glass vessel. The 
freshly collected saliva was stored on ice until analysis (see 3.4.9.3). The sample collection at 
0 min was referred to as fastened state, whereas the follwing time points (15, 30, 60 and 120 
min) were referenced to the time at which the subjects administered the corresponding food 
product. The subjects are characterised in Table 40. 
 
Table 40: Characterisation of study subjects for metabolic transit in saliva 
Parameter Subjects 
Sex 13 female, 21 male 
Age (years) 28 (21-60) 
BMI (kg/m2) 22.6 (18.8-27.2) 
Omnivore 20 
Vegan 2 
Vegetarian 12 
Smoker 7 
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3.5. Results and discussion 
 
3.5.1. Stability of carbonyl compounds during simulated digestion 
When manuka honey is taken up with the diet, mainly the monosaccharides glucose and 
fructose, but also significant amounts of methylglyoxal and dihydroxyacetone can reach the 
gut. Whereas there is profound knowledge of the metabolic transit of sugars and their 
gastrointestinal metabolism (Löffler et al., 2007), there are only limited information available 
dealing with the metabolic fate of MGO and DHA. The results of this section are partly 
originating from the experimental work of master student Constanze Polster and are originally 
published in her master thesis (Polster, 2015). 
 
Stability of MGO and DHA in manuka honey 
The simulated gastrointestinal digestion is a model experiment to evaluate the stability of 
certain compounds during digestion. Concerning MGO and DHA, metabolic reactions like 
degradation or enzymatic modification were unlikely since the simulated gastrointestinal 
fluids contained only peptidases, which are not able to metabolise MGO and DHA. 
Nevertheless, the measurement of MGO and DHA during the simulated digestion process, 
enabled the estimation of the stability of these compounds under physiological conditions. 
The conditions (e.g. salt and enzyme concentration, pH value and temperature) during the 
gastric and ileal phase were chosen to simulate human physiological circumstances (Hellwig, 
2011). Besides the gastric and ileal fluids also saliva contains potential reaction partners for 
MGO. Although saliva contains mainly water (99.5 %), it comprises also proteins like mucine 
and enzymes like lysozyme and amylase (Löffler et al., 2007). To assess whether these 
compounds react with MGO thus leading to an apparent decrease of MGO in food, human 
saliva was incubated with manuka honey and a MGO standard solution (see section 3.4.5 for 
experimental). The incubation did not lead to a decrease of MGO, which is shown in Table 
41. This might be due to the short incubation time of 5 min, the limited amount of proteins (≤ 
0.5 %) or the slightly acidic pH value of 5.5-6.5 (Benedé et al., 2014; Minekus et al., 2014). 
The results of the simulated saliva phase showed that high amounts of MGO in food may 
reach the gut without prior degradation. 
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Table 41: Concentration of MGO after 5 min incubation in human saliva, based on initial MGO 
concentration 
Sample 
Manuka honey solubilized in 
human saliva 
(MGO:176 mg/l) 
MGO standard solution 
solubilized in human saliva 
(MGO: 175 mg/l) 
MGO (%) of initial 
concentration after  
5 min incubation 
98.4 ± 2.6 100.8 ± 1.5 
 
Following the hypothesis that MGO in manuka honey reaches the gastrointestinal system, a 
simulated digestion of manuka honey with continuous monitoring of the bioactive compounds 
MGO and DHA was performed. 
 
 
Figure 51: Stability of (A) MGO during simulated gastrointestinal digestion of MGO standard solution 
or manuka honey and (B) stability of DHA during simulated gastrointestinal digestion of manuka 
honey 
 
Figure 51 shows the gastrointestinal stability of MGO and DHA. For analysing free MGO and 
DHA at each time point, methanol was added to the samples directly after sample collection 
to precipitate proteins and thus terminate reactions with proteins. The supernatant was 
separated from proteins and analysed according to 3.4.6. For MGO, absolute concentrations 
were calculated, whereas for DHA only peak areas were compared. The determination of 
MGO can be achieved with an external calibration of an aqueous standard since the MGO 
derivatization to the quinoxaline derivative is complete. In contrast DHA did neither 
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completely react to a qunioxaline derivative nor formed only one reaction product with o-PD. 
These limitations were overcome in honey by quantifying DHA via the standard addition 
method and by modifying the derivatization procedure (Atrott, 2013). However, because of 
the size of the sample set and the limited amount of sample volume for each time point, this 
was not performed during the simulated digestion experiment. Therefore, only the peak areas 
of the main DHA quinoxaline derivative (elutes at 12.5 min when performed according to 
1.4.5) was compared for each time point. 
The behaviour of MGO during simulated digestion (see Figure 51A) showed that MGO is 
stable in the presence of gastric fluids at pH 2. In contrast during ileal phase, the MGO 
concentration rapidly decreased down to 10 % of the initial concentration. The comparison of 
manuka honey with the MGO standard solution showed that the MGO concentration in 
manuka honey appeared to decrease a bit faster. However, in the end of the incubation after 
6 h of ileal digestion, there were only minor differences between the MGO concentrations of 
the samples, indicating that the matrix did not exert a significant influence on MGO stability. 
The results for MGO confirmed the findings of Degen et al. (2013), who also described a 
rapid decrease of MGO during ileal digestion down to a level of 20 % of the initial MGO 
concentration. The stability of MGO during the gastric phase was surprising since the 
available reaction sites at protein residues were as many as in the ileal phase. However, the 
acidic pH of 2 ensured that the amino groups were protonated and thus less available for 
reactions with MGO. To prove this hypothesis, an additional simulated digestion experiment 
was performed in which the pH 2 of the gastric phase was either kept also after the addition of 
the pancreatic enzymes or the pH value was set at 7.5 already at the beginning of the gastric 
phase (see section 3.4.5 for experimental). The results are presented in Figure 52. 
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Figure 52: Stability of MGO standard solution in gastric fluids (GF) and ileal fluids (IF) at pH 2 or 
pH 7.5 
 
When the pH value was set to 7.5 in the presence of the gastric fluids, MGO decreased to 
74 % of the initial MGO concentration. However, when the gastric pH of 2 was kept also 
when pancreatic fluids were added, MGO did not decrease. Only when the pH was set to 7.5, 
MGO started decreasing. This unambiguously showed that not the type of enzymes but the 
pH value was the critical factor for the loss of MGO during the simulated digestion. Glycation 
reactions due to MGO are well described at physiological pH values (Lo et al., 1994; Rabbani 
and Thornalley, 2008). 
In contrast to MGO, the precursor compound DHA seemed to be stable over the whole 
simulated digestion period. In comparison to MGO, the hydroxyketone DHA has only one 
reactive keto groups, which can react with amino groups of proteins to form Schiff base 
adducts (Li et al., 2008; Seneviratne et al., 2012). In the literature, this is mainly described for 
dihydroxyacetone phosphate, which is endogenously present as a metabolic intermediate of 
glycolysis. In the presence of human serum albumin (HSA), DHA appears to be even more 
reactive than DHAP, especially at pH levels greater 7 (Seneviratne et al., 2012). However, the 
authors report a significant decrease of DHA and DHAP only after 10 days of incubation. 
This might explain why no decrease of DHA was found in this work, since the maximum 
incubation time during simulated digestion is 8 h (6 h at basic pH). Similar results for DHA 
stability during simulated digestion compared to the present work were reported recently 
(Parkar et al., 2017). The stability of DHA could also be due to competitive reactions of MGO 
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and DHA. Since MGO is more reactive, its presence might suppress reactions of DHA with 
amino groups. However, technically there is an excess of reaction sites for DHA and MGO 
present during simulated digestion, which is shown in Table 42. The amount of amino acids 
was calculated based on the results of the acidic hydrolysis of the digestion enzymes 
performed by Zeitz (2013) and corrected for the dilution factors used in the present work. 
 
Table 42: Concentration of lysine, arginine and cystin based on the analysis of acidic hydrolysates by 
Zeitz (2013) in simulated ileal phase. MGO and DHA concentrations are calculated from the initial 
concentrations under consideration of the dilution factor 
Compound Lysine Arginine Cystin MGO DHA 
Concentration 
in simulated 
ileal phase 
(µmol/l) 
771 607 301 325 566 
In total (µmol/l) 1679 891 
 
To check whether the stability of DHA was due to the simultaneous presence of MGO, a 
simulated digestion of a DHA standard solution could be performed. However, for the 
application in food this is only of minor relevance, since there is no food described with high 
concentrations of DHA alone. Regardless of the application in food, it would be interesting to 
study the reactivity of DHA since its phosphorylated form also appears to be an important 
physiological intermediate. 
 
Stability of MGO and DHA in cyclodextrin complexes 
The commercial product cyclopower contains α-cyclodextrin and manuka honey in the ratio 
175:1. To elucidate whether CD influences the MGO and DHA stability during simulated 
digestion, cyclopower and two model complexes, which contained α-CD and MGO, were 
digested according to 3.4.5. The model CD-complex 1 contained α-CD and MGO in the ratio 
175: 1, whereas the model CD-complex 2 contained both compounds in an equimolar ratio.  
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Figure 53: Stability of (A) MGO during simulated gastrointestinal digestion of a MGO standard 
solution and CD complexes of manuka honey (cyclopower) or CD complexes of MGO in the ratio 
175:1 (complex 1) and in the ratio 1:1 (complex 2) and (B) stability of DHA during simulated 
gastrointestinal digestion of the CD complex of manuka honey (cyclopower) 
 
Figure 53 shows the results of the MGO and DHA analysis of the digestion samples. For 
MGO, the simulated digestion of cyclopower and the model CD-complex 1 resulted in a 
decrease of MGO down to 13 and 19 % of the initial concentration, respectively. Compared to 
the decrease to 8 % when a MGO standard solution is incubated, this indicated a slightly 
stabilizing effect of α-CD. However, this effect is only found when α-CD is present in a great 
excess compared to MGO. The model CD-complex 2 contained MGO and α-CD in an 
equimolar ratio and did not stabilize MGO towards reactions during the simulated digestion 
(decrease of MGO to 9 %). Figure 53B shows the stability of DHA during the simulated 
gastrointestinal digestion of cyclopower. The complexation of manuka honey with α-CD did 
not influence DHA stability, since DHA showed the same stability in the presence or absence 
of α-CD. 
The slightly stabilizing effect of α-CD on MGO, when an excess of α-CD was present, might 
be due to either an encapsulation of MGO (compare chapter 1.5.4) or interactions of amino 
acid side chains with the inner side of α-CD. The interaction of MGO and DHA with α-CD 
was shown to be rather weak, therefore a strong effect on the stability of MGO and DHA was 
not expected. However, amino acid residues of the gastrointestinal proteins might interact 
with α-CD and thus are less available for reactions with MGO and DHA. The slight 
enhancement in the stability of MGO is probably without physiological relevance and 
confirmed the rather weak interactions between MGO and CD. The stability of DHA in the 
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presence and absence of α-CD is an interesting result, which needs further research. We 
speculate that DHA reaches the colon and may have an effect on the intestinal microbiota. 
Moreover, DHA could also reach the blood system via gastrointestinal resorption. The 
metabolic transit of DHA will be discussed in section 3.5.3.2 in detail. 
 
3.5.2. Amino acid modification during simulated digestion 
In her master thesis, Zeitz (2013) identified bile extracts and enzymes as the main reaction 
partners of MGO. The MGO derivative of arginine, MG-H1, was identified as the major 
reaction product and accounted for 5 % of the MGO loss. The lysine modification CEL was 
not detected. It was concluded that the incomplete recovery of MGO is due to the low release 
of 12 % of proteinogenic amino acids during the enzymatic hydrolysis (Zeitz, 2013). The low 
release might be due to reactions of MGO and the enzymes used for enzymatic hydrolysis 
leading to a reduced enzymatic cleavage. To increase the recovery of protein-bound amino 
acids after enzymatic cleavage, the sample preparation was adjusted. Instead of directly 
incubating the digestion samples with the solutions for enzymatic hydrolysis, the digestion 
samples were treated with methanol to separate MGO and proteins. The precipitated proteins 
were washed and subjected to enzymatic hydrolysis. After enzymatic hydrolysis of the 
precipitated protein, only 2 % of lysine residues and 5 % of arginine residues were recovered 
in comparison to the acid hydrolysis of the same protein. Apparently the hydrolytic enzymes 
were not able to cleave the precipitated protein, which might be due to denaturation followed 
by aggregation and blockage of the enzymatic cleaving sites. The same experiment was 
performed with lysozyme to check whether the low lysine and arginine recovery is due to the 
protein structure or the methanol treatment. With lysozyme as a model protein, 78 % of lysine 
residues were recovered when solubilized lysozyme was enzymatically cleaved, whereas only 
16 % of lysine residues were recovered when lysozyme was treated with methanol prior to 
enzymatic hydrolysis. Thus, the methanol treatment of digestion samples to separate MGO 
and proteins followed by enzymatic cleavage is unsuitable for sample preparation. To prevent 
protein denaturation, the digestion samples were dialyzed against water instead treatment with 
methanol. After lyophilisation, the retentates were enzymatically hydrolysed. The enzymatic 
hydrolysis of the model protein lysozyme after dialysis resulted in a 86 % and 96 % recovery 
of lysine and arginine residues, respectively. A blank, which contained the enzymes of the 
simulated gastric phase but no MGO gave 79 % recovery of lysine and 84 % recovery of 
arginine residues after enzymatic hydrolysis. This result showed that digestive gastric 
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enzymes can be enzymatically cleaved when they have not been denatured. However, when 
the digestion samples, which additionally contained the ileal enzymes after 6 h incubation, 
were enzymatically hydrolysed, only 34 % of lysine and 54 % of arginine residues were 
recovered. These results point to the fact that indeed dialysis is a more appropriate sample 
preparation for the digestion samples, compared to protein precipitation, but that the release of 
amino acids after incubation is mainly dependent on the enzyme species. Apparently, the 
gastric enzymes pepsin and mucin might be cleaved more effectively by the enzymatic 
hydrolysis, whereas the ileal enzymes trypsin and pancreatin might be more resistant to this 
treatment. Moreover, the “enzymatic load” is much higher when the ileal samples are 
subjected to enzymatic hydrolysis compared to the gastric phase. Ultimately, the enzymes 
used for simulated digestion are able to cleave the enzymes added for enzymatic hydrolysis, 
thus making them ineffective.  
When manuka honey was digested for 2 h with gastric fluids and 6 h with pancreatic fluids 
and the final sample was enzymatically hydrolysed, 29 % of lysine and 45 % of arginine 
residues were recovered. In comparison to the blank, which contained no honey, this was a 
5 % decrease of lysine and a 9 % decrease of arginine residues. Taken together, the 
modification of lysine and arginine explained 7 % of the MGO loss, which was detected 
during the 8 h incubation. Up to now, there is no complete recovery of the MGO loss 
possible. On the one hand this was probably due to the reduced release of protein-bound 
amino acids after enzymatic hydrolysis and on the other hand lysine and arginine are only 
some of the residues which were modified by MGO. The results of the enzymatic hydrolysis 
of the digestion samples are summarized in Table 43. 
 
Table 43: Summary of the lysine and arginine recovery after enzymatic hydrolysis of the digestion 
samples with sample preparation via methanol precipitation or dialysis 
Recovery after 
enzymatic 
hydrolysis 
Precipitated 
lysozyme  
Precipitated 
Ileal 
enzymes 
Dialysed 
lysozyme 
Dialyzed 
gastric 
enzymes 
Dilayzed 
ileal 
enzymes 
Lysine ( %) 16 2 86 79 34 
Arginine (%) - 5 96 84 54 
 
To overcome the effects, which were caused by self-hydrolysis of the digestive enzymes and 
to fully recover the MGO loss, the simulated digestion should be performed in the presence of 
a non-enzymatic protein (e.g. casein) instead of pepsin, mucin, trypsin and pancreatin. It 
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should be tested whether the loss of MGO is the same in the presence of casein and if so 
whether the incubated protein can be enzymatically hydrolysed more effectively. Moreover, 
the MGO modification of casein residues should be studied by analysing MGO-derived MRPs 
via LC-MS/MS. 
 
3.5.3. Metabolic transit of carbonyl compounds 
The intake of carbohydrate rich food, which was heated or fermented, mostly comes along 
with the uptake of dicarbonyl compounds. The aim of this study was to obtain more profound 
knowledge about the metabolic transit of those compounds. Therefore, the excretion of 
carbonyl compounds and their metabolites was studied in urine (section 3.5.3.1) and in blood 
(3.5.3.2 ). The samples were obtained in small intervention studies with healthy subjects (see 
section 3.4.10). 
 
3.5.3.1. Metabolic transit in urine 
Urine is an ultrafiltrate of blood, which is produced in the kidneys. Urine production regulates 
the water and electrolyte balance system of the human body and ensures clearance of 
metabolic by-products. Thus, the urinary excretion of dietary compounds is a reflection of 
their metabolic transit. In this study, the influence of dietary 3-DG and MGO on their 
concentration and their metabolites in human urine was studied. During the first trial, four 
healthy subjects chose their food with no dietary restrictions on day 1 and 7 and followed a 
raw-food diet on day 2 to 6. The raw-food diet was chosen to ensure a diet virtually free of 
dicarbonyl compounds. The subjects were asked to collect their 24 h urine, which was 
subsequently analysed for MGO and 3-DG and the metabolites 3-DF and 3-DGA. 
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Figure 54: Urinary excretion in 24 h urine of 3-DG (A), 3-DF (B), 3-DGA (C) and MGO (D) during a 
mixed diet (day 1 and 7) and a raw-food diet (day 2-6) 
 
Figure 54A shows the dietary influence of 3-DG on its urinary concentration. The urinary 3-
DG excretion of all subjects was higher at day 1 and 7, when the participants consumed a 
mixed diet, whereas the 3-DG excretion was lowered from day 2 to 6. It was concluded that 
the reduction of dietary dicarbonyl compounds by eating a raw-food diet, subsequently 
reduced the 3-DG level in vivo and therefore led to a decrease of urinary 3-DG. The median 
urinary concentration of 3-DG during a mixed diet was 7.6 µmol/24 h urine on day 1 and was 
reduced to 2.3 µmol/24 h urine on day 2. The same pattern can be seen for the 3-DG 
metabolites 3-DF and 3-DGA. The median urinary excretion of 3-DF (panel B) was 137.9 
µmol/24 h urine on day 1 and decreased to 72.5 µmol/24 h urine on day 2. The metabolite 3-
DF is formed via the enzymes aldose reductase and aldehyde reductase and the loss of the 
dicarbonyl function of 3-DG leads to a decreased reactivity towards amino groups. In 
contrast, the oxidative metabolite 3-DGA, which was found in urine of subjects with a mixed 
diet at a median concentration of 28.2 µmol/24 h urine, 3-DF appeared to be the main 
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metabolite of 3-DG. However, the 3-DGA excretion was also decreased when the mixed diet 
was replaced with a raw-food diet to a median level of 20.8 µmol/24 h urine (panel C). The 
remaining level of 3-DG, 3-DF and 3-DGA during the raw-food diet (day 2-6) can be 
explained by endogenously formed 3-DG, which was also metabolized to 3-DF and 3-DGA. 
Endogenous 3-DG can either be formed from glucose via the Maillard reaction (Maessen et 
al., 2015) or can arise from the enzymatic degradation of fructosamines (Van Schaftingen et 
al., 2012). Although dietary 3-DG exerted an influence on the endogenous level of 3-DG and 
its metabolites, apparently it was not the only source of 3-DG in vivo.  
In contrast, the endogenous level of the dicarbonyl compound MGO (see Figure 54D) was not 
influenced by the diet. The urinary MGO concentration ranges from 0.1 to 0.7 µmol/24 h 
urine during mixed diet and raw-food diet, with no apparent increase on the days with mixed 
diet. Endogenous MGO can also be formed from glucose (Maessen et al., 2015) or as a by-
product of glycolysis from dihydroxyacetone phosphate (Phillips and Thornalley, 1993). 
MGO can be enzymatically metabolized via the glyoxalase pathway to ultimately form D-
lactate, which is excreted by the urine. However, Degen et al. (2013) did not find a dietary 
influence of MGO on urinary D-lactate levels. Based on the findings of the simulated 
digestion experiments (see section 3.5.1), it is more likely that dietary MGO which reaches 
the ileum, reacts with proteins to form MGO-derived Maillard reaction products and thus 
becomes unavailable for absorption from the gut. The modified proteins might then reach the 
colon and may be fermented by bacteria. The ability of intestinal bacteria to degrade MRP 
was recently shown by Hellwig et al. (2015). Although in the mentioned study only free and 
not protein-bound MRPs were incubated in human faecal suspensions, it clearly demonstrated 
that colonic bacteria are able to degrade modified amino acids and may use them as a source 
of carbon or nitrogen. The metabolic transit of glycated proteins and their stability towards 
colonic bacteria will be an interesting upcoming research topic.  
The following section will deal with the results of the dietary intervention with manuka 
honey, multifloral honey, cyclopower capsules or α-cyclodextrin on the urine metabolome 
during a raw-food diet. 
 
Manuka honey 
During this 5-day intervention, four healthy subjects followed a mixed diet (day 1 and 5), 
which was changed to a raw-food diet on day 2 lasting for 3 days. On day 3 of the study, the 
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subjects consumed 125 g of manuka honey, which contained 275 µmol 3-DG and 769 µmol 
MGO. All subjects were asked to collect their 24 h urine, which was subsequently analysed.  
Figure 55 shows the urinary excretion of 3-DG and its metabolites and MGO during the 
intervention week with manuka honey. 
 
Figure 55: Urinary excretion in 24 h urine of 3-DG (A), 3-DF (B), 3-DGA (C) and MGO (D) during a 
mixed diet (day 1 and 5) followed by a raw-food diet (day 2-4) and a dietary intervention on day 3 
with 125 g manuka honey 
 
The median level of urinary 3-DG at day 1 (mixed diet) was 6.9 µmol/24 h urine, which 
decreased to 3.2 µmol/24 h urine at day 2 (raw-food diet). On day 3, the uptake of 125 g 
manuka honey, containing 275 µmol 3-DG, increased the median urinary 3-DG level to 5.6 
µmol/24 h urine. At day 4, the subjects consumed only raw-food and the median 3-DG level 
decreased again to 2.6 µmol/24 h urine. On day 5, all subjects had a mixed diet which led to 
an increase of 3-DG uptake and therefore also an increase of urinary 3-DG. Although the 
pattern was the same for all study participants, it became clear that there were strong inter-
individual differences between the uptake and metabolism rate of 3-DG. For example, 
168  Chapter C     
 
 
 
 
participant number 7 had exceptional high levels of 3-DG excretion (approx. 14-16 µmol/24 h 
urine) during the mixed diet and also showed a high increase of 3-DG after the uptake of 
manuka honey. However, the endogenous 3-DG level during the raw-food diet (day 2 and 4) 
was almost the same for all participants. This may be due to various factors including the 
gastrointestinal resorption rate of 3-DG, the enzyme activity of metabolizing enzymes and the 
stability of 3-DG in the presence of other food stuff. For example participant 8 had no 
increased level of 3-DG excretion after the uptake of manuka honey. In contrast to all other 
subjects who consumed a vegetarian diet, participant 8 ate raw minced meat on day 2 and 3 of 
the intervention study. Löbner et al. (2015) showed that the dicarbonyl compound MGO can 
react with creatine to form N-(4-methyl-5-oxo-1-imidazolin-2-yl)sarcosine (MG-HCr). In 
consideration of the structural similarities of MGO and 3-DG, it is likely that creatine can also 
scavenge 3-DG. Recent studies in our laboratory have shown that indeed 3-DG reacts with 
creatine, although to a lesser extent than MGO (personal message by S. Treibmann, 
unpublished data). This might explain the missing increase of urinary 3-DG concentration 
after manuka honey intervention in subject 8.  
Another reason for inter-individual differences of the 3-DG level in urine might be the 
activity of the metabolizing enzymes. The median excretion of the metabolite 3-DF on day 1 
(mixed diet) was 239.2 µmol/24 h urine, which decreased to 87.1 µmol/24 h urine on day 2 
(raw-food diet). The uptake of 275 µmol 3-DG with manuka honey led to an increase of the 
median 3-DF level to 148.1 µmol/24 h urine. On day 3, all subjects consumed a raw-food diet 
and additionally 125 g manuka honey. The increase of the metabolite 3-DF compared to day 2 
(raw-food only) was in the same range for all participants. That showed that, at least for these 
four participnats, inter-individual differences in the activity of the 3-DG reducing enzymes 
were rather small. The big variance in the 3-DF excretion on day 1 and 5 (mixed diet) was 
probably rather due to differences in the food matrix and composition which was taken up by 
the subjects. The influence of a food matrix on the 3-DG resorption and metabolism to 3-DF 
could be studied by administering the same raw-food diet to all participants and additionally 
serve manuka honey in the presence or absence of a protein or creatinine rich matrix.  
The second metabolite of 3-DG, namely 3-DGA, showed the same excretion pattern as 3-DF: 
The median urinary excretion rate was 31.0 µmol/24 h urine on day 1, which decreased to 
18.3 µmol/24 h urine on day 2 and showed a slight increase to 23.4 µmol/24 h urine after the 
uptake of 125 g manuka honey. In comparison to 3-DF, the concentration of 3-DGA in the 
urine is 2-10 times smaller. This, again, emphasized the role of 3-DF as the main metabolite 
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of 3-DG. This might be due to a rather wide distribution of the aldose reductase enzymes in 
the human body, which was found to be present in high concentrations in the liver but also in 
all other relevant tissues (Nishimura et al., 1990). In contrast, the oxoaldehyde 
dehydrogenase, which catalyses the oxidation of 3-DG to 3-DGA, was found in high 
concentrations in erythrocytes (Fujii et al., 1995). The authors concluded that erythrocytes can 
actively take up 3-DG, enzymatically degrade it to 3-DGA and therefore could function as a 
scavenger for 3-DG in vivo. This pathway could serve as an additional protective mechanism 
in the blood vessels when high concentrations of 3-DG are present. Hahne (2014) observed in 
her master thesis that in erythrocytes the oxidation of 3-DG to 3-DGA was indeed the main 
metabolic route.  
For MGO, no correlation between dietary intake and the urinary MGO level was found. The 
urinary MGO excretion ranged between 0.2-1.1 µmol/24 h urine during the 5 day intervention 
week. There was no decrease when the diet was changed from mixed to raw-food and also no 
significant increase when the subjects consumed 125 g of manuka honey on day 3. Based on 
the results of the simulated gastrointestinal digestion (see section 3.5.1), approximately 90 % 
of MGO which was taken up with the diet, reacted with proteolytic enzymes and thus became 
unavailable for resorption. Regarding the administered dose of 769 µmol MGO in this 
intervention study, that means only 77 µmol MGO would be available for gastrointestinal 
resorption. Richard (1991) estimated the daily endogenous MGO formation to be 
approximately 400 µmol. Compared to the dietary MGO uptake of 100 to 300 µmol per day, 
which is achieved with a common western diet (Degen et al., 2012), the endogenous MGO 
concentration exceeds the dietary amount. Therefore, the variations of the daily urinary MGO 
excretion seen in Figure 55D are more likely due to variations of endogenously formed MGO. 
 
Multifloral honey 
During this 5-day intervention, four healthy subjects followed a mixed diet (day 1 and 5), 
which was changed to a raw-food diet on day 2 lasting for 3 days. On day 3 of the study, the 
subjects consumed 125 g of a multifloral honey from Germany, which contained 202 µmol 3-
DG and only minor amounts of MGO (< 5 mg/kg, < 7 µmol/125 g). All subjects were asked 
to collect their 24 h urine, which was subsequently analysed. Figure 56 shows the urinary 
excretion of 3-DG and its metabolites and MGO during the intervention week with mutifloral 
honey. It became clear that the pattern and the concentrations of 3-DG and 3-DF excretion 
were very similar to the intervention week with manuka honey. Interestingly, participant 8, 
who already showed a very low 3-DG increase during the manuka honey trial, was the only 
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subject whose 3-DG excretion did not increase after the consumption of multifloral honey 
containg 202 µmol 3-DG. Since the study was performed in two different weeks with a two 
weeks break in between, this indicated that either the metabolism of 3-DG in participant 8 
was very efficient and/or the resorption of 3-DG was hindered. Moreover, the participant 
consumed 100 g minced meet at day 2 and 3 of the multifloral honey intervention. The 
influence of the food matrix on the 3-DG absorption was discussed previously. However, the 
fact that subject 8 partcipated in both studies, allowed us to compare the intra-individual 
differences. There was no significant difference in the 3-DG excretion during the mixed diet 
(manuka honey trial: 5.7-6.2 µmol/24 h urine and multifloral honey trial: 5.3-6.7 µmol/24 h 
urine) or the raw-food diet (manuka honey trial: 3.1-3.8 µmol/24 h urine and multifloral 
honey trial: 3.5-4.6 µmol/24 h urine). This indicated a rather well controlled metabolic system 
of 3-DG elimination. 
 
Figure 56: Urinary excretion in 24 h urine of 3-DG (A), 3-DF (B), 3-DGA (C) and MGO (D) during a 
mixed diet (day 1 and 5) followed by a raw-food diet (day 2-4) and a dietary intervention on day 3 
with 125 g multifloral honey 
Compared to the increase of the median 3-DG excretion after the consumption of manuka 
honey, the increase after the uptake of multifloral honey was something smaller. This might 
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be due to the lower concentration of 3-DG in the serving of multifloral honey (202 µmol 
instead of 275 µmol in manuka honey), but could also be due to inter-individual differences in 
the 3-DG metabolism. Except participant 8, the group of volunteers during the multifloral 
honey intervention was different compared to the manuka honey trial. These differences also 
became obvious in the urinary 3-DF excretion. Although the pattern of 3-DF excretion was 
similar to the 3-DG excretion, what gave evidence to 3-DF being the main metabolite of 
3-DG, the daily median excretion rates were lower compared to the manuka honey week. For 
participant 8, the 3-DF excretion on day 2 and 4 (only raw-food diet) was higher during the 
multifloral honey week compared to the manuka honey week (multifloral honey week: 
91.9 - 126.6 µmol/24 h urine; manuka honey week: 47.4 – 68.6 µmol/24 h urine). Although 
the participants followed a raw-food diet, they were still consuming glucose by eating fruits or 
vegetables. The dietary glucose can lead to a post-prandial increase of dicarbonyl compounds, 
e.g. 3-DG, in vivo (Maessen et al., 2015). The fact that participant 8 excreted the same amount 
of 3-DG during the raw-food diet of both intervention weeks, but an increased amount of 3-
DF, indicated that the body ensured a 3-DG homeostasis by varying the level of 3-DF 
excretion.  
In contrast to 3-DF, the 3-DGA excretion was not significantly influenced by dietary 3-DG 
from multifloral honey. Again, that showed the importance of 3-DF as the main metabolite of 
3-DG. Moreover, it may be that 3-DGA is only an intermediate in the 3-DG metabolism and 
therefore no significant increase during a 3-DG uptake was detected. For gluconic acids, an 
oxidative pathway ultimately leading to CO2 is discussed (Stetten and Stetten, 1950). Whether 
this pathway is also applicable for deoxygluconic acids was not studied yet. 
For MGO, there was no dietary influence found during the intervention with multifloral 
honey. The MGO concentration in urine ranged from 0.2-0.8 µmol/24 h urine during the trial 
week. This was in the same range as the urinary MGO excretion during the manuka honey 
week. There was also no increase of urinary MGO when a dose of 125 g of multifloral honey 
was administered to the participants on day 3, which is in accordance with the low level of 
MGO in the multifloral honey.  
 
Cyclopower and α-cyclodextrin 
The commercial product cyclopower contained 45% manuka honey and 55% α-cyclodextrin. 
The complexation of manuka honey and its bioactive compound MGO was supposed to 
increase the bioavailability during gastrointestinal digestion. To study whether the 
consumption of cyclopower enhances dicarbonyl availability, four subjects consumed 12 
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cyclopower capsules and four participants consumed the equivalent amount of α-cyclodextrin 
contained in 12 capsules (control group).  
The results of the urinary 3-DG, 3-DF, 3-DGA and MGO excretion during both interventions 
are shown in Figure 57 (α-cyclodextrin) and Figure 58 (cyclopower). The excretion of the 
dicarbonyl compounds and the metabolites of 3-DG showed the same pattern which was 
observed during the first trial when the subjects followed a mixed diet on day 1 and 7 and had 
a raw-food diet from day 2-6. During the mixed, diet the 3-DG and therefore also the 3-DF 
and 3-DGA excretion increased, which was probably due to the uptake of dietary 3-DG. 
During the raw-food diet, the subjects had a diet virtually free of dicarbonyl compounds 
which is reflected in the decrease of 3-DG, 3-DF and 3-DGA on day 2. The uptake of 2.7 g α-
cyclodextrin did not increase the excreted concentration of either 3-DG or its metabolites. 
This was expected since α-cyclodextrin is a fibre and does neither contain digestible 
monosaccharides nor dicarbonyl compounds. Therefore, an excretion pattern similar to the 
raw-food diet was expected.  
 
Figure 57: Urinary excretion in 24 h urine of 3-DG (A), 3-DF (B), 3-DGA (C) and MGO (D) during a 
mixed diet (day 1 and 5) followed by a raw-food diet (day 2-4) and a dietary intervention on day 3 
with 2.7 g α-cyclodextrin powder 
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For MGO, the same concentration in the urine was found compared to the other interventions. 
The urinary MGO excretion ranged between 0.2 and 0.8 µmol/24 h urine and no dietary 
influence was observed.  
The dose of 12 cyclopower capsules accounted for 6.9 µmol 3-DG and 9.0 µmol MGO, which 
was 30-40 times lower in comparison to the amount taken up with multifloral and manuka 
honey. The curve characteristics of the 3-DG, 3-DF and 3-DGA excretion resemble the 
excretion rates which were observed during the α-cyclodextrin week. The uptake of 12 
cyclopower capsules on day 3 did not increase the excretion of 3-DG or its metabolites. That 
was probably due to the low dose of dietary 3-DG compared to endogenously formed 3-DG. 
Although the cyclopower product aimed to complex bioactive compounds of manuka honey 
and thereby increase their bioavailability, there was no increase of MGO found when 12 
cyclopower capsules are consumed (see Figure 58D). This is in accordance with the studies of 
the molecular interaction between MGO and α-cyclodextrin (see section 1.5.4).  
 
 
Figure 58: Urinary excretion in 24 h urine of 3-DG (A), 3-DF (B), 3-DGA (C) and MGO (D) during a 
mixed diet (day 1 and 5) followed by a raw-food diet (day 2-4) and a dietary intervention on day 3 
with 12 cyclopower capsules 
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The weak interaction between MGO and α-cyclodextrin which was shown via 2-D NMR, are 
confirmed by the intervention study. Moreover, the results of the simulated gastrointestinal 
digestion of cyclopower were reflected in the missing MGO increase during the intervention. 
When cyclopower was digested under simulated conditions in vitro (see 3.5.1), the MGO 
content decreased to 14% of the initial concentration. That means, that only 1.3 µmol of the 
initial MGO dose of 9 µmol in 12 capsules would be available for gastrointestinal resorption. 
Compared to the endogenously formed MGO, which accounts for approximately 400 
µmol/day, this concentration is too low to have an impact on the urinary MGO content. The 
complexation of manuka honey apparently did not lead to an increased bioavailability of 
MGO. Based on these results, MGO in manuka honey and cyclopower capsules did not 
influence the “dicarbonyl load” of the human body. Dicarbonyl compounds, and especially 
MGO, are discussed as risk factors for ageing, cell vitality and diabetes (Brownlee et al., 
1984; Kalapos, 1999; Allaman et al., 2015). Concerning dietary MGO, the present results 
indicated that MGO from manuka honey or cyclopower did not influence the MGO level in 
vivo and therefore did not pose a risk to human health. Although MGO in manuka honey and 
cyclopower might not reach the blood circulation it might have an effect on gastrointestinal 
health. There are several reports on the positive effect of manuka honey towards the gastritis 
causing bacterium H. pylori (Al Somal et al., 1994; Keenan et al., 2010, 2012). Moreover, 
Parkar et al. (2017) found that faecal bacteria in the presence of the digesta of manuka honey 
and cyclopower, generated metabolites which favour gut health. Mannina et al. (2016) were 
able to show that the gastroduodenal digesta of manuka honey had an antibacterial effect 
against the pathogenic bacterium Staphylococcus aureus. These studies demonstrated that 
MGO might have a positive effect on the body although, based on our results, it did not reach 
the blood circulation. 
 
Discussion of carbonyl transit to the urine 
The results of the intervention study are summarized in Table 44. The concentrations during 
day 2 and 4 (raw-food diet) were considered to represent the endogenous level of the analytes, 
whereas the concentrations during day 1 and 5 (mixed diet) depended on the choice of food 
by the subjects. The results of the raw-food diet and the mixed diet demonstrated inter-
individual differences of the analyte levels in vivo. During the raw-food diet, the subjects 
consumed a diet virtually free of dicarbonyl compounds like 3-DG and MGO. Thus the inter-
individual differences might be due to varying activities of the enzymes, which are 
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responsible for dicarbonyl degradation or formation. For instance, the deglycation enzyme 
FN3K (see section 3.2.1), which catalyzes the release of 3-DG from Amadori products, was 
found to vary in its activity by the factor 4 in erythrocytes of humans (Delpierre et al., 2006). 
During the raw-food diet of this study, the concentration of 3-DG in the urine of 23 subjects 
was found to vary by factor 8, what corresponds with earlier findings. Moreover, during the 
mixed food diet, variations between the subjects by factor 4-8 occur. Although, the dietary 
intake of 3-DG ranges approximately from 0.1 to 1.0 mmol/day (Degen et al., 2012), only 
minor changes between the excretion variances of the raw-food diet and the mixed diet were 
found. This indicated that although the dietary 3-DG influence could lead to a wide range of 
3-DG in vivo, the inter-indivdual variations were independent from the amount of 3-DG 
which is taken up with the diet.  
 
Table 44: Concentrations of 3-DG, 3-DF, 3-DGA and MGO in 24 h urine of all subjects (n=23) during 
raw-food diet and mixed diet 
 
Level during raw-food diet 
(µmol/24 h urine) 
Median of urinary excretion of all subjects at  
Level during mixed diet 
(µmol/24 h urine) 
Median of urinary excretion of all subjects at  
Day 2 Day 4 Day 1 Day 5 
3-DG  
3.2  
(range: 1.0-8.4) 
2.6 
(range: 1.0-7.2) 
7.1  
(range: 4.2-16.8) 
5.9 
(range: 2.2-16.6) 
3-DF  
109.2 
(range: 53.3-334.2) 
62.0 
(range: 35.0-128.6) 
214.3 
(range: 77.6-899.6) 
190.1 
(range: 62.2-606.3) 
3-DGA  
23.8 
(range: 10.4-42.2) 
19.8 
(range: 10.8-42.7) 
32.4 
(range: 19.3-76.5) 
28.5 
(range: 13.2-56.0) 
MGO  
0.38 
(range: 0.17-0.73) 
0.41 
(range: 0.18-1.12) 
0.37 
(range: 0.20-1.01) 
0.42 
(range: 0.13-1.03) 
 
 
The results of the 3-DF excretion were in accordance with the results of Degen et al. (2014), 
who detected 3-DF concentrations in urine of subjects following a mixed diet between 91-306 
µmol/24 h urine and following a raw-food diet between 62-130 µmol/24 h urine (n=9). The 
formation of 3-DF from 3-DG is catalysed by the enzyme aldehyde reductase, which is 
ubiquitary present in human tissues, whereby the expression mainly occurs in the liver (Barski 
et al., 2005, 2008). During the raw-food diet, the 3-DF concentration in the urine of all study 
subjects varied by factor 4-6, whereas the variation increased during the mixed diet to a factor 
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of 10-12. This increase in inter-individual differences during the mixed diet indicated that 
3-DF is the metabolite which “buffered” dietary 3-DG variations. When high amounts of 
3-DG were taken up with the diet, the metabolic systems kept the level of 3-DG relatively 
constant, whereas the level of 3-DF increased rapidly. This hypothesis is backed up by the 
observation that 3-DGA, another metabolite of 3-DG, was varying by factor 4 between the 
different subjects independently from the diet which was consumed. Together with the fact 
that 3-DF occured in 30-fold higher concentrations in the urine compared to 3-DG and 5-fold 
higher concentrations than 3-DGA, this emphasized the role of 3-DF as the main metabolite 
of endogenous, but also dietary 3-DG.  
The urinary 3-DGA excretion was in accordance with the results of Collard et al. (2007), who 
detected a mean 3-DGA excretion of 16.7 µmol/g creatinine (n=4), which equals 21.7 
µmol/day when the daily creatinine excretion is approximately 1.3 g. No information about 
the dietary state of these subjects was available. The present work demonstrated for the first 
time, that the urinary 3-DGA level was influenced by the diet. The inter-individual differences 
of the 3-DGA concentration might be due to the varying enzyme activities of the meatbolising 
enzymes. Johnson et al. (1992) found varying activities of the enzyme ALDH by the factor 5 
(n=145). Moreover, the activity of 3-DGA was correlating with alcohol consumption. 
However, Hansell et al. (2005) found no significant effect of alcohol consumption on ALDH 
activity. The inter-individual differences of the urinary 3-DGA excretion in our study varied 
by factor 4, which is in accordance with the results of Johnson et al. (1992). 
During the intervention study, the subjects consumed either a dose of 275 (manuka honey) or 
202 µmol (conventional honey) of 3-DG at day 3. The recovery of 3-DG, 3-DF and 3-DGA in 
the urine of the subjects, who took part in the manuka honey intervention and the 3 subjects, 
who participated in the multifloral honey intervention are graphically shown in Figure 59. The 
results showed that 8.2-40.0 % of the dietary 3-DG can be recovered in the urine as the sum 
of 3-DG, 3-DF and 3-DGA. Kato et al. (1990) detected 6 % of isotopic labelled 3-DG in the 
urine of rats two hours after oral administration, whereas 60 % were detected in the small 
intestine. When the labelled 3-DG was administered intravenously, the main percentage of 
radioactivity was found to be present in the urine (72 %) after 3 h. The significantly lower 
recovery of 3-DG after oral administration compared to our study might be due to the one-
time sampling after 2 h of administration. The metabolic transit of 3-DG and its metabolites 
apparently takes a certain amount of time and therefore the analysis of 24 h urine is more 
reliable in this context. However, when 3-DG was administered intravenously 72 % of 3-DG 
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and its metabolites were already recovered in the urine after 3 h. This indicated that 3-DG is 
not biologically utilized by the rats, but rapidly excreted in the urine. The longer transit time 
after oral administration showed that the resorption of 3-DG and its transport to the urine is a 
rather slow process. 
 
Figure 59: Urinary recovery of 3-DG, 3-DF and 3-DGA from the dietary 3-DG during manuka honey 
intervention (3-DG dose was 275 µmol) and multifloral honey intervention (3-DG dose was 202 
µmol). Each pie chart stands for one participant. 
 
Degen et al. (2014) were able to recover 10-15 % of 3-DG, which was administered with a 
dose of honeydew honey, as 3-DF in the urine of healthy participants. This confirmed the 
results of the present study, where 7-32 % of 3-DG were recovered as 3-DF. Moreover, 
Richter (2012) performed in her master thesis a simulated gastrointestinal digestion of 3-DG 
in the presence of gastrointestinal enzymes. The results showed a 20-40 % loss of 3-DG after 
8 h of incubation in the digestive fluids. This led to the conclusion that a full recovery of 
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dietary 3-DG in urine was not possible, since a loss of 3-DG already occured during 
gastrointestinal digestion.  
In contrast to 3-DF, the metabolite 3-DGA appeared to play only a minor role in dietary 3-DG 
metabolism. Only 0-5.7 % of dietary 3-DG was recovered as 3-DGA in the urine of the 
subjects. The endogenous 3-DGA concentration was approx. 6 times higher than the 3-DG 
concentration, which indicated that 3-DGA was an important metabolite of endogenous 3-DG. 
Fujii et al. (1995) found significantly higher concentrations of 3-DGA in erythrocytes 
compared to plasma levels. The authors assumed that 3-DG is rapidly taken into erythrocytes 
and is converted to 3-DGA to prevent glycation of haemoglobin and blood vessels. Originated 
3-DGA is not excreted from erythrocytes back into blood plasma (Fujii et al., 1995). In our 
study, the urinary 3-DGA level was analyzed. The scavenging of 3-DGA into erythrocytes 
might explain the reduced recovery of 3-DGA in the urine. Further studies should focus on 
the quantification of 3-DGA in erythrocytes after dietary intervention with 3-DG rich food.  
Figure 60 shows the correlation of the urinary 3-DF excretion with 3-DGA. The regression 
coefficient of 0.5 indicated that the metabolites 3-DF and 3-DGA were excreted in a constant 
ratio and that the metabolising enzyme systems interacted. 
 
 
 
Figure 60: Correlation of urinary 3-DF with 3-DGA 
 
Moreover, the urinary excretion of 3-DF and 3-DGA correlated with the 3-DG level in urine, 
which confirmed 3-DF and 3-DGA were metabolites of 3-DG (see Figure 61). Closer 
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examination of the 3-DF to 3-DG plot revealed a two-branched graph with a steeper and a 
lower curve progression. This might indicate that there are individuals who are able to rapidly 
metabolize 3-DG and therefore excrete high amounts of 3-DF and 3-DGA, whereas others are 
only able to metabolize 3-DG to a lesser extent and thus excreting rather low levels of 3-DGA 
and 3-DF. Closer examination of the raw data revealed that the graph separation was caused 
by the 3-DG and metabolite data during the mixed diet but not during the raw food diet. 
Apparently, only when the body was challenged with higher amounts of dietary 3-DG, 
variations in the metabolic processes between the subjects became visible. An explanation for 
those “strong” and “weak metabolisers” might be differences in the enzyme activity of 
aldehyde reductase and aldehyde dehydrogenase. Variations of the level of 3-DG and its 
metabolites in urine of different subjects might indicate different metabolism characteristics 
for dicarbonyl compounds in food and the tendency of certain individuals to accumulate 
higher levels of dicarbonyl compounds from the diet. In contrast, endogenously formed 3-DG 
was equally well metabolised by all subjects, which can be seen in the lower, more uniform 
part of the curves in Figure 61. However, since dietary 3-DG was not fully recovered it might 
also be possible that other metabolic pathways, yet unknown, contributed to the metabolism 
of 3-DG, which might vary between different individuals. 
 
 
Figure 61: Correlation of urinary 3-DG level with urinary 3-DF (A), 3-DGA (B) and the sum of 3-DF 
and 3-DGA (C) of all participants 
 
3.5.3.2. Metabolic transit in blood 
The analysis of 24 h urine indirectly showed that dietary dicarbonyl compounds reach the 
blood circulation and are excreted via the urine. However, the study gave no information 
about the direct transit into the blood circulation. The analysis of plasma samples aimed to 
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gain information about the temporal course of the resorption and elimination process of 
dietary compounds. In contrast to the study of 24 h urine, the analysis of blood plasma gave a 
snapshot of the current metabolic state of an individual, which might elucidate the timing of 
dicarbonyl metabolism after dietary uptake.  
To study the contribution of dietary dicarbonyl compounds to the “dicarbonyl load” of the 
human body, two subjects consumed either 125 g of manuka honey, which contained 3-DG, 
MGO and DHA or 125 g of an artificial honey, which was a mixture of glucose, fructose and 
sucrose and contained virtually no dicarbonyl compounds. The blood withdrawal was 
performed in a hospital prior to the intervention, the subjects were asked to consume the 
honeys in 10 min and further blood was withdrawn after 30, 60 and 120 min. The subsequent 
analysis of the samples was performed according to 3.4.9.2. The glucose concentration of the 
samples was analyzed with a blood glucose meter directly in the hospital. 
 
Glucose 
Both subjects had a fasting glucose level below 5.6 mmol/l and therefore were classified as 
normoglycemic individuals (World Health Organization, 2016). Figure 62 shows the increase 
of plasma glucose level after the consumption of 125 g of manuka or artificial honey. 
 
 
Figure 62: Progression of plasma glucose level after the consumption of 125 g of manuka honey or 
artificial honey 
Dietary glucose is absorbed in the small intestine and transported via the blood circulation to 
the portal vein. The liver is considered to be the central organ of carbohydrate metabolism and 
is responsible for a constant blood glucose concentration. During the dietary intervention with 
manuka or artificial honey, an amount of approx. 43 g glucose was ingested. The liver was 
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temporary not able to keep a constant blood glucose concentration, what explained the 
increased blood glucose level 30 min after start of the intervention. The metabolism of 
glucose ensured the clearance of glucose from the blood stream and its transfer into tissues by 
phosphorylation. After 2 h, the blood glucose concentration was at the same level as prior to 
the intervention in both subjects. This indicated that both subjects had a normal glucose 
metabolism and did not suffer from diabetes or impaired glucose metabolism. The inter-
individual differences in the increase of glucose concentration might be due to different 
enzyme activities or varying affinities of the glucose transport protein SLGT1 in the tissues of 
the subjects. However, the slightly lower glucose increase during the manuka honey 
intervention could indicate a lower glycemic index of honeys in comparison to pure glucose. 
Atayoğlu et al. (2016) reported similar results for some Turkish honeys in comparison to 
glucose. In contrast, Raatz et al. (2015) found no difference in the glycemic response to 
honey, sucrose or high fructose corn syrup. In our study, the glucose concentration of the 
commercial manuka honey was not quantified, thus it might ultimately be that the subject, 
who consumed the artificial honey, ingested a slightly higher dose of glucose compared to the 
manuka honey. To check whether the different glucose increase was due to the honeys or the 
inter-individual differences, the study should be performed with a cross-over design. 
 
3-Deoxyglucosone 
The fasting subjects had a 3-DG level of 480 and 530 nmol/l, which was in accordance with 
previously published 3-DG concentration in plasma and serum (Niwa, 1999; Maessen et al., 
2015). Figure 63A shows the increase of 3-DG plasma concentration after the consumption of 
manuka or artificial honey. The uptake of artificial honey and manuka honey both led to an 
increase of 3-DG in plasma. This confirmed the results of Maessen et al. (2015), who showed 
that dietary glucose was degraded to 3-DG, which led to a postprandial increase of plasma 
3-DG concentration. With the consumption of manuka honey, besides glucose also dietary 
3-DG was taken up. However, the 3-DG concentration in plasma showed no higher increase 
when manuka honey was consumed instead of artificial honey. This raised the question 
whether dietary 3-DG was bioavailable or whether 3-DG in vivo is only a product of glucose. 
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Figure 63: Progression of plasma 3-DG (A), 3-DF (B), 3-DGA (C) and MGO (D) level after the 
consumption of 125 g of manuka honey or artificial honey 
 
3-Deoxyfructose 
The fasting levels of plasma 3-DF concentrations were 890 and 1360 nmol/l. Knecht et al. 
(1992) and Teichert et al. (2015) reported 3-DF levels of 494 and 2700 nmol/l in human 
plasma, respectively. The intervention with artificial honey did not lead to an increase of 
3-DF during the 2 h study time. However, when manuka honey was consumed, which 
contained dietary 3-DG, the plasma concentration of the metabolite 3-DF increased (see 
Figure 63B). In contrast to glucose and 3-DG, which showed the highest increase after 30 min 
followed by a decrease to the initial level, the 3-DF concentration increased continuously over 
the 2 h in which blood samples were taken. Since there was no further blood withdrawal, it 
was not possible to predict the highest 3-DF concentration after the intervention and also the 
time point at which the 3-DF level reached its initial concentration. The artificial honey did 
not contain significant levels of dietary 3-DG and its consumptions did not rise the 3-DF 
plasma level. This emphasized the role of 3-DF as a metabolite of dietary 3-DG. However, it 
was shown that the uptake of glucose led to a postprandial increase of 3-DG. This 
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endogenously formed 3-DG from glucose apparently was not metabolized to 3-DF. This 
indicated that the metabolism of dietary 3-DG underlied a different mechanism or occured in 
different cells than the metabolism of endogenously formed 3-DG. 
 
3-Deoxy-2-ketogluconic acid 
The subjects had a fasting plasma 3-DGA concentration of 226 and 327 nmol/l, which was in 
accordance with the findings of Fujii et al. (1995), who detected 450 nmol/l of 3-DGA in 
human plasma. The consumption of artificial honey led to a slight decrease of 3-DGA during 
the first 30 min of the intervention. In contrast, the subject who consumed manuka honey 
showed an increase to 176 % of plasma 3-DGA after 30 min, followed by a decrease to the 
initial 3-DGA concentration after 2 h (see Figure 63C). We assumed that the increase of 
plasma 3-DGA level was due to the dietary uptake of 3-DG with manuka honey and its 
metabolism to 3-DGA. Again, the missing increase of 3-DGA after the consumption of 
artificial honey, although glucose uptake produced postprandial 3-DG, indicated the unique 
role of dietary 3-DG and its metabolism. Additionally, in this study only plasma 3-DGA 
levels were analyzed. It was reported that erythrocytes scavenge 3-DG and metabolize it to 
3-DGA (Fujii et al., 1995). Further studies could show, whether the uptake of 3-DG rich food 
does also lead to an increase of 3-DGA in erythrocytes, which might be even more significant 
than the increase in plasma. 
 
Methylglyoxal 
In contrast to 3-DG and its metabolites, the plasma concentration of MGO did not change 
significantly during the intervention (see Figure 63D). The MGO level of both subjects varied 
between 2.6 and 3.8 µmol/l. Maessen et al. (2015) reported fasting state MGO concentration 
in plasma of 350 nmol/l, which increases to approx. 430 nmol/l after the consumption of 80 g 
glucose. During the study, no increase of plasma MGO neither due to glucose or dietary 
MGO was observed. In comparison to the published results, the MGO concentrations in this 
study were higher by factor 10. The sample preparation was the same as for 3-DG and its 
metabolites, for which the reported results matched with literature data. We assumed that a 
neoformation of MGO during the drying step of sample preparation may have occurred. Since 
this neoformation did not affect 3-DG, plasma glucose did not appear to be the cause. 
However, it might be that triose compounds like dihydroxyacetone phosphate (DHAP) or 
glyceraldehydes phosphate (GAP) formed MGO during drying of the plasma samples. To 
check whether the drying step caused the high MGO concentration, DHAP or GAP could be 
184  Chapter C     
 
 
 
 
added to the samples and the MGO concentration should be analysed. Although the absolute 
MGO concentrations should be considered with caution, the relative course of the MGO curve 
during the intervention did not show an increase, which confirmed the conclusion, that dietary 
MGO did not influence the “dicarbonyl load” in plasma. 
 
Dihydroxyacetone phosphate 
The study of the stability of DHA in the presence of simulated digestive fluids, showed that 
DHA was stable at different pH values over the incubation time of 8 h (see section 3.5.1). 
With the consumption of manuka honey, high amounts of up to 2700 mg/kg of DHA can be 
ingested (Atrott et al., 2012). Until now, there is no information available whether dietary 
DHA is resorbed during gastrointestinal digestion and how it is metabolized. 
Figure 64 shows the development of the DHAP level in plasma after the consumption of 
manuka honey or artificial honey. Whereas the consumption of artificial honey did not lead to 
an increase of DHAP, the uptake of manuka honey increased the plasma DHAP concentration 
by 400 %. This indicated that dietary DHA was phosphorylated and quickly metabolized via 
glycolysis. There were no absolute concentrations of DHAP in plasma given, because the 
quantification of DHAP was achieved with [13C6]3-DG as the internal standard. Absolute 
quantification requires the use of a more appropriate internal standard, with a similar chemical 
structure and close retention times to the derivative of DHAP. For the assessment of the 
dietary influence of DHA in manuka honey on the plasma DHAP level, the relative 
presentation of the results was sufficient.  
 
 
Figure 64: Progression of plasma DHAP level after the consumption of 125 g of manuka honey or 
artificial honey 
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The consumption of artificial honey, containing glucose which was metabolized via 
glycolysis, did not increase the DHAP concentration. This indicated that DHAP is a 
glycolytic intermediate, which was rapidly metabolized to pyruvate or lactate. However, when 
high amounts of dietary DHA were present, the concentration of DHAP could not be kept 
constant due to the formation of DHAP from DHA. On the one hand, dietary DHA was 
removed from the blood circulation through phopsphorylation and therefore was not available 
for glycation reactions. On the other hand, high levels of DHAP can lead to the formation of 
MGO (Thornalley, 1996), which is even more prone to glycation reactions than DHA. The 
consequences of the metabolism of dietary DHA should be studied with further research. 
 
3.5.3.3. Discussion of the metabolic transit of carbonyl compounds 
According to the results, the uptake of dietary glucose led to a postprandial increase of 3-DG 
in blood plasma. The cellular location of this metabolic reaction is not clear yet. It was 
assumed that only intracellular compartments with direct contact to plasma glucose could be 
responsible for the rapid increase of dicarbonyl compounds after glucose consumption 
(Maessen et al., 2015). The ability of 3-DG to cross cell membranes was already shown by 
Fujii et al. (1995) and Sakiyama et al. (2006). However, the metabolite 3-DGA is to polar to 
cross cell membranes (Fujii et al., 1995), what raises the question where extracellular and 
urinary 3-DGA originated from. It might be that extracellular concentrations of 3-DG and its 
metabolite were actually only representing a minor part of dicarbonyl compounds and its 
metabolites, whereas the majority of these compounds was located intracellularly. Maessen et 
al. (2015) already proposed to study circulating cells and endothelial cells to get a more 
detailed understanding of dicarbonyl concentrations in the circulation. The conclusion that 
dietary 3-DG underwent a different metabolism compared to 3-DG, which was formed 
postprandial after glucose consumption, was backed up by the study of Bryland et al. (2010). 
The authors administered 3-DG intravenously to healthy volunteers and recovered 9.6 % of 
3-DG in the urine. In the present study, only 0.3 to 4.5 % of the orally administered 3-DG was 
recovered as 3-DG in the urine. This indicated that 3-DG which reached the intestinal system, 
might be partially metabolised extracellularly to 3-DF by membrane-based enzymes and thus 
could not be recovered as 3-DG in the urine. In contrast, 3-DG which was directly 
administered to the circulation, bypassed this metabolic system. First evidence for the 
existence of these membrane-based, NADPH-dependent enzyme systems were also reported 
in the master thesis of Hoffmann (2012), who incubated Caco-2 cells with 3-DG and was able 
to recover 3-DF extracellularly. In the present study, a 3-DG to 3-DF ration of 1: 30 was 
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found in the urine, whereas the ratio of 3-DG to 3-DF in blood was 1:2. These results showed 
that 3-DF underlied rapid renal clearance and we assumed that 3-DF elimination shifted the 
balance towards effective 3-DG metabolism. The relatively small increase of 3-DF compared 
to 3-DG in blood might also be an indicator for the extracellular metabolism of 3-DG to 3-DF 
and subsequent (slow) absorption processes. Besides the knowledge about the metabolizing 
enzyme systems, the transport pathways of dicarbonyl compounds and their metabolites are 
an important factor to understand the metabolic transit of dicarbonyl compounds. Fructose is 
transported into cells via passive diffusion with participation of the transport protein GLUT5. 
Due to the similar structure of fructose and 3-DF, it was assumed that 3-DF is mainly formed 
extracellularly and might cross cell membranes subsequently. The slow increase of 3-DF in 
contrast to the rapid increase of 3-DG after the consumption of dietary 3-DG, indicated slow 
resorption processes (see Figure 63). The same conclusion could be drawn for 3-DG: Due to 
its similar structure to glucose, its transport might be dependent on the transport proteins 
responsible for glucose resorption. However, Sakiyama et al. (2006) showed that cellular 
3-DG uptake was not slowed down in the presence of glucose and therefore assumed that its 
transport was not dependent on the same transport protein. The findings of the present study 
and the current knowledge about the transport of glucose, 3-DG and its metabolites 3-DF and 
3-DGA are presented in Figure 65. To summarize, dietary 3-DG can be metabolized rapidly 
and effectively in healthy subjects and it is not expected to pose a risk to human health. For 
MGO, no increase in the urine or in plasma was detected after dietary MGO administration, 
which suggested negligible bioavailability. The metabolic transit of DHA and its potential 
metabolism to DHAP should be addressed in further research. Based on the current 
information, the human gastrointestinal system detoxifies dietary dicarbonyl compounds 
rapidly.  
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Figure 65: Schematic illustration of the metabolic routes for dietary glucose and 3-DG in cells 
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3.6. Summary of Chapter C - Metabolic transit of carbonyl compounds 
Chapter C deals with the metabolic transit of dietary carbonyl compounds. Although 
dicarbonyl compounds are consumed in considerable amounts with the daily diet, little is 
known about their stability during gastrointestinal digestion and their resorption into the 
human body. Therefore, manuka honey containing methylglyoxal (MGO) and 
dihydroxyacetone (DHA) was incubated in simulated gastric and ileal fluids and the stability 
of the compounds was tested subsequently. Moreover, the influence of the fibre 
α-cyclodextrin on their stability was examined. To gain more profound knowledge about 
potential resorption and metabolic reactions, an intervention study with 18 healthy volunteers 
was performed, whereby all subjects followed a nutrition protocol and collected their 24 h 
urine. Moreover, two subjects participated in a “sugar tolerance test”, whereby either 125 g 
manuka honey or artificial honey was consumed and blood samples were withdrawn prior to 
the intervention and 30, 60 and 120 min afterwards. The results of chapter C can be 
summarized as follows: 
1 MGO in manuka honey was found to be stable during simulated digestion with human 
saliva and simulated gastric fluids. During simulated ileal digestion, the MGO 
concentration decreased to 9 % of the initial concentration. The main factor influencing 
the decrease of MGO was the change of pH value from 2 (gatric fluid) to 7-8 (ileal fluid). 
It was assumed that the acidic environment of the gastric fluids provides mainly 
protonized amino acid residues of protein side chains, which hindered MGO-derived 
protein modification. The honey matrix had no stabilising effect on MGO compared to a 
synthetic MGO solution. In contrast to MGO, the manuka honey compound DHA 
appeared to be stable during all simulated digestion steps. The consequences of 
gastrointestinal stability of DHA should be subject of further research. 
2 The complexation of MGO with α-cyclodextrin resulted in 5 % more stability compared 
to the uncomplexed dicarbonyl compound. However, the excess of reactions partners for 
MGO in vivo and the almost identical progession of the decrease in the uncomplexed 
versus complexed MGO, suggested no enhanced stability with α-cyclodextrin. 
3 The recovery of MGO by measuring protein glycation was not achieved due to low 
release of amino acids from the digestive enzymes during enzymatic hydrolysis. A 
dialysis step prior to enzymatic hydrolysis increased the yield of lysine and arginine from 
12 to 42 % compared to previous work (Zeitz, 2013). The results of the amino acid 
analysis need to be questioned critically, since amino acids were not released properly. 
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Model experiments with casein instead of digestive enzymes should be performed to 
achieve better release rates after enzymatic hydrolysis. 
4 It was shown that the urinary concentrations of 3-deoxyglucosone (3-DG), 3-
deoxyfructose (3-DF) and 2-keto-3-deoxygluconic acid (3-DGA), but not MGO, were 
influenced by the diet. During intervention studies, up to 40 % of dietary 3-DG was 
recovered as the sum of 3-DG, 3-DF and 3-DGA. The metabolite 3-DGA had only a 
minor role in the metabolism of dietary 3-DG in comparison to 3-DF.  
5 The complexation of manuka honey with α-cyclodextrin in the commercial product 
“cyclopower” did not enhance the bioavailability of 3-DG or MGO. The urinary 
excretion of the compounds was not increased after consumption of 12 capsules (3 times 
the recommended daily dose). 
6 The uptake of dietary glucose resulted in an increase of 3-DG in the plasma. No 
differences in the plasma 3-DG levels were observed when the subjects consumed a 
glucose/fructose mix with no 3-DG or manuka honey, which naturally contains high 
amounts of 3-DG.  
7 The concentrations of 3-DF and 3-DGA in plasma increased only after the consumption 
of dietary 3-DG. This led to the conclusion that dietary 3-DG and 3-DG, which is formed 
postprandial from glucose, have different metabolic routes. 
8 The concentration of MGO did not increase after the consumption of either a 
glucose/fructose mix without MGO or manuka honey with natural high MGO levels. 
9 The plasma concentration of dihydroxyacetone phosphate (DHAP), a metabolite of 
glycolysis, increased after the consumption of manuka honey, which contained high 
concentrations of dihydroxyacetone (DHA). In contrast, the oral administration of a 
glucose/fructose mix did not influence the DHAP concentration. This is the first evidence 
that dietary DHA might be bioavailable and is metabolized via glycolytic routes.  
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4 Further studies and outlook 
 
4.1. Antibacterial effect of manuka honey 
 
4.1.1. The inhibition of Helicobacter pylori with manuka honey 
The studies were based on the hypothesis that manuka honey and its bioactive compounds 
MGO and DHA inhibit microbial urease and thus might inhibit Helicobacter pylori growth. 
The effect of manuka honey, MGO and DHA on jack bean urease in vitro was shown 
previously (see section 1.5.5). The antibacterial studies were performed at the German 
Institute of Human Nutrion (DIFE) in Potsdam, Germany. The methodological aspects of this 
section are described in chapter 1.4.11. During the beginning of the studies a contamination of 
the H. pylori cell culture (freeze-dried culture) with B. subtilis occurred. The contamination 
was confirmed by DNA sequencing and the study was started again with a new H. pylori 
culture (active culture), for which the identity was confirmed by a second DNA sequence test. 
The aim was to study the inhibitory effect of manuka honey, MGO and DHA on H. pylori by 
reading the optical density at 600 nm of the incubated cells. Unfortunately, it was not possible 
to observe a change of the optical density during the incubation of the cells neither in media 
alone (control) nor in the honey solutions (inhibition samples). This normally is a sign for 
absence of bacterial growth. It was described earlier, that H. pylori can change its morphology 
from a spiral to a coccoid form during incubation (Cellini, 2014). Stressing conditions, 
including antimicrobial agents in sub-inhibitory concentrations, facilitate entering the viable 
but non-culturable state in which bacterial cells acquire the coccoid form. Figure 66 shows H. 
pylori cells at the beginning of the incubation and after 48 h, respectively. 
 
 
Figure 66: Microscopic picture of H. pylori cells prior to incubation (A) and after 48 h incubation (B) 
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The optical density or turbidity of the sample was measured at 600 nm and was an expression 
of light refraction in the sample. The morphological change from long, spiral cells to small 
coccoid cells led to a decrease of light refraction. Thus, there was no increase of the cell 
number detectable via the measurement of optical density. Due to the limited amount of time 
left at the German Institute of Human Nutrition after the microtiter plate experiment, it was 
not possible to try another approach to detect bacterial growth. Further studies should focus 
on counting the cell number at different time points during incubation.  
Later on, a student at the German Institute of Human Nutrition in Potsdam, Germany, was 
able to continue this project under the supervision of the TU Dresden. This time, liquid media 
containing H. pylori was incubated with different concentrations of honey solutions and MGO 
or DHA for 0, 24 and 48 h. After incubation, the cells were cultured on fresh blood agar plates 
and cells were counted as a measure of bacterial growth. With this approach, the bactericidal 
effect of manuka honey, MGO and DHA was tested. According to the results, there was no 
permanent inhibition of H. pylori after incubation with manuka honey (max. conc. 30 %), 
MGO (max. conc. 1000 mg/l) or DHA (max. conc. 500 mg/l). All samples showed 
unhindered growth on fresh blood agar. However, the study provided no information about 
the bacteriostatic effect of manuka honey and its bioactive compounds. For most bacterial 
infections, a treatment with bacteriostatic agents might be sufficient, since the body is able to 
fight the infection with endogenous mechanisms after the immune system recovered (Pankey 
and Sabath, 2004). The results of the study did not allow quantifying the bacteriostatic effect 
of manuka honey on H. pylori, thus no final statement of its efficiency compared to 
conventional honeys can be made. 
During the incubation experiments, two interesting observations were made. After the cells 
were incubated for 48 h in the media containing manuka honey (30 and 20 % (w/v)), MGO 
(1000 and 500 mg/l), the urease inhibitor acetohydroxamic acid (5 and 2.5 mg/l) or the 
antibiotics tetracycline hydrochloride or metronidazole, the cell suspension was centrifuged 
and the lactate concentration was measured enzymatically in the supernatant. Figure 67 shows 
the results of lactate analysis. Lactate represents the final product of the glyoxalase system, 
which degrades methylglyoxal in vivo (Racker, 1951). Moreover, lactate was found to be the 
final product of glycolysis, not only but preferentially when low amounts of oxygen are 
present (Rogatzki et al., 2015). The formation of lactate by H. pylori cells in the presence of 
MGO might indicate that the glyoxalase enzyme system is present in H. pylori. The 
detoxification of MGO via its reduction to lactate is crucial for bacteria to survive in the 
presence of high amounts of MGO. Even higher amounts of lactate were formed by H. pylori 
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in the presence of manuka honey, whereby the lactate production might be the sum of lactate 
produced from MGO via the glyoxalase pathway and lactate which is formed as the product 
of increased glycolytic activity. It is questionable whether the formation of lactate and thus 
the decrease of the pH in the incubation samples will influence H. pylori survival since the 
bacterium is known for its acid tolerance. However, the unbalanced triggering of on metabolic 
pathway might induce oxidative stress in the cells, which ultimately threatens their survival. 
 
Figure 67: D- and L-Lactate concentration of cell supernatant. H. pylori cells were incubated for 48 h 
under microaerophilic conditions at pH 7 with the compounds mentioned above 
 
The second observation during the incubation experiment was made when the cell supernatant 
was analysed for its MGO content. Originally, this analysis was performed to test the stability 
of MGO in the incubation media. It was shown during previous studies that the MGO 
concentration decreased by 50 % after 30 h incubation of manuka honey in bacterial media 
without bacterial cells (see section 1.5.2.3). A more drastic decrease was found in the 
incubation samples containing H. pylori cells, media and manuka honey or MGO and DHA. 
The added MGO could not be recovered, when media with manuka honey or MGO was 
mixed with H. pylori cells and a sample for MGO analysis was taken immediately after 
mixing. However, when the cells were incubated without MGO, with manuka honey or MGO 
for up to 24 h, MGO was formed or released from the cells in the media. This might be due to 
an increase of glycolysis activity and thus the formation of MGO as a by-product. The MGO 
concentration in the media never exceeded 2 mg/l, which is a non-toxic dose. Interestingly, 
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when the bacteria cells were incubated with DHA, higher amounts of up to 16 mg/l of MGO 
were formed. The highest amounts of up to 77 mg/l of MGO were formed when the cells were 
incubated with MGO and DHA. The increased formation of MGO in the presence of DHA 
might either be due to the non-enzymatic dehydration of DHA to MGO, as it occurs in honey, 
or DHA might be metabolized by the microorganisms to DHAP which is a potent precursor of 
MGO (Thornalley et al., 1999). Nevertheless, the formation of toxic amounts of MGO did 
only occur when DHA and MGO were present. This unbalanced metabolic state of the cells 
indicated that the detoxifying system for MGO was overloaded and thus MGO can 
accumulate in the cells and the media. Although manuka honey contains MGO and DHA, no 
MGO formation during the incubation with manuka honey was detected, which might be due 
to a low dosage. The results provide preliminary indications for the mechanism of bacterial 
inhibition with MGO and DHA, which needs further elucidation in the future. Some ideas for 
the inhibition mechanism are presented in the following section. 
 
 
Figure 68: MGO concentration of cell supernatant. H. pylori cells were incubated for 48 h under 
microaerophilic conditions at pH 7 with the compounds mentioned in the diagram 
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4.1.2. The mechanism of bacterial inhibition with manuka honey 
Although there are several reports about the positive effect of manuka honey on bacterial 
infections, the mechanism by which manuka honeys kills bacteria is not fully elucidated yet. 
Rabie et al. (2016) performed an ultrastructural study on the bacterial inhibition caused by 
MGO. The authors showed that MGO effectively inhibited Gram positive (B. subtilis and S. 
aureus) and Gram negative (P. aeruginosa and E. coli) bacteria. At a concentration of 2 mM 
MGO, the authors observed the loss of fimbriae and flagella, the bacteria were rounded with 
shrinkage and lost their membrane integrity. The authors concluded that the morphologic 
changes led to limited bacterial adherence and motility. Henriques et al. (2010) suggested that 
the inhibition of S. aureus with manuka honey was due to hindered processes in the cell 
division machinery. The authors did not focus their study on the role of MGO. A possible 
reason for the signal cascade initiated by MGO might be the reaction of MGO with elements 
of the bacterial DNA. It was shown that MGO reacts with the DNA base guanine and forms 
guanine-adducts (Kalapos, 1999). Until now, these potential MGO-DNA adducts have not 
been studied in living cells. The analysis of cell material, which was incubated with MGO 
with the focus on DNA-adducts, could be an interesting new research topic. Moreover, it was 
recently discovered that manuka honey contains high amounts of up to 2000 mg/kg of 3-
phenyllactic acid (3-PA) (Ministry for Primary Industries, 2017). Lactic acids are described as 
compounds with a broad antimicrobial spectrum (Mu et al., 2012; Axel et al., 2016). The role 
of 3-PA in the inhibitory mechanism of manuka honey needs further research. 
 
 
4.2. Reactions of carbonyl compounds in honey 
 
4.2.1 Reaction sites for carbonyl compounds in honey 
The main focus of the present work was to study the reactivity of manuka honey MGO 
towards proteins and amino acids. It was shown, that modifications at the amino groups of 
proteins and amino acids occured and assisted in distinguishing manuka honey from 
conventional honeys. Besides the reaction with proteins and amino acids, MGO may also 
react with other honey compounds to form unique reaction products. Recently, a method to 
distinguish manuka honey from other monofloral honeys was published by the Ministry of 
Primary Industries NZ (Ministry for Primary Industries, 2017). According to the MPI report, a 
“monofloral manuka honey” must contain the chemical markers phenyllactic acid (PLA) in 
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amounts above 400 mg/kg and the compounds 4-hydroxyphenyllactic acid (HPLA), 
2-methoxybenzoic acid (2-MB) and 2’-methoxyacetophenone (MAP) at a minimum level of 
1 mg/kg each and a certain level of DNA from manuka pollen. The structures of the chemical 
markers are shown in Figure 69. 
 
 
Figure 69: Chemical markers proposed by the Ministry of Primary Industries NZ for identifying 
manuka honey 
 
Although the MPI claims that all chemical markers are stable during honey storage, other 
authors found a decrease of 2-MB and MAP during storage (Bong et al., 2017). Until now, 
little is known about the reactivity of MGO and DHA towards the four proposed chemical 
markers. Possible MGO-derived reaction products and thus the stability of the markers in the 
presence of MGO should be subject of further research. Moreover, according to oral reports 
from Manuka Health NZ Ltd. (Mandy Suddes, email conversation), the DNA test fails for 
genuine manuka honey. This might be due to the formation of DNA-MGO adducts, which are 
not accessible anymore for the polymerase reaction which leads to a hindered replication of 
DNA and ultimately to the failure of the test. Furthermore, MGO could directly react with the 
enzymes necessary for the test, e.g. polymerase, which also leads to an inhibition of the test. 
The role of MGO in the detection of manuka DNA should be elucidated further in the future.  
 
4.2.2 Functional consequences of carbonyl reactions with proteins 
Honey contains 0.03-0.4 % proteins depending on the floral origin (Bogdanov, 1981). It is 
presumed that proteins can influence the flow behaviour of honey (Witczak et al., 2011). 
Especially high-molecular weight components might be responsible for the non-Newtonian 
flow behaviour of some honeys like heather, buckwheat or manuka honey. In chapter B, 
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section 2.5.2.1, it was shown that manuka honeys with significant amounts of MGO have 
higher amounts HMW fractions compared to non-manuka honeys. Moreover, the HMW 
fraction of manuka honey was stable against reducing agents like dithiothreitol, leading to the 
conclusion that HMW fractions in manuka honey are more likely caused by MGO-derived 
reactions than disulphide bonds. Preliminary rheological studies were performed to analyse 
the influence of MGO and cross-linked proteins on the flow behaviour of manuka honey. The 
methods used for the studies are described in section 2.4.18.  
Newtonian fluids are characterized by their linear relationship between shear stress (Τ) and 
the shear rate (D). Its viscosity (η) is independent of the applied shear rate. In contrast, non-
Newtonian fluids show shear-thinning behaviour, which means that an increase of the applied 
shear rate leads to a decrease of its viscosity. It is presumed that certain intramolecular 
interactions are decreased during shearing and thus the fluid becomes less viscous. When the 
shear rate is slowly decreased again, some fluids can rebuild their intramolecular structures, 
resulting in the same shear stress as measured prior to shearing. However, when 
intramolecular structures are disrupted more severely and cannot be rebuild quickly, this leads 
to a decreased shear stress compared to the initial value. This behaviour is called thixotropic 
or partially thixotropic. Concerning honey, the current knowledge about rheological 
behaviour appears to be diverse: Some Polish and Greek honeys are described as Newtonian 
fluids (Lazaridou et al., 2004; Juszczak and Fortuna, 2006), Brazilian honey samples are 
described as non-Newtonian fluids between 10-15 °C and Newtonian fluids from 20-30 °C 
(Silva et al., 2016) and heather honeys are consistently characterized as non-Newtonian fluids 
(Witczak et al., 2011; Osés et al., 2017). Manuka honey was also described to be a non-
Newtonian fluid (Stephens, 2006). The reason for different rheological behaviours is either 
attributed to the crystallisation state of the honey (Smanalieva and Senge, 2009) or the 
presence of high-molecular weight components (Witczak et al., 2011). 
The first attempt in our studies was to measure a thixotropy loop for some conventional and 
manuka honey samples. Therefore, the samples were sheared with an increasing shear rate for 
3 min, kept at a constant shear rate for 3 min followed by a decrease of the shear rate to the 
initial value. Figure 70 and Figure 71 show the shear stress and viscosity curves of honeydew 
honey, polyfloral honey, heather honey and two manuka honeys with varying MGO content. 
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Figure 70: Shear stress curves (“thixotropy loop”) of honeydew, polyfloral, heather and manuka 
honey. 
 
Figure 71: Viscosity curves of honeydew, polyfloral, heather and manuka honey. 
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It became visible that not only manuka and heather honey, but also the polyfloral honey 
displayed non-Newtonian behaviour. The measurement revealed two problems: First, the 
honey samples were measured in their original, commercial state, without prior harmonisation 
of the water content. The water content of the honeydew honey was 18.1 %, of the polyfloral 
honey 16.5 %, the heather honey 17.7 %, the manuka honey with MGO 200 mg/kg 16.7 % 
and of the manuka honey with MGO 640 mg/kg 18.2 %. The varying moisture contents of the 
honeys led to different initial viscosities, what can be seen in Figure 71. To compare the 
honeys and their rheological behaviour more fairly, the moisture of the sample should be 
equal. The second problem was that according to the rheology expert of Thermo Fisher 
Scientific Dr. Eberhard Pietsch, the thixotropy loop with shear rates up to 100 s-1 is not 
suitable to measure structural changes and their recovery, because the shear rate is quite high 
and might destroy internal structures irreversibly. Therefore another method, the “creep 
recovery” test was performed. For this method, one conventional honey, namely rewarewa 
honey and three manuka honeys with MGO 30, 250 and 550 mg/kg were stored for two 
weeks in desiccators with defined humidity, which was adjusted with saturated salt solutions. 
Ultimately, the honeys were stored at a humidity of 31 %, 54 % and 75 %. The “creep 
recovery” test was performed by applying a low shear rate of 0.5 s-1 for 60 s to receive a 
steady initial viscosity value. Afterwards, the sample was exposed to a shear rate of 10 s-1 for 
30 s to strain intramolecular interactions. In the end, the shear rate was set back to 0.5 s-1 for 
300 s so the sample can rebuild its intramolecular structure. Figure 72 shows the creep 
recovery measurement of a conventional honey without MGO, namely rewarewa honey, and 
of a manuka honey with approx. 550 mg MGO/kg. The initial viscosity, which was reached 
approximately after 60 s, was lower for the rewarewa honey than for the manuka honey. This 
might be due to different water contents of the honeys, since the samples were measured in 
their commercial conditions (without prior storage under controlled humidity).  
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Figure 72: Creep recovery of rewarewa and manuka honey, samples were tested at 20 °C and under 
commercial conditions (no controlled humidity) 
 
However, it is shown that although the viscosity of the rewarewa honey samples decreased 
during the increased shear rate, it recovered almost to the initial value after the stress is 
released. In contrast, the viscosity of the manuka honey sample decreased strongly when a 
higher shear rate is applied and only 50 % of the initial viscosity was recovered. The 
difference between initial viscosity after 60 s and the viscosity value of the end of the 
recovery phase was called Δη and is a measure of the stability of intramolecular structures. 
Figure 73 compares the Δη of the different honeys without moisture control or with moisture 
adjusted at 31, 54 and 75 %. Since the creep recovery appeared to depend on the moisture 
content, the sample which were not stored in controlled humid atmosphere cannot be 
compared since all honeys had different starting conditions. However, for the samples, which 
were stored at 31, 54 and 75 % moisture, equal starting conditions for moisture can be 
assumed and the rheological effects can be related to other molecular parameters.  
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Figure 73: Difference of the initial viscosity and viscosity after shear stress (Δη) of rewarewa and 
three manuka honey samples, which were stored at controlled humidity for two weeks 
 
In general, the lower the moisture content of the samples, the higher was the initial viscosity 
and also the Δη value. Samples with higher initial viscosity values experienced higher shear 
stress. This might result in a more severe disruption of intramolecular networks, which were 
not easily rebuild during the release of shear stress. With increasing moisture of the samples, 
the Δη value decreased. Thus, lower moisture contents were apparently more suitable to 
measure the influence of shearing on intramolecular structures. To achieve a moisture content 
of 31 %, the honey samples were spread in thin layers on petri dishes and stored in a 
desiccator filled with MgCl2* 6 H2O for two weeks. However, it was not tested whether the 
moisture of 31 %, which was indicated by a hygrometer, was equally distributed in the 
samples as well. Moreover, the influence of the room humidity under which the sample were 
measured with the rheometer, was not tested. The analysis time was tried to be kept as short 
as possible, but since the sample needs to be placed on the geometry of the rheometer and is 
allowed to adopt to the temperature of the device (20 °C) for 5 min, the measurement took at 
least 10 min in total in which the sample was not kept under the controlled moisture. 
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Besides the imperfections of sample preparation and measurement, the rheological 
measurements pointed to the trend that the manuka honeys gave higher Δη values than the 
rewarewa honey. This might indicate that manuka honeys have different intramolecular 
structures than non-manuka honeys. Together with the results of the protein studies (see 
section 2.5.2.1), this led to the hypothesis that MGO-derived protein cross-links in manuka 
honey, might be responsible for the shear thinning behaviour of manuka honey. However, the 
results displayed in Figure 73, do not present clear evidence for a MGO-dependent effect, 
since only at 31 % moisture an increase of Δη with increasing MGO contents of the honeys 
was visible. Moreover, another possible cause for intramolecular interactions and a change of 
the viscosity of the samples might be the crystallisation state of sugars. Since the honeys do 
not always contain the same ratio of fructose and glucose, which profoundly influences the 
crystallisation process, no statements concerning its influence can be made. To test solely the 
effect of honey proteins on the rheological behaviour, honey proteins should be isolated via 
dialysis and resolubilised in a defined artificial honey matrix, stored at controlled moisture of 
31 % and measured with the creep recovery test. Furthermore, additional commercial samples 
without MGO and also manuka honeys with varying MGO contents should be tested to prove 
the hypothesis that Δη is a suitable parameter to detect MGO-derived reactions in honey. 
 
4.2.3 The origin of dihydroxyacetone in manuka nectar 
The reason for increased amounts of MGO in manuka honey was shown to be the high 
amounts of DHA in the nectar of the manuka plant. Although almost a decade has passed 
since this discovery, the origin of DHA in the manuka nectar is still unknown. The following 
prepositions made for the origin of DHA ought to be regarded as research ideas which are not 
yet proven.  
1.)  Triose phosphate isomerase deficiency 
The glycolytic enzyme triose phosphate isomerase (TPI) catalyzes the transition of 
dihydroxyacetone phosphate (DHAP) to glyceraldehyde phosphate (GAP). The enzyme is 
crucial for glycolysis, since only GAP can be further metabolized for energy metabolism. A 
deficiency of TPI may lead to an increase of DHAP in the cells. Ultimately, the 
dephosphorylation of DHAP might be due to enzymatic processes (e.g. kinases) or might be 
initiated by the pH value.  The dephosphorylated compound DHA could be transported to the 
nectar via the plant phloem.  
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2.)  Turn-on of pentose phosphate pathway 
If glycolysis is hindered in manuka plants because of TPI deficiency, there need to be another 
way for energy metabolism. An alternative biochemical pathway might be the pentose 
phosphate pathway (PPP). Dorion et al. (2012) showed that transgenic potato roots with 
reduced cytosolic TPI have increased carbon metabolism through the PPP. The oxidative part 
of the PP produces ribulose-5-phosphate, which is transformed to various sugar phosphate 
intermediates during the non-oxidative part of the PPP. Finally, GAP is formed which can 
enter the rear part of glycolysis and serves energy gain. However, the turn-on of the PPP does 
not only explain the compensation of energy metabolism, but might also be responsible for 
the increase of other chemical compounds in manuka nectar compared to non-manuka plant 
varieties. For example, ribulose-5-phosphate, produced in the PPP, is the precursor molecule 
for the formation of lumazine derivatives like riboflavin. Daniels et al. (2016) reported the 
discovery of 3,6,7-trimethyllumazine only in manuka nectar and honey, but not in any other 
NZ honey samples. An increase of lumazine derivatives might be due to increased amounts of 
ribulose-5-phosphate and the subsequent turn-on of certain metabolic pathways in the nectar 
and phloem of manuka plants. Moreover, another intermediate of the non-oxidative part of the 
PPP, erythrose-4-phosphate, plays an important role in the biosynthesis processes of plants. 
Erythrose-4-phosphate is one of the starting substrates of the Shikimate pathway, which is 
used for the biosynthesis or aromatic amino acids like phenylalanine and tyrosine and delivers 
starting material for phytochemical pathways. The recently proposed chemical markers by the 
NZ Ministry of Primary Industries, phenyllactic acid (PLA), 4-hydroxyphenyllactic acid 
(HPLA), 2-methoxybenzoic acid (2-MB) and 2’-methoxyacetophenone (MAP) might arise 
from the turn-on of this biochemical pathway. 
3.)  Biochemical reason  
If the starting point of the unique biochemistry of the manuka plant is a TPI deficiency, there 
are some explanations for this mutation. The simplest explanation might be a genetic mutation 
in the manuka plant, which leads to unique reaction products, but does not affect the plants 
survival positively or negatively. However, some authors presumed that TPI deficiency might 
also have a positive effect on the life cycle of plants. According to Valancin et al. (2013) and 
Dorion et al. (2012), TPI deficiency is correlated with increased oxygen uptake and growth 
rate of the plants and Chen and Thelen (2010) speculated that plastidial TPI may have an 
essential role in the regulation of seedling establishment. This might be especially important 
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for manuka plants because of their short flowering season and thus limited amount of time for 
reproductive processes. 
 
 
4.3. Metabolic transit of carbonyl compounds  
 
5.3.1 Impact of the diet on carbonyl compounds in saliva 
In addition to the studies of the influence of dietary dicarbonyl compounds on urine and blood 
concentrations (see section 3), the influence of dietary carbonyl compounds on saliva was 
studied within the master thesis of Lisa-Marie Blasse (Blasse, 2017). The methods used for 
the analysis of carbonyl compounds in saliva are described in section 3.4.9.3. A GC-MS 
method for the simultaneous quantification of glucose, fructose, 3-DG, 3-DF, 3-DGA, MGO, 
DHA and DHAP was developed and applied to human saliva samples. Moreover the analytes 
lactate, pyruvate, glyoxal and glucose-6-phosphate were implemented in the method, but for 
their quantification further method improvement is necessary. Human saliva was collected 
from healthy individuals in fasting state and after intervention with a carbohydrate-rich meal 
(see 0). Saliva production was not stimulated and the samples were collected by the spitting 
method. In total, 34 subjects participated in the study.  
The comparison of the fasting state saliva samples with the literature revealed that most of the 
analytes were present in higher concentrations in blood plasma, whereby the ratio between 
saliva to plasma was varying strongly between the analytes. For example, the median glucose 
excretion was 24.52 ± 15.83 µmol/l (n=35), which was 180 times lower than the plasma 
concentration of 3900 - 5500 µmol/l (World Health Organization, 2016). The median fructose 
concentration was 1.03 ± 0.65 µmol/l (n=38), which was 100 times lower than the plasma 
concentration of 100 µmol/l (Anderstam et al., 2013). This indicated that certain metabolites 
were transported differently from blood to saliva and that active or passive processes might be 
involved in the complex composition of saliva. More detailed information on the 
concentrations of carbonyl compounds in fasting saliva can be found in the thesis of Blasse 
(2017).  
To study the dietary influence of carbonyl compounds on the saliva, five different 
intervention studies were performed. The subjects consumed either 75 g of glucose (n=10), 40 
g of fructose (n=6), a glucose/fructose mix (34.7/30.3 g) (n=4), 65 g of manuka honey MGO 
550 (n=8) or 65 g of rewarewa honey (n=9). Saliva samples were collected prior to the 
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intervention (at 0 min) and 15, 30, 60 and 120 min after the intervention. Figure 74 shows the 
progression of salivary concentrations of glucose and fructose after the five different 
interventions. The uptake of dietary glucose mainly led to an increase of salivary glucose, 
whereas consumption of fructose led to an increase of salivary fructose. The food stuff which 
contained fructose or glucose also led to an increase of fructose and glucose, respectively. 
 
 
Figure 74: Salivary concentration of glucose (A) and fructose (B) prior (0 min) and after consumption 
of glucose, fructose, manuka honey, conventional honey or a glucose/fructose mix 
 
Interestingly, the glucose concentration reached a maximum of approx. 170 µmol/l at 15 min 
after the ingestion of 75 g glucose, whereby the fructose concentration reached a maximum 
also after 15 min, but at a concentration of 400 µmol/l. Although only 40 g of fructose were 
consumed, the increase in salivary fructose was more pronounced compared to salivary 
glucose. This was probably due to the active resorption of glucose and immediate trapping of 
free glucose as glucose-6-phosphate in cells. In contrast, fructose is passively resorbed during 
gastrointestinal digestion, which leads to a less controlled level of fructose in the system. 
After its resorption, fructose is metabolized to fructose-1-phosphate or fructose-6-phosphate, 
which enters the glycolysis (Löffler et al., 2007). During the studies, it became clear that a 
part of the ingested sugar solutions stayed in the oral cavity even after swallowing, teeth 
brushing and mouth rinsing. Therefore, the results reflect the sum of the compounds, which 
remained in the oral cavity and flowed back into saliva and the compounds, which were 
transported via the gastrointestinal system to the blood and finally into saliva.  
Figure 75 shows the postprandial concentration of 3-DG, 3-DF and 3-DGA in saliva. An 
increase of more than 400 % of the initial 3-DG concentration occurred after the consumption 
of manuka honey or conventional honey. After the consumption of fructose, the salivary 
 Further Studies and Outlook  205   
 
 
 
3-DG concentration was 3-times higher than the fasting 3-DG concentration, whereas the 
consumption of glucose did not increase the postprandial concentration of 3-DG.  
 
 
Figure 75: Salivary concentration of 3-DG (A), 3-DF (B) and 3-DGA (C) prior (0 min) and after 
consumption of glucose, fructose, manuka honey, conventional honey or a glucose/fructose mix 
 
In section 3.5.3.2 it was shown that the consumption of artificial honey, containing glucose 
and fructose led to a postprandial increase of 3-DG. It was assumed that dietary glucose is 
responsible for this spike in 3-DG. However, the current results showed that the postprandial 
increase of 3-DG was even further enhanced by dietary fructose than glucose. The 
progression of the curves of the 3-DG metabolites 3-DF and 3-DGA confirmed our previous 
hypothesis: The ingestion of dietary 3-DG, in the form of manuka or conventional honey, led 
to an increase of 3-DF and 3-DGA. In contrast, 3-DG which is formed in vivo from fructose 
did not lead to a significant increase of 3-DF or 3-DGA. This again pointed to the fact that 
intestinal reductase or dehydrogenase enzymes on the apical side might exist, which 
metabolize dietary 3-DG in the moment it reaches the gut. This detoxifying mechanism for 
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the reactive dicarbonyl compound 3-DG might have evolved during human evolution as an 
adaption to heated and carbohydrate rich food. Moreover, the ratio of 3-DG to 3-DF in 
fastened state saliva was with 1:2 very similar to the ratio, which was found in blood samples. 
This indicated that saliva is an appropriate body fluid to monitor biochemical processes and 
that dietary 3-DG, which was metabolized to 3-DF extracellularly was not rapidly transported 
into blood or saliva but is excreted with the urine (see section 3.5.3.3 for discussion). 
 
 
Figure 76: Salivary concentration of MGO (A) and DHA (B) prior (0 min) and after consumption of 
glucose, fructose, manuka honey, conventional honey or a glucose/fructose mix 
 
Figure 76 shows the concentration of salivary MGO and DHA after the interventions. The 
level of MGO was not influenced by the dietary interventions, even though 560 µmol of 
MGO were consumed with the ingestion of manuka honey. These results were in accordance 
with the results of urine and blood samples after the consumption of MGO with manuka 
honey, which also showed no postprandial increase of MGO in vivo. Apparently MGO was 
either quickly degraded in the metabolic system or it reacted with gastrointestinal compounds, 
e.g. enzymes, during digestion and could not be recovered as MGO. The precursor compound 
for the formation of MGO in manuka honey is DHA. The fate of dietary DHA during 
digestion is only poorly studied. Figure 76B shows the increase of DHA in human saliva after 
the consumption of manuka honey containing natural DHA. The increase of less than 1 
µmol/l is very low compared to the ingested dose of approx. 900 µmol DHA. In section 
3.5.3.2 it was shown that the consumption of a DHA rich manuka honey by one subject led to 
an increase of the phosphorylated form of DHA, DHAP, in plasma by 400 %. In saliva, no 
significant increase of DHAP could be shown (data not displayed). The final fate of dietary 
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DHA and the role of DHAP could not be determined. An intervention study with at least five 
subjects, who consume manuka honey and subsequent analysis of DHA and DHAP in blood 
and saliva samples, should be performed to better understand DHA metabolism. However, 
neither MGO nor DHA in manuka honey seemed to significantly increase the MGO, DHA or 
DHAP level in vivo, respectively. MGO, and DHAP as a precursor of MGO formation, are 
discussed as risk factors for the formation of advanced glycation end-products (AGEs), which 
were correlated with diseases like diabetes. Based on the results of the current work, dietary 
MGO or DHA were not resorbed during digestion and therefore do not induce consecutive 
reactions. 
Taken together, the biofluid saliva is a cheap, fast and convenient alternative to urine and 
blood and was suitable to study biochemical processes in humans. The dietary influence of 
certain metabolites could be monitored by collecting saliva during dietary interventions. 
However, it should be noted that the concentrations of most bioanalytes were lower in saliva 
compared to blood, which makes it less suitable for minor compounds. Moreover, the 
influence of incomplete elimination of the test meal from the oral cavity should be studied 
further and if necessary, the intervention procedure should be standardised (e.g. amount of 
swallows). In the interest of simplification, the collection of saliva was performed after 
unstimulated spitting in a glas vessel. The saliva was filtered and no further sample clean-up 
was applied. The sample collection could be improved with the use of salivettes and the 
sample clean-up could be enhanced with a protein precipitation prior to derivatisation. 
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5 Summary 
 
The presented work deals with three key topics regarding manuka honey: The antibacterial 
activity of manuka honey in comparison to conventional honeys in chapter A, unique 
chemical reactions in the honey matrix, which might serve as quality control parameters for 
manuka honey in chapter B and the metabolic transit of dicarbonyl compounds during 
gastrointestinal digestion in chapter C. 
 
The antibacterial studies in chapter A showed that bacterial species are affected differently by 
bioactive compounds present in honey. Methylglyoxal (MGO), which is solely present in 
manuka honeys and hydrogen peroxide, which is formed in most conventional honeys by 
glucose oxidase, are strong inhibitors of the growth of S. aureus and E. coli. The strain of 
P. aeruginosa used for this work was not inhibited by MGO, whereas B. subtilis was not 
inhibited by hydrogen peroxide. To compare and quantify the effect of MGO and hydrogen 
peroxide, a mathematic model was created. By comparing the slopes of the linearized dose-
response curves, it was found that S. aureus, E. coli and P. aeruginosa were more sensitive to 
hydrogen peroxide than to MGO. However, the natural amounts of MGO in honey are higher 
than the formation of hydrogen peroxide. Although most bacteria are more sensitive to 
hydrogen peroxide, MGO is the predominantly antibacterial compound in honey, because of 
its higher concentrations compared to hydrogen peroxide formation. The inclusion of manuka 
honey in α-cyclodextrin had only minor consequences on bioavailability and antibacterial 
activity. The commercial product cyclopower does not enhance the antibacterial activity of 
manuka honey on S. aureus, E. coli and P. aeruginosa. With the help of the newly developed 
quantitative model, it was shown that the growth of B. subtilis is synergistically inhibited with 
cyclopower compared to manuka honey and α-cyclodextrin alone. The study of bacterial 
enzymes as possible targets for bacterial inhibition with manuka honey revealed that MGO 
and DHA inhibited jack bean urease, which was used as a model for Helicobacter pylori 
urease. The concentration of MGO and DHA in manuka honey positively correlated with its 
urease inhibition. Conventional honeys, which lack MGO and DHA, showed significantly less 
urease inhibition. Based on the unique presence of MGO, manuka honey has extraordinary 
effects on bacteria, which might lead to further application to fight the emerging crisis of 
antibacterial resistance to antibiotics.  
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Customers, who buy high-priced manuka honey with promised beneficial health effects, want 
to be sure that the product they are buying is genuine manuka honey. The NZ Ministry of 
Primary Industries is currently trying to establish a manuka honey definition, which confirms 
its origin with botanical marker compounds. In the present work, an approach based on 
unique chemical reactions in manuka honey was followed. It was shown that the exceptional 
high amounts of MGO induced the formation of 2-acetyl-1-pyrroline (2-AP). In manuka 
honey containing ≥ 250 mg/kg MGO, the 2-AP concentration was significantly increased 
compared to conventional honey. Moreover, honey proteins form MGO-derived reactions 
products, which were studied by measuring the molecular size of honey proteins. Manuka 
honey proteins significantly shifted to high molecular weights (HMW) with a size above 510 
kDa. The amount of HMW protein in non-manuka honey was significantly lower. The 
cleavage of disulphide bonds led to a decrease of HMW fraction of conventional honeys but 
not of manuka honeys. It is hypothesized that MGO cross-linking of proteins is mainly 
responsible for the formation of HMW adducts in manuka honey. The formation of HMW 
adducts was also shown with fluorescence analysis, whereby manuka honey proteins had 
higher fluorescence intensities at λex=350 nm and λem=450 nm compared to non-manuka 
honeys. The artificial addition of MGO and its precursor dihydroxyacetone (DHA) to a non-
manuka honey did not lead to an increased fluorescence up to the level of commercial manuka 
honeys. The MGO-derived modifications of proteins were further studied by quantifying the 
protein-bound Maillard reaction products N-ε-carboxyethyllysine (CEL) and methylglyoxal-
derived hydroimidazolone 1 (MG-H1) after enzymatic hydrolysis of honey proteins and LC-
MS/MS analysis. Their amount was significantly higher in manuka compared to conventional 
honeys and correlated with the MGO content of the honey. Most of the MGO-derived 
reactions could be simulated by spiking a conventional honey or a low MGO manuka honey 
with artificial MGO and subsequent storage at elevated temperatures. Higher storage 
temperatures were associated with a quick increase of 5-hydroxymethylfurfuraldehyd (HMF). 
The HMF level in honey is used as a quality parameter and should not exceed 40 mg/kg 
(Codex Alimentarius Commission, 2001). High concentrations of HMF may point to a 
fraudulent addition of MGO and the production of artificial high-price manuka honey 
products. Taken together, the Maillard reaction in honey could be used to control the natural 
origin of MGO and DHA. 
 
The consumption of honey and especially manuka honey exposes humans to high levels of 
dietary dicarbonyl compounds like MGO and 3-deoxyglucosone (3-DG). Both compounds are 
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discussed as potential risk factors for the development of age-related diseases. The present 
studies contribute to the understanding whether dietary dicarbonyl compounds increase the 
endogenous level of dicarbonyl compound and thus might be considered harmful. The 
simulated digestion of manuka honey in the presence of gastric and ileal fluids showed that 
only 9 % of the initial concentration could be recovered after 8 h. The honey matrix had no 
stabilising effect on MGO compared to a synthetic MGO solution. In contrast to MGO, the 
manuka honey compound DHA was stable during all simulated digestion steps. The 
consequences of gastrointestinal stability of DHA should be subject of further research. The 
complexation of MGO with α-cyclodextrin did not enhance the stability of MGO. The 
metabolic transit of dietary MGO and 3-DG was further studied with an intervention study 
with healthy volunteers, who collected their daily urine. It was shown that the urinary 
concentrations of 3-DG and its less reactive metabolites 3-deoxyfructose (3-DF) and 2-keto-3-
deoxygluconic acid (3-DGA), but not MGO, were influenced by the diet. Apparently, MGO 
was not resorbed into the blood circulation and therefore did not influence the endogenous 
MGO level. During the intervention studies, up to 40 % of dietary 3-DG was recovered as the 
sum of 3-DG, 3-DF and 3-DGA. The metabolite 3-DGA had only a minor role in the 
metabolism of dietary 3-DG in comparison to 3-DF. The complexation of manuka honey with 
α-cyclodextrin in the commercial product “cyclopower” did not enhance the bioavailability of 
3-DG or MGO. Neither of the compounds showed increased urinary excretion after 
consumption of 12 capsules, which is three times the recommended daily dose. The 
concentrations of 3-DF and 3-DGA in plasma only increased after the consumption of dietary 
3-DG and not after the uptake of carbohydrate rich meals in general. This led to the 
conclusion that dietary 3-DG is effectively metabolized to 3-DF extracellularly on the apical 
site of the intestinal epithelium and is resorbed slowly into the circulation. In contrast, 3-DG, 
which is formed (intracellularly) postprandial from glucose, bypasses this metabolic system 
and cannot be metabolized as rapidly to 3-DF. Preliminary results obtained with saliva instead 
of urine as a bio fluid to study the dietary influence of dicarbonyl compounds confirmed the 
hypothesis. Based on the present results, dietary dicarbonyl compounds are effectively 
metabolized during digestion.  
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6 Annex 
 
ROESY-NMR data 
 
Annex-Figure 1: ROESY-NMR spectrum of glucose with DHA and MGO in equimolar ratio, protons 
are assigned to DHA, MGO and glucose 
 
Annex-Figure 2: ROESY-NMR spectrum of starch with DHA and MGO in equimolar ratio, protons 
are assigned to DHA, MGO and starch 
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Dose-response curves 
 
 
 
Annex-Figure 3: Dose-response curves of urease inhibition by acetohydroxamic acid (A), MGO (B) 
and DHA (C). 
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